Developing RNA aptamer technology for targeting cancer stem cells by Xiang, Dongxi
Developing RNA aptamer technology for targeting 
cancer stem cells 
By Dongxi Xiang
M.D., MSc
Submitted in fulfilment of the requirements for the degree of
Doctor of Philosophy 
Deakin University
January, 2015
 
 
I am the author of the thesis entitled
Developing RNA aptamer technology for targeting cancer stem cells
submitted for the degree of Doctor of Philosophy
This thesis may be made available for consultation, loan and limited copying in 
accordance with the Copyright Act 1968.
'I certify that I am the student named below and that the information provided in the form is correct'
Full Name: ........................................Dongxi Xiang……………………………………………
                                                               (Please Print)
Signed: ......................................... ………………………………………..
 
Date: ...............................................17 April 2015………………………………………………
DEAKIN UNIVERSITY
CANDIDATE DECLARATION
 
 
DEAKIN UNIVERSITY
CANDIDATE DECLARATION
I certify the following about the thesis entitled (10 word maximum) 
“Developing RNA aptamer technology for targeting cancer stem cells” 
submitted for the degree of Doctor of Philosophy
a. I am the creator of all or part of the whole work(s) (including content and layout) and that 
where reference is made to the work of others, due acknowledgment is given.
b. The work(s) are not in any way a violation or infringement of any copyright, trademark, 
patent, or other rights whatsoever of any person.
c. That if the work(s) have been commissioned, sponsored or supported by any organisation, I 
have fulfilled all of the obligations required by such contract or agreement.
I also certify that any material in the thesis which has been accepted for a degree or diploma by any 
university or institution is identified in the text.
'I certify that I am the student named below and that the information provided in the form is correct'
Full Name: .....................................Dongxi Xiang............……………………….
Signed: ........................................ .........................................
Date: ..............................................16 January 2015............…….…….………….
 
 
ACKNOWLEDGEMENT
I would like to express my utmost thanks and gratitude to my supervisor Professor 
Wei Duan for giving me the opportunity to embark on this journey. I will be forever 
grateful for the time and effort he has dedicated in guiding me to expand my 
knowledge and experience in research. Thank you for always knowing when, how and 
where I needed reminding of a big picture in academia and for providing inspiration 
during hard times throughout the past three years. The same sincere acknowledgement 
go to my associate supervisor Doctor Sarah Shigdar for her wonderful mentorship, her
kind help in experimental designs, technical training and polishing my academic 
documents. Your advice on managing well the research and daily life or enjoying 
small games to freshen my brain definitely make a big difference. Thank you both for 
training me step by step, challenging me sometimes, and bringing me to where I want 
to be, without which my PhD wouldn’t have been possible. 
I would like to thank Doctor Wenrong Yang and Mrs Qiong Li for your kind support 
and encouragement both in academic and my daily life. To Professor Alister Ward, 
thank you for your encouraging words and for having faith in my abilities over the 
years.
My huge thanks go to my past and present lab mates: Jia Lin, Lei Li, Manju Marappan, 
Tao Wang, Hadi Al Shamaileh, Joanna Macdonald, Wang Yin, Michael O’ Connor, 
Patrick Houghton, Justin Henri and Shauna Louise, thank you all for making our lab 
such as friendly and collaborative environment. 
i
 
Finally to my dear Parents without your support and constant encouragement nothing 
would have been possible. Special and heartfelt thank you for supporting me to come 
to Australia to fulfil my dreams, for your endless love, understanding and standing by 
me no matter what and when. I love you at every minute throughout my life.
ii
 
PUBLICATIONS
Articles in peer-reviewed international journals
(Total citations: 136; h-index: 6; i10-index: 5 by 17 April 2015)
1. Xiang D, Zheng C, et al. Superior performance of aptamer in tumor penetration over 
antibody: implication of aptamer-based theranostics in solid tumors. (Revision
submission). Theranostics. (IF = 7.83)
2. Xiang D, Shigdar S, Qiao G, Wang T, Kouzani A, Zhou S, Kong L, Li Y, Pu C and 
Duan W. Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the 
Next Generation of Cancer Medicine. Theranostics 2015; 5(1): 23-42. (IF = 7.83)
3. Xiang D, Zhou S, Li Y, Wei M, Qiao L, Pu C, Zhu Y, Shigdar S and Duan W.
Aptamer-mediated cancer gene therapy. Current Gene Therapy 2014 Dec 23. 
[Epub ahead of print] Pubmed: 25537777. (IF = 4.91)
4. O'Connor ML*, Xiang D*, Shigdar S, Macdonald J, Li Y, Wang T, Pu C, Wang Z, 
Qiao L and Duan W. Cancer stem cells: A contentious hypothesis now moving 
forward. Cancer Lett 2014; 28; 344(2): 180-7. (*co-first author) (IF = 5.01)
5. Li L*, Xiang D*, ¶, Shigdar S, Yang W, Li Q, Lin J, Liu K, and Duan W. Epithelial 
cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG 
nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells.
Int J Nanomedicine 2014; 9: 1083-96. (*co-first author, ¶ co-corresponding) (IF 
= 4.2)
6. Xiang D ¶, Zheng Y, Duan W, Li X, Yin J, Shigdar S, O’Connor M, Marappan M, 
Zhao x, Miao Y, Xiang B and Zheng C. Inhibition of A/Human/Hubei/3/2005 
(H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. Int J 
Nanomedicine 2013; 8: 4103-13. (¶ co-corresponding) (IF = 4.2)
iii
 
7. Xiang D, Chen Q, Pang L, Zheng C. Inhibitory effects of silver nanoparticles on 
H1N1 influenza A virus in vitro. J Virol Methods 2011;178(1-2): 137-42. (IF = 
2.1)
8. J Lin, S Shigdar; D Fang, Xiang D, Wei M, Danks A, Kong L, Li Y, Qiao L and 
Duan W. Improved efficacy and reduced toxicity of doxorubicin encapsulated in 
sulfatide-containing nanoliposome in a glioma mode. PLoS ONE 2014; 9(7): 
e103736. (IF = 3.73) 
9. Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, Lim L, Kong L, Li L and 
Duan W. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett
2013; 1; 330(1): 84-95. (IF = 5.01) 
10. Shigdar S, Li Y, Bhattacharya S, O’Connor M, Pu C, Lin J, Wang T, Xiang D,
Kong L, Wei M, Zhu Y, Zhou S and Duan W. Inflammation and cancer stem cells. 
Cancer Lett 2014; 10; 345(2): 271-8. (IF = 5.01)
11. Shigdar S, Macdonald J, O'Connor M, Wang T, Xiang D, Al. Shamaieh H, Qiao 
L, Wei M, Zhou S, Zhu Y, Kong L, Bhattacharya S, Li C and Duan W. Aptamers 
as theranostic agents: modifications, serum stability and functionalisation. 
Sensors (Basel) 2013;13(10): 13624-37. (IF = 2.05)
Research papers in preparation
1. Xiang D, Shigdar S, et al. Development of aptamer-doxorubicin conjugate for 
cancer stem cell-targeted therapy.
iv
 
Conference contributions
Published abstract
1. Xiang D, Shigdar S, Duan W. Targeting cancer stem cells in vivo using RNA 
aptamers. The 18th World Congress on Advances in Oncology, 16th International 
Symposium on Molecular Medicine, Greece. October 10-12, 2013. Int J Mol Med,
32: supplementary 1, S12, 2013. 
Invited addresses
1. Xiang D, Shigdar S, Duan W. Transforming a conventional anticancer drug into a 
cancer stem cell killer. The 18th SIS World Congress on Breast Healthcare, 
Orlando, Florida, US. October 16-19, 2014.
2. Xiang D, Shigdar S, Duan W. Aptamer-drug conjugates as effective cancer stem 
cell targeting therapeutics. EMBL Australia PhD Symposium 2014, Sydney, NSW, 
Australia. December 3-5, 2014.
3. Xiang D, Duan W. Targeting cancer stem cells using RNA aptamers for clinical 
application. Australia Bioforum of HCH Conference 2014, Melbourne, Australia, 
June 24, 2014. 
Poster presentations
1. Xiang D, Shigdar S, Duan W.  Aptamer-guided drug delivery for seeking and 
eliminating the roots of cancer: cancer stem cells. 27th Lorne Cancer Conference, 
VIC Australia. February 12-14, 2015. 
2. Shigdar S, Xiang D, Wang T, et al. The new kid on the block –are aptamers more 
effective targeted therapeutics? 26th Lorne Cancer Conference, VIC Australia. 
February 13-15, 2014.
v
 
3. Shigdar S, Xiang D, Duan W. Aptamers as effective cancer stem cell targeting 
modalities. 1st Oxford Symposium on Aptamers. Oxford, UK. March 24-25, 2014. 
4. Shigdar S, Wang T, Lin J, Xiang D, Li L, Duan W. The multifaceted nature of 
aptamers. TM’s 2nd World Cancer Online Conference. January 8-11, 2013. 
5. Shamaileh H, Wang T, Xiang D, Shigdar S and Duan W. A novel strategy for 
delivery of siRNA to colorectal cancer stem cells to improve conventional 
chemotherapy. EMBL Australia PhD Symposium 2014, Sydney, NSW, Australia. 
December 3-5, 2014.
6. Wang T, Shigdar S, Shamaileh H, Xiang D, Duan W. A CSC targeted aptamer 
based siRNA in vivo delivery system. The 2014 Australian High Content Screening 
and RNAi Meeting. Melbourne Australia. July 17-18, 2014.
7. Wang T, Shigdar S, Marappan M, Xiang D, Shamaileh H, Chen L, Macdonald J, 
Duan W and Hasimu H. An aptamer-based sirna in vivo delivery system targeting 
cancer stem cells. 5th FIP Pharmaceutical Sciences World Congress. Melbourne 
Australia. April 13-16, 2014.
8. Wang T, Shigdar S, Shamaileh H, Xiang D, Duan W. An aptamer based siRNA 
delivery system targeting tumorigenic cells in a chemo-resistant breast cancer 
model. The 29th International Association for Breast Cancer Research Conference, 
Sydney, Australia. September 14-17, 2014.
9. Duan W, Shigdar S, Lin J, Xiang D, Li L and Wang T, “RNA aptamer-guided 
nanodrug delivery for the 21st century cancer medicine”, 6th Annual Meeting of 
the Australian chapter of the Controlled Release Society, Melbourne. November 
26-27, 2012. 
vi
 
AWARDS/PROFESSIONAL MEMBERSHIP
1. 2/2015 Battelle Research Award (Society of Toxicology, USA) 
2. 1/2015 Chinese government schoarship for outstanding self-financed students 
abroad 
3. 11/2014 Smart Geelong Researcher of the Year Award 2014 finalist
4. 2/2012 – 2/2015 Australian Postgraduate Awards (APA) 
5. 10/2014 The Breast Journal Award Oral presentation (The 18th SIS World 
Congress on Breast Healthcare) 
6. 5/2012 Bellberry PhD Top-up Scholarship (Deakin University, Australia) 
vii
 
TABLE OF CONTENTS
ACKNOWLEDGEMENT..........................................................................................i
PUBLICATIONS ..................................................................................................... iii
AWARDS/PROFESSIONAL MEMBERSHIP.....................................................vii
ABSTRACT.............................................................................................................xiv
CHAPTER 1 ...............................................................................................................1
INTRODUCTION......................................................................................................1
1.1 Literature review ......................................................................................................................... 1
1.1.1 Introduction ......................................................................................................................... 1
1.1.2 Pathophysiologic challenges for drug transport to solid tumors .......................................... 2
1.1.2.1 Abnormal blood and lymphatic vessels ....................................................................... 2
1.1.2.2 Elevated interstitial fluid pressure (IFP) ...................................................................... 3
1.1.2.3 Dense interstitial structure and extracellular matrix..................................................... 4
1.1.2.4 High tumor cell density................................................................................................ 4
1.1.2.5 Tumor acidic environment ........................................................................................... 5
1.1.3 Tumor heterogeneity: another obstacle for anticancer treatment......................................... 5
1.1.3.1 The Evolving Cancer Models ...................................................................................... 5
1.1.3.1.1 CSC theory: An emerging concept....................................................................... 5
1.1.3.1.2 Defining the CSCs model..................................................................................... 6
1.1.3.1.3 The CSC model and the controversies ................................................................. 8
1.1.3.2 Existence of CSCs........................................................................................................ 9
1.1.3.2.1 Human leukemic stem cells.................................................................................. 9
1.1.3.2.2 Evidence for CSC in solid tumors ...................................................................... 10
1.1.3.2.3 The current fluid CSC model based on heterogeneity and cell plasticity........... 12
1.1.4 Overcoming chemoresistance:  CSCs may hold the answer .............................................. 14
1.1.4.1 CSC chemoresistance................................................................................................. 15
1.1.4.2 Mechanisms of CSC chemoresistance ....................................................................... 15
1.1.4.2.1 ABC transporters................................................................................................ 16
1.1.4.2.2 Aldehyde dehydrogenase activity ...................................................................... 17
1.1.4.2.3 CSC Signaling pathways.................................................................................... 17
1.1.4.2.4 Carcinoma associated fibroblasts ....................................................................... 18
1.1.4.3 Treatment Strategy: targeting CSCs via surface markers........................................... 19
1.1.5 Aptamer and aptamer-mediated drug delivery for targeted cancer therapy....................... 20
1.1.5.1 Aptamer ..................................................................................................................... 20
1.1.5.2 Aptamer and aptamer-guided active targeting system ............................................... 23
1.1.5.3 Free Aptamer as molecularly targeted therapeutics ................................................... 27
1.1.5.3.1 DNA aptamer targeting vimentin for tumor therapy .......................................... 27
1.1.5.3.2 Aptamer-mediated tumor cell apoptosis and limitation of tumor progression ... 28
1.1.5.4 Aptamer–drug delivery system .................................................................................. 29
1.1.5.5 Aptamer–nanoparticle-drug delivery system ............................................................. 31
1.1.5.5.1 Liposomes .......................................................................................................... 32
1.1.5.5.2 PLGA-PEG nanoparticles .................................................................................. 33
1.1.5.5.3 Superparamagnetic iron oxide NPs .................................................................... 34
1.1.5.6 Aptamer-mediated nucleic acid therapy for cancer therapy....................................... 36
1.1.5.6.1 Aptamer-guided nucleic acid therapy................................................................. 36
1.1.5.6.2 Aptamer-siRNA chimera for targeted cancer nucleic acid therapy.................... 37
1.1.5.6.3 Aptamer-miRNA active targeting system .......................................................... 39
1.1.5.6.4 Aptamer-mediated shRNA delivery for cancer therapy ..................................... 40
1.1.5.7 Aptamer-mediated co-delivery system....................................................................... 41
1.1.6 Future perspective: aptamer-mediated chemotherapy for targeting CSCs......................... 43
1.1.7 Conclusion ......................................................................................................................... 44
viii
 
1.2 Hypothesis and specific aims..................................................................................................... 45
1.2.1 Study hypothesis ................................................................................................................ 45
1.2.2 Study aims ......................................................................................................................... 46
CHAPTER 2 .............................................................................................................47
MATERIALS AND METHODS ............................................................................47
2.1 Ethics Statement ........................................................................................................................ 47
2.2 Materials and equipment........................................................................................................... 47
2.2.1 Chemicals and reagents ..................................................................................................... 47
2.2.2 Equipment, services and consumables............................................................................... 51
2.2.3 Antibodies.......................................................................................................................... 53
2.2.4 Animals used in this study................................................................................................. 54
2.2.5 Aptamers used in this study ............................................................................................... 54
2.3 Methods ..................................................................................................................................... 56
2.3.1 Cells culture ....................................................................................................................... 56
2.3.2 Tumor implantation and evaluation ................................................................................... 57
2.3.3 Determination of particle size of aptamer and antibody .................................................... 58
2.3.4 Development of aptamer-drug conjugate........................................................................... 58
2.3.5 Evaluation of conjugate molar ratio and DOX loading efficiency..................................... 59
2.3.6 Stability of Apt-DOX conjugates ...................................................................................... 59
2.3.7 Analysis of cellular uptake and retention of Apt-DOX ..................................................... 60
2.3.8 Determination of binding affinity ...................................................................................... 61
2.3.9 Confocal microscopy analysis of tumorsphere preparation of aptamer and antibody ....... 62
2.3.10 Chromatographic instrumentation and system................................................................. 63
2.3.11 Establishing standard curves of DOX in plasma ............................................................. 63
2.3.12 Pharmacokinetics (PK) study........................................................................................... 64
2.3.14 Establishing standard curves of DOX in tissues .............................................................. 64
2.3.15 Bio-distribution assay ...................................................................................................... 65
2.3.16 ELISA.............................................................................................................................. 65
2.3.17 In vivo imaging ................................................................................................................ 66
2.3.18 Tumor dissociation .......................................................................................................... 66
2.3.19 Flow cytometry analysis of cell surface markers and aldehyde dehydrogenase (ALDH) 
activity ........................................................................................................................................ 67
2.3.20 Fluorescence-activated cell sorting.................................................................................. 68
2.3.21 In vitro tumorsphere formation assay and ex vivo limiting dilution combined with 
tumorigenicity assay (LDA) ....................................................................................................... 69
2.3.22 In vivo tumorigenicity assay ............................................................................................ 70
2.3.23 Immunohistochemistry (double staining of CD31 and aptamer or antibody).................. 71
2.3.24 Immunohistochemistry (Ki-67 staining).......................................................................... 73
2.3.25 TUNEL assay .................................................................................................................. 73
2.3.26 Evaluation of antitumor efficacy and survival rate .......................................................... 74
2.3.27 Protein extraction and immunoblotting assay.................................................................. 74
2.3.28 Statistical analysis............................................................................................................ 75
CHAPTER 3 .............................................................................................................77
SUPERIOR PERFORMANCE OF APTAMER IN TUMOR PENETRATION 
OVER ANTIBODY: IMPLICATION OF APTAMER-BASED 
THERANOSTICS IN SOLID TUMORS ..............................................................77
3.1 Introduction............................................................................................................................... 77
3.2 Results ....................................................................................................................................... 79
3.2.1 EpCAM aptamers internalize into target cells more efficiently than antibody.................. 79
3.2.2 Aptamer is superior to antibody for tumorsphere penetration ........................................... 83
3.2.3 Aptamer is superior to antibody for in vivo tumor imaging............................................... 87
3.2.4 PEGylated-aptamer is superior to antibody for in vivo drug delivery................................ 88
ix
 
3.2.5 Comparison of penetration of aptamer and antibody in tumors......................................... 91
3.3 Discussion ................................................................................................................................. 94
CHAPTER 4 ...........................................................................................................101
DEVELOPMENT OF APTAMER-DOX CONJUGATE FOR TARGETING 
CSCs IN VITRO AND EX VIVO...........................................................................101
4.1 Introduction............................................................................................................................. 101
4.2 Results ..................................................................................................................................... 104
4.2.1 Engineering aptamer for effective conjugation of DOX.................................................. 104
4.2.2 In vitro stability of Apt-DOX .......................................................................................... 106
4.2.3 Retention of functionality of Apt-DOX conjugate .......................................................... 108
4.2.4 Characterization of the cellular internalization and retention of the Apt-DOX conjugate
.................................................................................................................................................. 109
4.2.5 Evaluation of the capability of Apt-DOX conjugate in eliminating self-renewal cells in 
vitro........................................................................................................................................... 113
4.2.6 Apt-DOX reduced tumor growth and eradicates CSCs ex vivo ....................................... 117
4.3 Discussion ............................................................................................................................... 120
CHAPTER 5 ...........................................................................................................127
APTAMER-GUIDED DOX DELIVERY FOR TARGETING CSCs IN VIVO
..................................................................................................................................127
5.1 Introduction............................................................................................................................. 127
5.2 Results ..................................................................................................................................... 129
5.2.1 PEGylation improves pharmaceutical profile and tumor delivery of Apt-DOX in vivo .. 129
5.2.2 Establishment of standard curves for DOX distribution in various tissues...................... 131
5.2.3 Biodistribution of Apt-DOX in NOD/SCID mice ........................................................... 132
5.2.4 Apoptosis induction and proliferation inhibition of tumors induced by Apt-DOX ......... 135
5.2.5 Aptamer-guided DOX delivery improved antitumor efficacy in vivo ............................. 136
5.2.6 Apt-DOX treatment diminished tumorigenicity of colorectal CSCs ............................... 139
5.2.7 Targeting HT29 colorectal CSCs by Apt-DOX in vivo ................................................... 142
5.2.8 Delivery of DOX by EpCAM aptamer targets CSCs....................................................... 145
5.2.9 Introduction of DNA double-stranded breaks of Apt-DOX treatment............................. 146
5.2.10 Reduction of gross toxicity of DOX by Apt-DOX ........................................................ 148
5.3 Discussion ............................................................................................................................... 150
CHAPTER 6 ...........................................................................................................156
CONCLUSIONS AND FUTURE PERSPECTIVES ..........................................156
6.1 General conclusions ................................................................................................................ 156
6.2 Future perspectives ................................................................................................................. 158
References ...............................................................................................................160
x
 
TABLE OF FIGURES
Figure 1-1. Evolution of cancer models. ......................................................................6 
Figure 1-2. The Fluid CSC model................................................................................7 
Figure 1-3. Timeline representing key recent milestones in the progression of CSC 
analysis. ......................................................................................................................10 
Figure 1-4. The convergent CSC model. ...................................................................14 
Figure 1-5. Isolation of aptamer and aptamer-target cell interaction.........................21 
Figure 1-6. General scheme of drug delivery to tumors. ...........................................25 
Figure 1-7. Schematic illustration of aptamer-mediated cancer therapy. ..................27 
Figure 1-8. Schematic illustration of aptamer-guided cancer nucleic acid therapy. ..37 
Figure 1-9. Schematic illustration of co-delivery of therapeutic drugs and therapeutic 
small RNA using free aptamer or aptamer-conjugated nanoparticles. ......................42 
Figure 3-1. Cell binding and internalisation of EpCAM aptamer and antibody in 
vitro. ...........................................................................................................................82 
Figure 3-2. EpCAM aptamer penetrates tumorsphere more effectively than EpCAM 
antibody......................................................................................................................85 
Figure 3-3. EpCAM aptamer is retained much longerer inside tumorsphere than 
EpCAM antibody. ......................................................................................................86 
Figure 3-4. Outstanding in vivo imaging properties of EpCAM aptamer over 
EpCAM antibody. ......................................................................................................88 
Figure 3-5. Advanced tumor accumulation and retention of PEGylated aptamer than 
that of antibody to HT29 xenograft tumors................................................................91 
Figure 3-6. Time-dependent penetration of PEGylated aptamer and antibody in 
relation to blood vessels in HT29 xenograft tumors. .................................................93 
Figure 4-1. Schematic illustration of a new paradigm for CSC-targeted therapy by 
aptamer-guided drug delivery. .................................................................................103 
Figure 4-2. Schematic diagram of the predicted intercalation of DOX to engineered 
EpCAM aptamer. .....................................................................................................105 
Figure 4-3. Determination of successful intercalation of DOX to aptamers............106 
Figure 4-4. DOX release profile from conjugate. ....................................................108 
Figure 4-5. Determination of dissociation constant of Apt-DOX conjugate. ..........109 
Figure 4-6. Specific drug delivery and retention of Apt-DOX. ...............................111 
Figure 4-7. Cellular uptake and retention of Apt-DOX. ..........................................113 
xi
 
Figure 4-8. Impairment of CSC self-renewal capacity by aptamer-guided DOX 
treatment in vitro. .....................................................................................................117 
Figure 4-9. Apt-DOX reduced tumor growth and eradicates CSCs ex vivo. ...........119 
Figure 5-1. Pharmaceutical profile of PEGylated Apt-DOX. ..................................130 
Figure 5-2. Standard curves for DOX determination in various tissues. .................132 
Figure 5-3. Bio-distribution of Apt-DOX in vivo. ...................................................134 
Figure 5-4. Apt-DOX treatment enhanced apoptosis and inhibited proliferation of 
HT29 xenograft tumor..............................................................................................136 
Figure 5-5. Administration of Apt-DOX inhibits tumor growth in HT29 tumor 
model........................................................................................................................137 
Figure 5-6. Aptamer-guided DOX delivery inhibited tumor growth and extended 
survival rate of mice-bearing HT29 tumors. ............................................................138 
Figure 5-7. A representative single suspensions dissociated from treated HT29 colon 
tumors.......................................................................................................................143 
Figure 5-8. Aptamer-guided DOX delivery targeted colorectal CSCs. ...................144 
Figure 5-9. Apt-DOX was delivered into EpCAM+/CD44+/CD24+ cells in treated 
xenograft tumors and eliminates CSCs. ...................................................................146 
Figure 5-10. Mechanism of Apt-DOX induced cell death. ......................................148 
Figure 5-11. Aptamer-guided DOX delivery reduced gross adverse effects. ..........149 
xii
 
LIST OF TABLES
Table 1-1. Application of free aptamers as cancer-targeted therapeutics……………29
Table 1-2. Application of aptamer-drug conjugates as cancer-targeted 
therapeutics………………………………………………………………………….31
Table 1-3. Application of aptamer-functionalised drug-encapsulated NPs as cancer-
targeted therapeutics………………………………………………………………...36
Table 4-1. In vitro limiting dilution assay of colorectal tumor cells……………….116
Table 4-2. CSC frequency of ovarian and breast tumor cells treated by DOX and Apt-
DOX and other controls in vitro with limiting dilution assay……………………..116
Table 4-3. Ex vivo limiting dilution assay of single suspension cells after in vitro
treatment…………………………………………………………………………...118
Table 5-1. Pharmacokinetic parameters of free DOX, PEGylated Apt-DOX and 
control PEGylated Apt-DOX after i.v. administration at a dose of equivalent to 5 
mg/kg DOX………………………………………………………………………..131
Table 5-2. In vitro limiting dilution assay of colorectal tumor cells prepared from 
xenograft tumors after in vivo treatment…………………………………………...141
Table 5-3. Aptamer-guided DOX delivery increased tumor latency and reduced CSC 
frequency in HT29 xenograft tumors………………………………………………142
xiii
 
ABSTRACT
Tumor heterogeneity, evident from the co-existence of non-cancer stem cells and 
cancer stem cells in a tumor, represents a major obstacle to successful cancer 
treatment. Even though most proliferating and differentiated cancer cells can be 
decimated by radio- or/and chemotherapy, cancer stem cells are suggested to be spared 
by cytotoxic agents, thereby leading to therapeutic resistance across a broad variety of 
solid malignancies. A rational targeting strategy capable of eradicating these ‘roots of 
cancer’ that feed tumor repopulation has been perceived as a magic bullet to treat 
cancer patients with chemoresistance. 
Data provided in this thesis demonstrated that nucleic acid aptamers, as chemical 
antibodies, possess a number of superior attributes over monoclonal antibodies in 
terms of deeper tumor penetration, more efficient intracellular accumulation and 
prolonged retention in tumor cells (Chapter 3). In fact, an EpCAM (epithelial cell 
adhesion molecule) aptamer was capable of not only penetrating  3-D tumorspheres 
efficiently from 30 min to 240 min incubation time, but were also be retained for at 
least 24 h. In contrast, the EpCAM counterpart antibody with a comparable 
equilibrium dissociation constant (K’d) barely reached the core of tumorsphere after 
6 h, with a poor retention as it almost disappeared from the core of the tumorsphere 
after 4 h. Most importantly, the aptamer achieved at least 4-time better tumor 
penetration than that of the antibody throughout the xenograft tumor studied 3 h after 
intravenous administration. The superior tumor penetration ability demonstrated for 
aptamers to antibodies suggests that aptamers are ideal escort modalities for the 
xiv
 
development of active targeting-based theranostics for both cancer therapy and in vivo
imaging (Chapter 3).   
A novel strategy for targeting cancer stem cells has been established in this study via 
direct conjugating a traditional anticancer agent, doxorubicin, into a cancer stem cell-
targeting RNA aptamer (EpCAM) (aptamer-doxorubicin). The aptamer-doxorubicin 
conjugate could specifically target EpCAM-expressing cancer cells, release the drug 
inside cells and sustain longer drug retention compared to that of free drug counterpart. 
Aptamer-guided doxorubicin delivery resulted in a 16.7-fold, 16-fold and 2.6-fold 
decrease in tumorsphere formation or cancer stem cell frequency in colorectal, ovarian 
and breast cancer cells compared to that treated with free doxorubicin, respectively. 
These results indicate that the aptamer-doxorubicin system could effectively impair 
the tumorigenicity of cancer stem cells in at least 3 key types of solid tumors. As 
revealed by the ex vivo limiting dilution assay, treatment with aptamer-doxorubicin 
successfully suppressed tumor growth as evident from the absence of tumor formation 
in mice received an inoculating cell dose of 1 × 104 cells that had been treated by the 
regimen, pronged tumor-free latency (6 weeks compared to 2 weeks latent period in 
the mice treated with free doxorubicin) and extended survival rate. These remarkable 
improvements in inhibition of self-renewal were most likely derived from the 
eradication of cancer stem cells in the treated colorectal cancers cells. Thus, these data 
paved the way to further exploration of this conjugate for in vivo targeting of cancer 
stem cells (Chapter 4). 
To facilitate the in vivo drug delivery property, the EpCAM aptamer was engineered 
via the conjugation of a terminal 20 kDa polyethylene glycol (PEG) to facilitate its 
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serum retention. The PEGylated aptamer-doxorubicin improved the pharmacokinetic 
profile, as evident from the increased doxorubicin accumulation in tumors (100-200% 
and 22 % higher, at 3 and 24 h compared with that of free doxorubicin, respectively), 
as well as an enhanced safety profile with reduced cardiac exposure (from 70% to 39% 
lower, at 3 and 24 h compared with that of free doxorubicin, respectively) (Chapter 
5). The treatment of cells with the aptamer-doxorubicin conjugates  in vivo resulted in 
a significant increase in sensitivity to doxorubicin in HT29 colorectal tumors as 
evidenced by the 25-fold decrease in proliferation (via Ki-67 assay) and the 3.75-fold 
increase in apoptosis (via TUNEL assay) in the tumors treated compared with those 
treated with free doxorubicin (Chapter 5). In addition, treatment of tumor-bearing 
mice with aptamer-doxorubicin resulted in a significantly higher inhibition efficacy 
on tumor growth (3-fold smaller tumor size) compared with the mice receiving free 
doxorubicin (P < 0.01). Finally, mice receiving free doxorubicin or negative control 
aptamer-doxorubicin succumbed to the tumors at around Day 51, while those treated 
with aptamer-doxorubicin had a remarkably prolonged survival rate (at least 2 weeks 
longer) (Chapter 5). 
To explore whether the marked suppression of tumor growth and greatly improved 
overall survival were attributed to the elimination of cancer stem cells, the mechanisms 
underlying the efficacy of aptamer-doxorubicin were explored. The in vivo limited 
dilution assay revealed a strong inhibition effect of the aptamer-doxorubicin treatment 
on the cancer stem cells in HT29 colorectal tumors, with a 30-fold lower tumor 
forming frequency and a much longer latency than those tumors treated with free 
doxorubicin. No tumors was formed in mice inoculated with 1 × 103 tumor cells 
dissociated from  xenograft HT29 tumors  that had been treated with aptamer-
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doxorubicin. There was also a ~20 days longer tumor-free period in mice receiving 1 
× 103 tumor cells dissociated xenograft HT29 tumors that had been treated with 
aptamer-doxorubicin than those treated with free doxorubicin. This cancer stem cell-
targeting effect was further confirmed by a universal reduction in the cancer stem cell 
population in tumors via ALDEFLUOR assay after the aptamer-doxorubicin treatment 
(Chapter 5). Furthermore, physical evidence was presented for this EpCAM aptamer-
doxorubicin to be internalized into cancer stem cells in the xenograft HT29 tumors as 
well as the functional consequence of reversing drug resistance to doxorubicin in 
cancer stem cells using sorted colorectal cancer stem cells that had been dissociated 
from HT29 colorectal xenograft tumors treated with aptamer-doxorubicin or free 
doxorubicin. Promisingly, the intravenously administered aptamer-doxorubicin was 
detected in colorectal cancer stem cells and led to a marked increase (4-fold) in the 
sensitivity of these cancer stem cells to doxorubicin-induced apoptosis. Furthermore, 
aptamer-doxorubicin induced an approximately 3.5-fold increase in the 
phosphorylation of H2A.X protein than those treated by free doxorubicin, suggesting 
that aptamer-doxorubicin efficiently induced DNA damage response and cell death 
pathways after DNA damage via the same signaling pathways known to be activated 
by free doxorubicin, but more efficiently and/or potently (Chapter 5).   
Therefore, the results from this thesis suggest that instead of developing a new drug 
to target cancer stem cells, a novel strategy of effective targeting cancer stem cells 
could potentially revolutionize the future cancer treatment. This new strategy utilizes 
a cancer stem cell-targeting aptamer to transform a conventional chemotherapeutic 
agent (doxorubicin) into a cancer stem cell-killer, thereby overcoming drug resistance 
in cancer stem cells. Further experimentations based on the results obtained in this 
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study might lead to greatly accelerated progress in developing novel and efficacious 
cancer stem cell-therapeutics as we can captilize on the available clinical safety and 
pharmacology data for existing chemotherapy drugs accumulated over several 
decades. Moreover, as both the aptamer and the therapeutic agent used in our system 
target the consequences of oncogenic transformation in bulk tumor cells as well as in 
cancer stem cells, the success of this project will bring us a few vital steps closer 
towards the goal of providing a cure for cancer.  
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CHAPTER 1
INTRODUCTION
This Chapter was adapted from the following published review articles:
1. Xiang D, Shigdar S, Qiao G, Wang T, Kouzani A, Zhou S, Kong L, Li Y, Pu C and 
Duan W. Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the 
Next Generation of Cancer Medicine. Theranostics 2015; 5(1): 23-42.
2. O'Connor ML*, Xiang D*, Shigdar S, Macdonald J, Li Y, Wang T, Pu C, Wang Z, 
Qiao L and Duan W. Cancer stem cells: A contentious hypothesis now moving 
forward. Cancer Lett 2014; 28; 344(2): 180-7. (*co-first author)
3. Xiang D, Zhou S, Li Y, Wei M, Qiao L, Pu C, Zhu Y, Shigdar S and Duan W.
Aptamer-mediated cancer gene therapy. Current Gene Therapy 2014 Dec 23. [Epub 
ahead of print] Pubmed: 25537777.
1.1 Literature review
1.1.1 Introduction
The success of cancer chemotherapy depends on adequate delivery of therapeutic 
agents to tumor sites while sparing normal tissues. Inadequate amounts of drug 
reaching cancer cells after initial treatment is a major factor underlying drug resistance 
and tumor recurrence, which are due to an outgrowth of residual tumor cells [1]. Other 
factors, such as abnormality in tumor microenvironment and tumor cell heterogeneity, 
also contribute to the failure of cancer treatment. The abnormal tumor physiology, 
such as vasculature changes, gives rise to a set of transport barriers that limit drug 
delivery to both primary and metastatic tumors, and in return promotes systematic 
drug resistance [2]. Both preclinical and clinical studies have revealed the complexity 
and vast intricate nature of cancer development and progression. Although these recent 
successes have provided invaluable insight into the molecular and cellular 
mechanisms underlying tumorigenesis, the mechanism by which cancers manage to 
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evade current treatment remains elusive [3].  As the oncology field continues to evolve, 
the re-emergence of the cancer stem cell (CSC) hypothesis in the last 20 years has 
spurred intense debate on the validity of the CSC concept, as well as its clinical utility. 
Aptamers, as a new class of cancer targeting ligands, are short chemically synthesized
single-stranded RNA or DNA oligonucleotides that specifically bind to molecular 
targets with high affinity and specificity. They can be further chemically modified to 
acquire desirable attributes for clinical applications [4]. A wide range of 
chemotherapeutic agents can be linked to aptamers, via physical or chemical 
conjugation, to enhance cancer treatment efficacies. This chapter will provide a 
concise overview of the CSC research field, focusing on recent evidence that has shed 
light on many of the challenges unresolved since the re-introduction of CSCs to the 
field and discussing the latest advances in aptamer-based cancer therapy.  
1.1.2 Pathophysiologic challenges for drug transport to solid tumors 
During the course of pharmacological treatment of cancer, delivery and metabolism 
of a chemotherapeutic agent is a complex journey starting from the site of 
administration and ending where the tumor cell is located. The five main factors 
underpinning the delivery of drugs to the tumor are discussed below [5, 6].
1.1.2.1 Abnormal blood and lymphatic vessels
Efficient drug delivery to solid tumors relies on a good blood circulation in the tumor, 
followed by drug transportation through vascular walls [5, 6]. In the normal 
angiogenesis system, there is a balance between the growth of new blood vessels and 
shrinking of the old ones under the influence of antiangiogenic factors [7, 8]. In 
contrast, tumor angiogenesis is characterized by uncontrolled overproduction of new 
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blood vessels that are inhomogeneous in size and density, thus hampering fluid 
perfusion and drug transportation and resulting in further drug resistance, gene 
mutagenesis, metastases and/or recurrence [9-11]. The lymphatic system functions to 
return interstitial fluid to the blood circulation and to clear macromolecules as well as 
detached tumor cells [12, 13]. The impaired lymphatic drainage is a prominent 
characteristic of solid tumors and this, coupled with a leaky tumor vasculature, results 
in an enhanced accumulation and retention of molecules with a molecular mass of 40 
kDa or higher in the tumor, an important phenomenon known as the enhanced 
permeability and retention (EPR) effect [9, 14, 15]. The compressed lymphatic vessels 
lose their function of returning interstitial fluid, resulting in fluid retention and 
elevation of interstitial fluid pressure (IFP), generating another barrier for drug 
transport [9, 16].
1.1.2.2 Elevated interstitial fluid pressure (IFP)
Interstitial fluid is the extracellular solution that baths and surrounds most tissues, 
excluding the extravasation fluid from the lymph and blood vessels [17]. The 
interstitial fluid mediates the exchange of oxygen, nutrients and waste products 
between cells and their surroundings through the interstitial space among capillaries, 
blood vessels and the lymphatic system [18]. IFP is the hydrostatic and colloid osmotic 
pressures exerted by the free interstitial fluid.  In contrast to normal interstitium, the 
IFP is often elevated in solid tumors partly because of low lymphatic drainage and
leaky tumor vessels [17-20]. The elevated IFP is a major obstacle for anticancer drug 
transport [21]. Many factors can lead to an increased IFP, including individual or 
combined effects of hyper-permeable blood vessels and a defective lymphatic system 
[22-24]. Chemotherapeutic drugs are transported and distributed through the tumor 
interstitial space via diffusion and convection, for small and large molecule transport, 
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respectively [25-27]. Drug diffusion depends on diffusivity and concentration 
gradients, while convection of large molecules relies on hydraulic conductivity and 
pressure differences [28]. High molecular weight drugs mainly travel to the interstitial 
space by convection, but the uniform IFP and negligible fluid pressure gradients 
weaken the convection power, leaving diffusion largely responsible for drug transport 
in solid tumors [29, 30]. Increased IFP decreases vascular and capillary functions and 
limits drug exposure, distribution and uptake by tumor cells, resulting in the failure of 
anticancer therapy [5, 31].
1.1.2.3 Dense interstitial structure and extracellular matrix 
Extracellular matrices in healthy tissue serve many functions, including maintaining 
cellular homeostasis, sequestering tissues or cellular growth factors from one to 
another, and eliciting protease activities for regulating cellular functions [32]. The 
abnormal extracellular matrices in the tumor are largely composed of structural 
macromolecules (collagen) and space-filling proteins (polysaccharides) that make the 
tumor interstitium a highly viscous space [32, 33]. This viscoelastic and tortuous area
forms a major barrier for effective drug transport [31]. Components such as collagen, 
glycosaminoglycan and fibroblasts are responsible for the reduced hydraulic 
conductivity and increased interstitium tension, resulting in a poorer convection and 
elevated flow resistance [5, 6]. In addition, the dense interstitial matrices mediate solid 
stress and compress blood and lymphatic vessels, leading to further restrictions on 
drug distribution.
1.1.2.4 High tumor cell density
High cell density is also responsible for the increase in IFP, compression of blood 
vessels, and extracellular matrix that lead to a dense and tortuous tumor 
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microenvironment [10, 34]. In contrast, low cell density along with larger interstitial 
spaces facilitates more effective drug transport to their targets. 
1.1.2.5 Tumor acidic environment 
The leaky tumor vessel is inadequate to supply enough nutrients, resulting in a 
reduction in the transport of oxygen to tumor cells [35, 36]. Together with hypoxia, 
the nutrient-deprived niche provides a physiological-associated pressure stimulating 
the development of malignant tumor cells as well as resistance to chemotherapy [37-
40]. The low pH (pH 5.7-7.4) in the tumor can naturally induce cell death, but cells 
that live in such conditions are difficult to be killed, even with drug treatment, 
contributing to failure of cancer therapies and disease progression [37-40].
1.1.3 Tumor heterogeneity: another obstacle for anticancer treatment
1.1.3.1 The Evolving Cancer Models
1.1.3.1.1 CSC theory: An emerging concept 
Cancer research in the second half of the last century was dominated by the clonal 
evolution model, a concept whereby each cell within a tumor has equal potential in 
acquiring stepwise genetic and/or epigenetic changes, conferring growth advantages 
and generating new tumors (Fig. 1-1a) [41-43]. However, as initially eluded to in the 
19th century and pioneered by the discovery of many types of differentiated cells in 
teratocarcinoma in the early 1940’s, another model emerged in the mid-1990’s [44].
This model proposes that only a subpopulation of cells within a tumor has the ability 
to self-renew, differentiate and regenerate similar tumors, as demonstrated with 
xenotransplantation into immunodeficient mice [45-48]. Termed cancer stem cells 
(CSCs), these ‘roots of cancer’ operate in a hierarchical fashion, similar to what is 
conceptualized in normal stem cells [49] (Fig. 1-1b).  That is, CSCs are the driving 
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force of tumorigenesis due to the ability of self-renewal and multi-lineage 
differentiation through either asymmetric or symmetric cell division. In contrast, their 
offspring, progenitor cells and differentiated cancer cells, lose the ability to self-renew 
and to proliferate extensively, thus no longer possessing tumorigenic potential [45].
The emergence of the CSC model has spurred both intense debate and discordance 
amongst cancer researchers. 
Figure 1-1. Evolution of cancer models. 
(a) The clonal evolution model. All cells are derived from a single cell and are divided 
into subpopulations, resulting from specific mutations and selection fitness. (b) The 
CSC model. A mirror to the cellular hierarchy in normal tissue, with the exception of 
unregulated control of CSCs driving tumorigenesis. (Adapted from [1])
1.1.3.1.2 Defining the CSCs model
All factors contributing to the unique properties of normal stem cells are encapsulated 
by the word ‘stemness’ [50]. Initially, this terminology encompassed any 
characteristic that contributed to the overall separation between stem cells and their 
progeny [51, 52].  It is now used as a general term to describe the unique properties of 
stem cells, the ability of self-renewal and multi-potent differentiation.  As evidence 
emerged of a possible subpopulation of tumor cells that contained similar properties 
to those found in normal stem cells, the phrase was taken on to also describe the 
features of CSCs. Recent research has shown that CSCs may originate from normal 
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stem cells and this could have significant implications in current biological knowledge 
and cancer research [53-55].  This was first postulated by Smalley and Ashworth’s 
(2003) experiments that suggested CSCs may come from normal stem cells that have 
gained malignant mutations and have lost their ability to self-regulate cell proliferation 
[56].
Despite the attractiveness of the CSC concept, it has been countered by other evidence 
implicating progenitor cells as reacquiring self-renewal capacity through genetic 
mutations and epigenetic modifications [57-59]. These conflicting results do not 
necessarily indicate that these models are mutually exclusive.  Rather, different 
subtypes of tumors can behave differently, as well as being influenced by their 
microenvironment that, in turn, can govern metastatic colonization [60, 61].  The 
earlier CSC model is a static one.  However, data emerging in the last three years has 
revised the model to a dynamic one, where the hierarchical feature of the CSCs turns 
out to be more transient than once thought (Fig. 1-2). That is, new progenies acquire 
the ability of self-renewal through de-differentiation of progenitor cells, as well as 
reversal of terminally differentiated cells [62]. The implications of CSCs and their 
offspring gaining self-renewal suggest the necessity to evolve current cancer 
treatments to target both bulk terminal differentiated cells and those with self-renewal 
potential [63].
 
Figure 1-2. The Fluid CSC model. 
Both progenitor cells and differentiated cells are able to re-acquire self-renewal 
potential. (Adapted from [1])
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1.1.3.1.3 The CSC model and the controversies
The origin of cancer from a distinct entity was first hinted at by studies conducted in 
the 19th century. Stephen Paget formulated a seed and soil theory regarding breast 
cancer that unfortunately was refuted and ridiculed [64, 65].  Progressing through the 
late 20th century, the CSC concept re-emerged with the aid of scientific and 
technological advancements. The most definitive evidence on the existence of CSCs 
was presented by Bonnet and Dicks in the mid-1990s through their seminal work on 
leukemia CSCs.  Capitalizing on the in-depth knowledge of the hematopoiesis system, 
they showed that leukemic stem cells possess characteristic functional properties of 
stem cells (Fig. 1-3) [66].  Their studies entailed first isolating subpopulations of cells 
expressing CD34+CD38-, followed by transplantation into immuno-comprised 
NOD/SCID mice. Remarkably, these CD34+CD38- leukemic stem cells could 
reconstitute the full spectrum of phenotypes from patients with acute myeloid 
leukemia [66]. These experiments were the first to highlight the importance of defining 
CSCs by a functional assay, as opposed to relying on certain profiles of cell surface 
marker proteins, which can vary dramatically.  Approximately 6 years later, Al-Hajj 
and colleagues were the first to demonstrate CSCs in solid tumors (breast cancer), 
while Singh et al., utilized an in vitro tumorsphere assay to highlight self-renewal 
properties in human brain tumors [67, 68].  CSCs have also been identified in other 
solid tumors, including lung, colon, prostate and pancreatic cancers, all supporting the 
model that cancer derives from a subpopulation of CSCs capable of self-renewal to 
initiate and sustain tumor growth [68-72].  All these studies employed a functional 
assay in which serial dilutions of isolated single cell suspensions of cancer cells were 
inoculated into immunodeficient mice.  In fact, this assay is the currently accepted 
gold standard for studying the degree of stemness in a subpopulation of human cancer 
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cells that drives tumorigenicity. However, it is this very assay that constitutes a focal 
point of the debate of the CSC model as it has been argued that this method may 
measure the ability of human cells to grow in mice and not necessarily the actual 
frequency of clonogenic cells in situ in the tumor.  Indeed, there is an on-going debate 
on the validity of the CSC model, based on concerns with the current gold standard 
CSC assay and strong experimental evidence for the stochastic model of tumor 
development [73-76]. Firstly, at least in some cancers, the cells that are able to initiate 
a tumor appear to be quite numerous.  It follows that if the cancer initiating cells are 
not rare, it negates the hierarchical model of CSCs [74]. Secondly, the importance of 
the tumor microenvironment in tumorigenesis has been well elucidated.  Introducing
human tumor cells in Matrigel containing a cocktail of growth factors to a foreign 
species such as a mouse, may compromise the growth of human cancer cells [77].
Thirdly, the nature of the proteolytic enzymes used, the length of incubation, and the 
temperature at which the tumor cells are dissociated into single cells in order to 
perform xenotransplantation might further result in the under-estimation of the 
frequency of CSCs, even with the same type of tumor.
1.1.3.2 Existence of CSCs
1.1.3.2.1 Human leukemic stem cells
Even with these concerns, leukemic stem cells (LSCs) have by far been the most 
widely accepted model for the CSC hypothesis [44].  This is, at least in part, because 
the work with human LSCs has addressed some of the key concerns on the 
methodologies used to identify CSCs. Firstly, the definition and functional 
characterization of LSCs are based on the best defined stem cell hierarchy of 
hematopoiesis [78, 79], affording less confusion as to what defines a LSC.  Secondly, 
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although microenvironment plays an important role in the biology of both normal stem 
cells and CSCs, cells associated with the hematopoietic system possess a greater 
flexibility in the adaptation to the environment in which they grow due to their 
necessity to travel throughout the body [80]. Thirdly, there is no need to use proteolytic 
enzymes to dissociate leukemia cells. In an attempt to address the CSC niche issue, 
some researchers have produced a humanized microenvironment in immunodeficient 
mice for the xenotransplantation assay [81].
Figure 1-3. Timeline representing key recent milestones in the progression of 
CSC analysis. 
(Adapted from [1])
1.1.3.2.2 Evidence for CSC in solid tumors
As for CSCs in solid tumors, technological advances allow the field to address one of 
the key arguments underlying the debate of the CSC model, e.g. the current gold 
standard assay (xenotransplantation) may test the potential of cells to form tumors in 
a mouse environment but not their actual capability or fate in the cancer specimen 
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from which they are derived.  In August 2012, compelling results emerged from the 
work carried out in three independent laboratories that have proved beyond doubt that 
CSCs exist in solid tumors [82, 83].  These studies have utilized lineage tracing and 
clonal analysis to follow the fate of individual marked mouse tumor cells throughout 
tumorigenesis in their native microenvironment for glioma, skin cancer and intestinal 
tumors [66, 84-86]. Parada and co-workers used the nestin-ǻ7.-IRES-GFP transgene, 
previously used to trace quiescent neural stem cells, to identify a subpopulation of 
cells found within mouse glioma tumors [85]. These cells were the source of entire 
new progenies of tumor growth after being treated with temozoloamide (TMZ), which 
was used to initially arrest tumor development. Clevers and colleagues, however, 
directed their investigation to demonstrate the role of single intestinal stem cells in the 
initiation and maintenance of intestinal adenoma by introducing a gene that would 
allow cells and their progenies to emit 4 different colors upon activation with the drug 
tamoxifen [84]. Finally, Blanpain and co-workers demonstrated the generation of 
cellular hierarchy dependent on the stage of tumor growth and progression from
benign skin tumors to cancer, accompanied by an expansion of the CSCs and a 
decrease in the population of non-CSCs [86]. Of note, some of the tumors studied are 
benign precursor lesions that progress infrequently to carcinomas. Regardless, these 
studies have demonstrated that a subpopulation of tumor cells containing self-renewal 
properties are responsible for the tumorigenesis in these models, thus strongly 
supporting the existence of CSCs in at least these three types of solid mouse tumors. 
Reassuringly, these three ground-breaking independent studies have reached the same 
conclusions. In addition to the compelling evidence for the existence of CSCs during 
unperturbed solid tumor growth, these elegant studies have also revealed that stemness 
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within CSCs is a fluid state dependent on stage of tumor development, tumor 
environment, and genetic phenotype.  
Regarding the entity and roles of CSCs in the development of human solid cancers, 
auto-transplantation performed some 50 years ago, in which cancer cell suspensions 
from various solid tumors were injected into the thigh or forearm of the same patient, 
showed that tumor growth occurred only after inoculation of at least 106 cells, 
demonstrating that there is functional heterogeneity in the proliferative ability of cells 
within a cancer mass [87]. Contemporary work using a molecular marking approach 
with green fluorescence protein-lentiviral vectors to visualize the contribution of 
individual cells in a patient-derived colon cancer sample in tumor formation has 
identified three functionally distinct sub-groups within the colon CSC compartment
[88]. Although the specific origins of tumor growth are yet to be determined, these 
studies highlight the roles of CSCs in tumor initiation, relapse and resistance to 
therapies. It is therefore obvious that in order to improve the outcome of cancer 
treatment, targeting both the majority of bulk cancer cells and CSCs is vital if there is 
to be any hope of improving prognosis [75].
1.1.3.2.3 The current fluid CSC model based on heterogeneity and cell plasticity  
Tumor heterogeneity can be defined as a combination of cell populations that have 
arisen from different genetic and epigenetic influences [89]. The heterogeneity of 
these subgroups have been used to explain differences in patient prognosis and 
response to treatment within the same subtype of cancer [90]. That is, the genetic 
background of a subpopulation within a tumor can directly influence its competiveness 
within the progeny. It is on this basis that the clonal evolution model was developed, 
as cells which have acquired a selective advantage against chemoresistance are able 
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to thrive and cause relapse. The original CSC model, however, is a static one, in which 
CSCs possess the sole ability of driving new tumor growth. This rigid model restricted 
heterogeneity as it suggests that identical CSCs drive tumor development and generate 
identical cellular progenies within the tumor. 
In 2011, three studies using cancer cell lines as well as primary tumors demonstrated 
the acquisition of self-renewal capabilities by non-CSC populations within a tumor 
and have brought both the clonal evolution and CSC model more closely together [91-
93]. Weinberg and colleagues investigated the possibility of non-CSC re-acquiring 
self-renewal potential and found that this inter-conversion was enhanced through 
oncogenic transformation [91]. Finally, non-CSCs in basal breast cancers were shown 
to switch to a CSC-like state, dependent on ZEB1, a regulator that has been associated 
with epithelial-mesenchymal transition [92]. In addition to solid malignancies, 
genetically diverse CSC populations within individual tumors have also been 
demonstrated in hematological cancers. Using xenotransplantation and DNA copy 
number alteration profiling, Dick and co-workers investigated the role of clonal 
evolution and CSC hierarchy in BCR-ABL1 lymphoblastic leukemia-initiating cells 
[94] and showed that leukemic stem cells are themselves subjected to clonal evolution. 
New consensus has emerged in which inter-tumor and intra-tumor heterogeneity of 
leukemia can be attributed to the differences and genetic diversity inherent in leukemia 
stem cells (Fig. 1-4). From a translational point of view, these recent advances stress 
the importance of developing cancer therapies that can target CSC and their progeny, 
as both may generate subclones that influence their degree of chemoresistance.
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Figure 1-4. The convergent CSC model. 
This model suggests that clonal evolution and the CSC model are both involved in 
tumor development forming a cellular hierarchy within a tumor and are likely to 
involve different subclones depending on the mutations/epigenetic changes occurred 
in specific cells with self-renewal capacity. (Adapted from [1])
1.1.4 Overcoming chemoresistance:  CSCs may hold the answer 
Cellular chemoresistance is responsible for up to 90% of ineffective chemotherapy. 
Recent studies suggest that CSCs are the culprit in tumor relapse, and the cause of 
modern treatment failures [63, 95-100].  It is therefore essential for future research to 
begin monitoring CSCs post-treatment and ask if the right cells are being targeted in 
cancer treatment [101].
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1.1.4.1 CSC chemoresistance
According to the traditional view of cancer, one or a small portion of cells in the tumor 
population acquires genetic variations that confer multidrug resistance [102].
Following chemotherapy, these cells possess a selective advantage for survival and 
proliferation, hence generating a relapsed tumor consisting of offspring consisting of 
drug-resistant clones. In the view of CSC concept, CSCs stand at the summit of cancer 
population that are naturally chemoresistant because of their predominant quiescence, 
enhanced capacity for DNA repair and elevated ABC-transporter expression.
Therefore, these factors enable CSCs to prevent the activation of pro-death signals that 
are otherwise invoked by the insults of cytotoxic drugs [102-107]. Thus, CSCs can 
survive both chemotherapy and radiotherapy and are responsible for cancer recurrence.
Compelling preclinical and clinical studies show that, with a few exceptions, most 
chemotherapeutic agents are efficacious in killing non-CSCs but are largely 
ineffective in eliminating CSCs [108]. Interestingly, the elimination of non-CSCs by 
chemotherapy tips the balance between non-CSCs and CSCs and allows more room 
for CSCs to expand and evolve into a more aggressive malignancy with higher self-
renewal capacity [53, 54, 109-112]. Todaro et al. revealed that the stem cell marker 
CD133+ characterized colon CSCs, and were treatment resistant due to the autocrine 
production of IL-4 that protected themselves from apoptosis [113]. Kucerova 
confirmed the same phenomenon that exposure of human medullary thyroid 
carcinoma cells to 5-Fluorouracil increased the subset of CD133+ tumor-initiating 
cells [114].
1.1.4.2 Mechanisms of CSC chemoresistance 
The resistance of CSCs to chemotherapy has been attributed to a multitude of factors, 
including increased expression of drug transporters, intracellular detoxification 
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enzymes and activation of pro-survival pathways that mediate drug efflux and 
metabolism, up-regulation of anti-apoptotic proteins, increased efficiency of DNA 
repair and alterations in cell cycle kinetics as well as microenvironmental influences 
[103, 115, 116].
1.1.4.2.1 ABC transporters 
ABC transporters are ATP-driven integral membrane proteins located on the plasma 
membrane and have been associated with CSCs in conjunction with their unique 
ability to efflux dyes or toxic agents out of the cell [112]. The over-expression of ABC 
transporters represents the principal mechanism associated with the multidrug 
resistance of CSCs. Increased drug efflux mediated by ABC transporters leads to 
decreased drug accumulation inside cancer cells [117]. In fact, the presence of ABC 
transporters has been extensively utilized in isolation of CSCs using a technique 
known as side populations assays (SP) through the efflux of Hoechst dye [118, 119].
Although the technique has fallen out of favor due to its association with other cells 
[120], the biological implications that CSCs contain efflux pumps that actively pump 
out toxic substances remain. Of the 48 known ABC transporter proteins, ABCB1 (P-
gp, MDR1), ABCG2 (BCRP1), ABCC11 (MRP8) and ABCB5 are strongly implicated 
in the CSC’s chemoresistance [115, 121]. Increasing data support that the expression 
level of ABC transporter have a close correlation with the increased drug resistance 
and poor prognosis of cancer patients [122, 123]. Therefore, it is essential for future 
research to develop strategies to overcome ABC transporter-derived chemoresistance 
if we are going to provide a cure for cancer patients.
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1.1.4.2.2 Aldehyde dehydrogenase activity 
Aldehyde dehydrogenases (ALDHs) are a group of intracellular enzymes that 
participate in the process of oxidation (detoxification) of exogenously and 
endogenously generated aldehydes [124-127]. ALDHs play important roles in control 
of differentiation pathways, self-protection of normal stem cells and confer resistance 
to alkylating agents [117, 128, 129]. ALDH has been widely used for identification, 
isolation and tracking of CSCs based on enzymatic activity of ALDH, and either the 
ALDH alone or in combination with other cell surface markers was used to identify 
CSCs in colon cancers [130-132]. In addition to being a marker for CSCs, ALDH can 
confer drug resistance to anticancer agents by metabolic inactivation, contributing to 
the cancer relapse of patients [133-136]. In addition, it is reported that the ALDH 
activity by reactive oxygen species (ROS) may protect against cell death [137]. The 
high expression of ALDH1 isoform in breast and ovarian cancer is associated with 
tumor invasion and metastases which correlates with poor clinical outcomes [138, 
139].
1.1.4.2.3 CSC Signaling pathways 
Several signaling pathways have been implicated in CSC chemoresistance in a variety 
of cancers [54, 140, 141]. In solid tumors, the Notch signaling pathways have been 
shown to be involved in tumor development, metastatic initiation and self-renewal 
processes [142, 143]. For example, McAuliffe and co-workers have demonstrated that 
over expression of Notch3 results in expansion of CSCs and increased 
chemoresistance in ovarian cancer. Inhibiting the Notch signaling pathway via J-
secretase inhibitors or siRNA knockdown of Notch 3 increases sensitivity of CSC to 
platinum therapy and the combination of cisplatin/J-secretase inhibitors was shown to 
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target both CSCs and bulk cells as evident from the G2/M cell cycle arrest and 
apoptosis [144]. Studies with glioma CSCs showed that the activation of the Sonic 
hedgehog (SHH) pathway also played important roles in CSC therapy resistance [145, 
146]. This, and other studies, underscores the necessity in exploring combination 
therapies that target both signaling pathways in combination with conventional 
chemotherapy drugs. However, challenges remain as these signaling pathways are
crucial in the homeostasis of normal stem cells as well. Therefore, targeting these 
signaling pathways may have a severe detrimental impact on the maintenance of 
normal healthy tissues [147]. Furthermore, the dysregulation of the Wnt pathway does 
not necessarily define CSCs in all tumors [148]. In addition, if a subclone of CSCs and 
its progenies developed mutations to confer resistance to the inhibition of a given 
signaling pathway, this subpopulation of CSC might evolve to overcome new 
combination therapies targeted to CSC signaling pathways [149]. Therefore, it will be 
critically important to develop new therapies that target CSC-related signaling 
pathways and avoid targeting normal stem cells in the future.
1.1.4.2.4 Carcinoma associated fibroblasts
Tumor surrounding microenvironment plays important roles in cancer evolution and 
drug transport for cancer therapy [150, 151]. Within this microenvironment, 
fibroblasts provide a key niche for the development of drug resistant tumors [103].
Carcinoma associated fibroblasts (CAFs) were found to enhance tumor formation after 
implantation of colon or breast carcinoma cells in mice [152, 153], and were 
particularly resistant to chemotherapy, such as doxorubicin [154, 155]. Recent studies 
suggest that CAFs commonly express growth factors, chemokines, and extracellular 
matrix (ECM) related proteins, including: hepatocyte growth factor (HGF), 
chemokine (C-X-C) ligand 12 (CXCL12), tenascin C and periostin [60, 103, 156-158].
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Such CAF secreted factors could influence the expression of drug transporter proteins 
in cancer cells and the development of CSCs, resulting in the increase of drug 
resistance and tumor metastases [103]. For example, HGF contributed to the 
progression of drug resistant cancers by de-differentiating colorectal non-CSCs to 
CSCs [159], and inducing CSC-associated markers, including: CD49b, CD49f, CD44 
and Sox9 [160]. In addition, CXCL12 was reported to upregulate the expansion of 
drug resistant cells by increasing activities of the CSC-like niche [156]. These studies 
show that the carcinoma fibroblast niche potentially regulates multi-drug resistance 
toward chemotherapeutics through drug efflux mechanisms [103]. However, further 
studies are still needed to validate these findings clinically.
1.1.4.3 Treatment Strategy: targeting CSCs via surface markers 
The CSC-specific or –associated cell surface marker proteins have been used 
extensively in the identification, prospective isolation and monitoring the change of 
the abundance of leukemic and solid CSCs in both preclinical and clinical settings 
[161]. These marker proteins include CD34, CD44, CD133, EpCAM, CD90 and 
others.  The expression of these cell surface marker proteins may not be a stable trait 
but rather varies in different stages of cancer progression.  Strong evidence linking 
CSC cell surface markers (the existence of CSC) and their resistance to conventional 
therapy comes from the recent clinical investigation into gliomas, which showed that 
the expression of CD133 is an independent indicator for poor patient prognosis [162].
For laboratory studies, it is essential to employ functional assays such as 
xenotransplantation combined with limiting dilution, to identify CSCs, rather than 
solely relying on the presence of a single or a combination of multiple CSC marker 
proteins.  However, for in vivo CSC-targeted treatment, the CSC surface marker 
protein provides us with one of the very few feasible options to target CSCs in patients, 
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given the technical and ethical limitations associated with xenotransplantation and 
lineage tracing. Other therapeutic strategies to target CSCs, such as targeting 
quiescence and self-renewal/maintenance pathways, as well as differentiation therapy, 
are promising but will need to overcome the challenges of specificity and potential 
toxicity before they can be translated into the clinic.
1.1.5 Aptamer and aptamer-mediated drug delivery for targeted cancer therapy 
1.1.5.1 Aptamer
Aptamers, nucleic acid-based ligands, are small single-stranded DNA or RNA 
oligonucleotides that are produced in vitro via a process known as systematic 
evolution of ligands by exponential enrichment (SELEX) [163, 164] (Fig. 1-5). 
Isolation of aptamers specific for the target of interest can be achieved via SELEX 
from a large pool (> 1 x 1014) of single-stranded oligonucleotides with random 
sequences [165, 166]. After the incubation of the random aptamer pool with the target 
followed by the removal of non-binding aptamers, the bound aptamer species are 
recovered. These recovered nucleic acid sequences are amplified with PCR (in the 
case of DNA aptamer) or RT-PCR (in the case of RNA aptamers). An enriched pool 
of potential binders generated from PCR amplification is used in the subsequent 
selection rounds (typically 6-10 rounds).   At the last round of SELEX, the resulting 
highly enriched pool of aptamers are cloned or subjected to next generation 
sequencing followed by further characterization and engineering of individual cloned 
aptamers (Fig. 1-5). In addition to selection against a purified or highly enriched target 
molecule, one can perform SELEX using live cells and even in a whole mouse to 
isolate cell- or organ-specific aptamers against a specific type of cells or an 
organ/tissue [167, 168]. Therefore, the power of SELEX enables one to generate 
20
 
specific aptamers against an inorganic or organic molecule, a protein, a cell and even 
an organ of interest.   
Figure 1-5. Isolation of aptamer and aptamer-target cell interaction. 
(a) Schematic illustration of RNA aptamer generation by SELEX. Negative control 
cells or proteins are incubated with a large pool (> 1 x 1014) of single-stranded RNA 
oligonucleotides with random sequences, followed by removal of bound RNAs. The 
unbound sequences are then subjected to positive selection by incubating with specific 
targets of cells or proteins. The bound aptamers are eluted and amplified by RT-PCR, 
followed by new SELEX rounds. After the last round of selection (typically 6-10 
round), the remaining RNA aptamers are converted to DNA and subjected to next
generation sequencing or conventional cloning followed by characterization and 
further engineering. (b) Schematic diagram depicting the aptamer-target interactions. 
Aptamers bind to targets at the cell surface through shape complementarity 
involving non-covalent bonds. (Adapted from [169])
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Aptamers fold into tertiary conformations and bind to their targets through shape 
complementarity at the aptamer-target interface [170]. Besides binding to small 
organic and inorganic molecules, aptamers have the unique ability to recognize and 
bind to large targets, such as proteins, whole cells or even organs [171-174]. An 
aptamer binding to a protein can modulate protein functions by interfering with protein 
interaction with natural partners. Similar to antibodies, aptamers gain entrance to 
target cells via receptor-mediated endocytosis upon binding to cell surface ligands 
[175, 176]. In addition, the in vitro generation of aptamers via SELEX confers a low 
cost advantage over the long and arduous development process of antibodies [175, 
177-179]. One important advantage of aptamers over antibodies is that, once selected, 
they can be chemically synthesized instead of being produced in animals or cultured 
mammalian cells, thus simplifying the production of therapeutic grade materials, 
which represents a key advantage for commercial development [180, 181].
Importantly, aptamers can penetrate into tumor cores much more efficiently than 
antibodies due to their ~20-25-fold smaller sizes compared with full sized monoclonal 
antibodies [182-184]. Given that the nucleic acid aptamers function in vivo through 
the blood plasma, several limitations of aptamers should be considered. Being 
polynucleotides, nucleic acid aptamers are naturally susceptible to enzymes 
degradation by exo- and/or endo-nucleases, leading to a reduced in vivo circulatory 
half-life. This drawback can be alleviated by introducing backbone or side chain 
chemical modifications to aptamers, incorporating unnatural nucleotide bases (locked 
and unlocked nucleic acids) and capping the aptamer ends, thus minimizing the 
susceptibility to endonuclease and exonuclease attack [185-187]. Short blood 
residence time is another challenge with in vivo aptamer applications, which is due to 
fast removal of aptamer from the circulation by renal filtration as most aptamers have 
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a size smaller than the renal filtration threshold of 40 kDa [187]. To achieve desired 
serum half-life, aptamers can be engineered by conjugation with a terminal 
polyethylene glycol (PEG), although this may compromise the extent of tumor 
penetration [186, 188]. It is worth noting that post-SELEX modifications following 
the selection of aptamers may alter the 3-D structure of the aptamers, leading to the 
loss or altered binding affinity and specificity.  Such risks can be prevented by using 
random aptamer pools containing modified nucleotides during the SELEX selection 
[187, 188]. In addition, the ability of aptamers to interact with cells may decrease due 
to repulsion of nucleic acids by negatively-charged cell membranes [173]. This can be 
refuted by increasing the binding affinity and specificity of aptamers toward their cell 
surface receptors to trigger receptor-mediated endocytosis [185].
1.1.5.2 Aptamer and aptamer-guided active targeting system 
The ultimate aim of anticancer research is to improve the rates of treatment response 
and overall survival in patients with cancer. To achieve this goal, a tumor targeting 
system that delivers therapeutic agents selectively to cancer cells is necessary [189].
Passive targeting based on EPR utilizes the fundamental differences in the 
organization of vasculatures between normal tissues and a tumor to achieve 
preferential accumulation of nano-sized anti-tumor agents in tumors [66]. Based on 
the EPR effect, a passive tumor-targeting strategy has reduced adverse effects over the 
conventional free drug approach [190]. However, there has been heated debate on the 
existence of EPR in patients and whether EPR plays a role in enhanced delivery of 
nano therapeutics in at least some types of tumors [191, 192].  Moreover, the clinical 
efficacy of nano-sized drugs guided by a passive targeting system is still far from 
optimal due to poor tumor penetration and drug uptake by cancer cells [190, 193]. To 
further improve treatment efficacy, an “active targeting” approach has attracted huge 
23
 
attention. The function of active targeting is to guide therapeutic agents with the aid 
of targeting ligands to tumor cells and promote their subsequent cellular entry through 
receptor-mediated endocytosis [194-196]. Development of novel molecular probes 
that bind to specific tumor biomarkers as actively guiding devices represents one of 
the major advances in the next generation of tumor therapeutics. 
The goal of surface modification of drug carriers by tumor specific recognition 
molecules, such as antibodies, peptides and aptamers, is to enhance specific drug 
accumulation, internalization and retention in tumors via specific ligand-mediated 
interactions thus increasing the therapeutic index [197, 198]. Targeting specificity and 
drug delivery capacity are two important aspects that need to be considered in the 
development of an active targeting system [194]. Antibodies are the most commonly 
used target ligands due to their high specificity and wide availability [175, 176].
Recently, aptamers have emerged as an attractive alternative to antibodies as a ligand 
for active targeting of tumors (Fig. 1-6). Effective delivery of drugs to tumors can be 
achieved via active targeting utilizing tumor-specific aptamers binding to their targets 
present on the surface of tumor cells.  For instance, epithelial cell adhesion molecule 
(EpCAM) is expressed at low levels in normal epithelium, but is overexpressed (up to 
1000-fold) in various solid tumors, including colon, hepatic and breast carcinomas,
which relates to poor prognosis [173, 199].
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Figure 1-6. General scheme of drug delivery to tumors. 
(a) Schematic illustration of drug delivery via passive targeting. Abnormal tumor 
microenvironment and EPR effect result in passive drug accumulation and retention 
in tumors. This passive tumor-targeting strategy exhibits limitations of poor cancer 
cell targeting and inadequate drug uptake. (b) Schematic illustration of aptamer-
guided active targeting of tumor. Aptamers undergo endocytosis after binding to cell 
surface targets, along with aptamer-conjugated therapeutic agents or drug-
encapsulated nanoparticles. Following the entrance and escape from endosomes 
and/or lysosomes, the released therapeutic agents or small RNAs engage their 
cytoplasmic or nucleic targets to eliminate cancer cells. (Adapted from [169])
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Aptamer-guided active targeting enables the increased delivery of therapeutic agents 
to tumors as well as a reduction in toxicity and side effects by minimizing the exposure 
of normal tissues to the therapeutic agent.  As an active targeting ligand, antibodies 
suffer from immunogenicity as even humanized antibodies may elicit immune 
responses in patients [181, 200, 201]. In contrast, being nucleic acids, aptamers are 
generally non-immunogenic or low-immunogenic [202, 203]. The chemical synthesis 
of aptamers confers additional advantages to aptamers, such as low batch-to-batch 
variation, and they are for large scale manufacturing with minimal risk of 
contamination by microorganisms and endotoxins [200, 204, 205].  Therefore, 
aptamers are being intensively investigated as specific targeting moieties for cancer 
therapy. Aptamer-mediated active targeting for cancer therapy can be categorized into 
four groups: free aptamer as molecularly targeted agents, aptamer–drug conjugates, 
aptamer–nanoparticle-drug delivery system and aptamer-mediated cancer nucleic acid 
therapy (Fig. 1-7).      
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Figure 1-7. Schematic illustration of aptamer-mediated cancer therapy.  
Four approaches are presented: free aptamer as chemotherapeutic agents, aptamer–
drug conjugates, aptamer–nanoparticle-drug delivery system and aptamer-guided 
cancer gene therapy. After specific binding of aptamers to their cell surface target, 
aptamer-conjugated therapeutic agents (including exogenous therapeutic nucleotides)
or drug-encapsulated nanoparticles are internalised into cancer cells via receptor-
mediated endocytosis. Subsequent escape from endosomes and/or lysosomes enables 
the released therapeutic agents to eradicate cancer cell. (Adapted from [169])
1.1.5.3 Free Aptamer as molecularly targeted therapeutics
1.1.5.3.1 DNA aptamer targeting vimentin for tumor therapy
To study the anti-tumor activity of a DNA aptamer, Zamay and colleagues selected a 
DNA aptamer NAS-24 (80-nt in length) that targets vimentin and investigated its 
efficacy in inducing apoptosis of mouse ascites adenocarcinoma cells in vivo [206].
They utilized arabinogalactan (AG), a natural polysaccharide with low toxicity (LD50 >
5g/kg) and high biocompatibility, to enhance in vivo delivery of anti-vimentin 
aptamers [207, 208]. In vivo anti-tumor efficacy of AG-NAS-24 self-forming complex 
was evaluated using an Ehrlich ascites adenocarcinoma mouse model in which one 
million adenocarcinoma cells were transplanted into the abdominal cavity of 
imprinting control region male mice. Starting from day 4 post cell inoculation, mice 
were treated with AG-NAS-24 complex (1.6 Ɋg/kg), free AG or aptamer daily via 
intraperitoneal injection for 5 days. On day nine, following the 5-day treatment, there 
was a 5-fold higher suppression of carcinoma growth in mice treated with AG-NAS-
24 compared with those treated with free aptamer, free AG or saline. Aptamer 
delivered by AG caused ~2-fold more apoptosis in ascites tumor cells than that treated 
by saline or AG alone [206]. After intracellular delivery of AG-NAS-24 complex, 
aptamers may promote vimentin degradation which causes morphological changes 
and apoptosis in cancer cells with higher vimentin expression [206]. This study 
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illustrates that intracellular delivery of NAS-24 aptamer could target vimentin and 
initiate signaling events leading to cellular apoptosis. 
1.1.5.3.2 Aptamer-mediated tumor cell apoptosis and limitation of tumor 
progression
Myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM) 
can enhance tumor angiogenesis, invasion, and limit the immunotherapeutic function 
of T-cells, resulting in further tumor aggression and metastasis [209-211]. In order to 
selectively target MDSCs and TAM activities for inhibiting the tumor progression, 
Roth et al. generated an RNA aptamer, cl.42 with 79 nucleotides, that specifically 
binds to IL-4 receptor-a (IL4Ra) with a Kd of 14 nM, which is a critical molecule for 
MDSC function [209]. In the IL4Ra+/+ or IL4Ra-/- 4T1 breast cancer-bearing mice, 
cl.42 aptamer or control aptamer (16 pmol/L/g) were administrated intravenously 3 
times a week.  In addition to a reduction of MDSCs and TAM expression in vivo,
tumor progression was significantly inhibited in the IL4Ra+/+ tumor-bearing mice 
treated with the cl.42 aptamer.  In contrast, no discernable anti-tumor effect was 
observed in mice bearing IL4Ra-/- 4T1 tumors or those treated with control aptamer. 
To better understand the effect of the anti–IL4Ra aptamer on MDSCs, Roth  et al
isolated immortalized mesenchymal stem cells (MSC2) and MDSCs from IL4Ra+/+
tumor-bearing mice.  Cell viability of MDSCs was analysed after treatment with cl.42 
aptamer or control aptamer for 1-4 days. Compared to untreated or control-aptamer 
treated groups, the cl.42 aptamer treatment resulted in a 2-fold decrease in viability on 
day 1, and a 3-3-fold higher increase in apoptosis in MSC2 cells. More importantly, 
only the IL4Ra–specific aptamer (150 nM), but not the control irrelevant aptamer, 
triggered MDSC apoptosis and drastically reduced phosphoSTAT6 (pSTAT6) 
signaling which is known to play a critical role in MDSC activation. This study 
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suggests that aptamer-triggered apoptosis in MDSCs via blocking of the IL4Ra-
STAT6 signaling pathway could be a promising strategy to arrest immune escape in 
cancer treatment. Recent studies which utilize free aptamers as molecularly targeted 
agents are summarized in Table 1-1.
Table 1-1 Application of free aptamers as cancer-targeted therapeutics.
(Adapted from [169])
Aptamer Target Cancer References
DNA aptamer DNA-binding 
proteins
Ovarian cancer 
Breast cancer
Mern et al. 2010a [212];
Mern et al. 2010b [212]
DNA aptamer MCF-10TA1 
cell
Breast cancer Tan  et al. 2011 [213]
DNA aptamer VEGF165 
protein
Human hepatocellular 
carcinoma 
Yung et al. 2013[214]
DNA aptamer AGE product Melanoma Yamagishi et al. 2014 
[215]
RNA aptamer CEA protein Colorectal cancer Lee et al.  2012 [216]
RNA aptamer MDSC and 
TAM
Multiple carcinomas 
(colon, mammary, 
fibrosarcoma, melanoma)
Serafini et al. 2012 [209]
AGE, advanced glycation end; CEA, carcinoembryonic antigen; MDSC, myeloid-derived suppressor 
cells; TAM, tumor-associated macrophage; VEGF, vascular endothelial growth factor.
1.1.5.4 Aptamer–drug delivery system 
Conventional therapeutic drugs often lead to severe adverse effects. Conjugating 
chemotherapeutic drugs to tumor-targeting aptamers can enhance the delivery of 
anticancer drugs to tumor cells while minimising the exposure of non-target sites to 
the chemotherapy agents [217]. Doxorubicin (DOX) is one of the most potent 
anticancer drugs ever developed and has been used for the treatment of a range of 
cancers, including acute lymphoblastic leukemia and malignant lymphomas, breast, 
ovarian, prostate, and bronchogenic carcinomas [218]. DOX can intercalate into 
genomic DNA, resulting in the disruption of DNA replication and apoptotic cell death 
[219]. However, its efficacy is impeded by dose-limiting cardiotoxicity, inspiring 
intense effort in transforming this free drug into a new and targeted DOX-delivery 
system [220]. Aptamers are known to form tertiary conformations with short double 
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stranded regions through intra-molecular base pairing [221], which are available for 
the intercalation of DOX to form a physical complex, a process requiring no 
modification of the drug or the aptamer. In order to investigate the anticancer efficacy 
of aptamer–DOX conjugates, Tan’s group developed two DNA aptamers sgc8c and 
TLS11a-GC that specifically bind to CCRF-CEM cells (T-cell acute lymphoblastic 
leukemia, T-cell ALL) and LH86 cells (a human hepatocellular carcinoma cell line), 
respectively [176, 222].  After intercalating DOX to the TLS11a-GC aptamer, they 
evaluated whether the aptamer-DOX conjugate could specifically kill their targets 
with a low toxicity towards non-target cells. Cell viability tests demonstrated that the 
aptamer–DOX conjugate exhibited high therapeutic potency similar to free DOX, but 
prevented the nonspecific uptake of membrane-permeable DOX to non-targeted cells. 
After the establishment of an in vivo liver cancer model, the tumor bearing NOD Cg-
Prkdc (SCID) IL2 mice were treated with DOX and TLS11a-GC-DOX complex (2 
mg/kg) via a tail vein injection on days 1, 2, 3, 4, 5, 9, 10 and killed on day 11. The 
TLS11a-GC-DOX complex had a more efficient anti-tumor effect (2-fold more 
decrease volume) compared to free DOX, which indicated that TLS11a-GC-DOX 
conjugates increased the local DOX concentration in the tumors with the aid of a 
targeting aptamer. This aptamer-drug intercalation approach thus represents a 
promising strategy for targeted drug delivery to cancer cells. Recent examples of 
developing aptamer-drug conjugates as targeted therapeutics for cancer are 
summarized in Table 1-2.
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Table 1-2 Application of aptamer-drug conjugates as cancer-targeted 
therapeutics. (Adapted from [169])
Aptamer Target Drug Cancer Research Group
DNA aptamer CCRF-CEM cell DOX T-cell ALL Tan et al. 2009 [223]
DNA aptamer LH86 cell DOX Human hepatocellular 
carcinoma 
Tan et al. 2012 [176]
DNA aptamer MUC1 protein DOX Lung cancer and 
breast cancer 
Yang et al. 2012 [224]
DNA aptamer HER2 protein DOX Breast cancer Yang et al. 2012 [225]
RNA aptamer EpCAM protein DOX Retinoblastoma Krishnakumar et al.
2012 [226]
RNA aptamer EGFR protein GEM Pancreatic cancer White et al. 2012 [227]
ALL: acute lymphoblastic leukemia; CCRF-CEM, T-acute lymphoblastic leukemia cell line; GEM, 
gemcitabine; LH86, human hepatocellular carcinoma cell line.   
1.1.5.5 Aptamer–nanoparticle-drug delivery system
The past decade has witnessed promising advances in the synthesis and 
characterization of various nano-materials, which have been optimized for anti-cancer 
drug delivery vehicles [228]. The hybrid aptamer–nanoparticle system significantly 
enhanced cancer-specific cytotoxicity both in vitro and in vivo [229, 230] (Fig. 1-7). 
Aptamer-guided nano therapeutics aid in circumventing pathophysiology barriers to 
enhance both the uptake and retention of drugs by tumor cells, leading to improved 
therapeutic efficacy [194, 231]. There are four major merits when nanoparticles are 
surface functionalized by aptamers for targeted cancer drug delivery [232]: 1) the 
specific recognition of aptamers to targets enables a targeted detection or binding to 
cancer cells; 2) the straightforward synthesis and chemical modification of aptamers 
can boost the translation of aptamers into clinical practice; 3) the biocompatible 
nanoparticle-loading ability facilitates the intensity of analytical signal, leading to 
effective cell recognition, drug delivery and anticancer treatment, and 4) aptamers 
linking to the surface of nanoparticles facilitates internalization and cellular uptake of 
drugs with the aid of aptamer-guided active targeting. Aptamers have been extensively 
used to functionalize nanomaterials for targeted drug delivery, which is briefly 
presented below.
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1.1.5.5.1 Liposomes
Liposomes have been successfully utilized as a very versatile drug delivery carrier. 
Various sizes and formulation methods of liposomes contribute to a wide range of 
options for drug delivery in tumor treatment [233, 234]. The liposome surface can 
easily be decorated with PEG, which can prolong the in vivo half-life in systemic 
circulation, resulting in the accumulation of chemotherapeutic agents at tumor sites 
[235, 236]. In addition, the outer lipid bilayer allows further incorporation of targeting 
molecules, such as antibodies and aptamers capable of delivering drugs by active 
and/or passive targeting [234, 237, 238].
Lu et al. developed AS1411 aptamer-functionalized liposomes encapsulating DOX 
(Apt-DOX-Lip) for targeted treatment of breast cancer [239]. Enhancement of cell 
internalization and cytotoxicity afforded by Apt-DOX-Lip was observed in MCF-7
cells in vitro compared to controls (P < 0.01). In an in vivo model, nude mice bearing 
MCF-7 tumors were treated with Apt-DOX-Lip or Ctrl- DOX -Lip (25 μg DOX 
equivalent per tumor via intratumoral injection) every 4 days until day 24. Apt-Dox-
Lip significantly inhibited MCF-7 tumor growth compared with the Ctrl-Dox-Lip 
group (P = 0.004). Intratumoral treatment of mice with Apt-Dox-Lip caused an earlier 
onset of tumor inhibition on day 8 as compared with that of day 16 in Ctrl-Dox-Lip 
treated mice. Apt-DOX-Lip exhibited superior tumor penetration compared with the 
control treatment in MCF-7 xenograft models (~1000 μm vs. ~ 500 μm), contributing 
to the enhancement of anti-tumor efficacy. This study concluded that aptamer-
functionalized drug-loaded liposomes could be a potential strategy for targeted drug 
delivery in anticancer treatment.
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1.1.5.5.2 PLGA-PEG nanoparticles
Biodegradable lipid-PLGA-PEG nanoparticles take advantage of polymeric 
nanoparticles and have emerged as a robust drug delivery platform.  They are 
composed of PLGA as a hydrophobic core for encapsulating drugs and a PEG shell 
which can prolong circulation half-life in vivo and link targeting ligands [240, 241].
PLGA-PEG nanoparticles conjugated with aptamers function via both active and 
passive targeting for anticancer drug delivery [26].
Farokhzad and co-workers encapsulated docetaxel (Dtxl) with PLGA-PEG 
nanoparticles that were functionalized with a 2-fluoropyrimidine modified RNA 
aptamer (A10) that binds to the prostate-specific membrane antigen (PSMA) [242, 
243]. These Dtxl-encapsulated bioconjugates (Dtxl-NP-Apt) effectively targeted 
PSMA-expressing LNCaP prostate cancer cells and were taken up by these cells 
leading to significant enhancement of cellular toxicity in vitro compared with that of 
control nanoparticles lacking PSMA aptamers (P < 0.004) and control cells that do not 
express PSMA proteins. After the establishment of LNCaP xenograft model in 
BALB/c nude mice, they treated the mice with Dtxl-NP-Apt and other controls at a 
reported tolerated dose of 40 mg/kg Dtxl [244]. Surprisingly, even a single 
intratumoral administration of Dtxl-NP-Apt could achieve  significant efficacy in 
tumor reduction (a 6.5-fold higher reduction in tumor volume than any of control 
treatment groups of saline, NP, or Dtxl), better survival time (109 days vs. 73 days in 
Dtxl-NP group) and decreased toxicity as compared with non-targeted NPs and 
controls (Fig. 4B). This study demonstrates the bioconjugation between PLGA-PEG 
nanoparticle and aptamer constitutes a promising strategy for future targeted cancer 
therapy.
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AS1411, a 26-nucleotide DNA aptamer which specifically binds to the external 
domain of nucleolin, has been extensively used for glioma-targeted therapy [245], as 
nucleolin is a nuclear matrix protein over-expressed on the cell surface of several types 
of cancers, including lung cancer, glioblastoma (C6 cells) and pancreatic cancer. Chen 
et al. developed AS1411 aptamer functionalized PLGA-PEG nanoparticles 
encapsulated with Paclitaxel (PTX) (Apt-PTX-NPs) and evaluated the aptamer-guided 
anti-glioma efficacy of PTX [246]. Following the same dose administration, this 
AS1411-PTX-NPs showed a 2.3-fold and 5.4-fold increase in circulation half-life and 
AUC compared to free Taxol, respectively. Mice or rats bearing glioma xenografts 
were intravenously administered with Taxol, PTX-NPs, Apt-PTX-NPs (equivalent to 
PTX of 3 mg/kg) every 2 days for seven consecutive injections. Until the 20th day on 
which the animals were humanely killed, Apt-PTX-NPs treated mice exhibited a 1.7-
fold higher tumor inhibition than those treated with PTX-NP, while the prolonged 
survival of tumor-bearing rats received Apt-PTX-NPs was observed compared with 
those treated with PTX-NP (P < 0.05) and Taxol (P < 0.01).   
1.1.5.5.3 Superparamagnetic iron oxide NPs
One of the most promising and biocompatible magnetic nanoparticles is the 
superparamagnetic iron oxide nanoparticles (SPIONs), which possess several positive 
characteristics that are highly suitable for in vivo diagnostic and therapeutic 
applications. They can be easily degraded in humans, leading to a short body residence 
and lower toxicity in vivo [247]. The surface of SPIONs is also available for 
modification with polymers, metal elements and various targeting ligands for 
applications in nanomedicine [247, 248].
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Farokhzad’s group formulated a multifunctional bioconjugate composed of A10 RNA 
aptamer modified SPIONs and DOX (TCL-SPION–Apt) for detection and therapeutic 
delivery of chemotherapeutic agents to prostate cancer cells [249]. The cellular uptake 
of TCL-SPION–Apt was observed in LNCaP cells as early as 3 h after dosing followed 
by a time-dependent increase, while there was no obvious intracellular uptake of TCL-
SPION–Apt in PC3 prostate cancer cells that do not express PMSA, nor with non-
targeted TCL-SPIONs. The TCL-SPION–Apt bioconjugates selectively delivered 
DOX to their targeted cells without significant loss in cytotoxicity. In addition, 
Abnous’s group developed a Epirubicin (Epi)-encapsulated versatile aptamer–SPION 
bioconjugate (Epi–Apt–SPION) for cancer imaging and therapy in vitro and in vivo
[250]. Using an in vitro cytotoxic assay and flow cytometric analysis, the Epi–Apt–
SPION complex was found to be capable of specifically and effectively delivering Epi 
to C26 cells (colon carcinoma cells) but not to non-targeted CHO-K1 cells (Chinese 
hamster ovary cells). The Epi–Apt–SPION complex was able to accumulate at the 
tumor and displayed a high MRI signal one hour post-injection. Furthermore, 
enrichment of Epi–Apt–SPION at the tumor resulted in more tumor volume reduction 
(~2-fold and ~3.3-fold, respectively) compared with that of free Epi- and saline-treated 
groups.   
In addition, aptamers can also be conjugated with other nanostructures for targeted 
and high-payload cancer therapy, such as single-walled carbon nanotubes, bovine 
serum albumin-based NPs, dendrimers and mesoporous silica nanoparticles [251-255]
(Table 1-3). However, more studies on potential toxicity and in vivo fate of the nano-
carriers are needed before successful translation of aptamer-nano-drugs from bench to 
bedside.
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Table 1-3 Application of aptamer-functionalised drug-encapsulated NPs as 
cancer-targeted therapeutics. (Adapted from [169])
Aptamer Target Payload Nanoparticle / 
carrier
Cancer Research Group
RNA
aptamer
PSMA Dtxl, 
DOX, 
miRNA, 
CUR, 
GEM, 
TMPyP4, 
PTX
PLA-PEG-COOH 
NPs, 
SPION, 
Atelocollagen 
Liposomes, 
PLGA NPs, 
MSNs, 
Carbon 
nanotubes, 
AuNPs, 
PLGA-PEG NPs
Prostate 
cancer, 
Breast cancer, 
Liver cancer, 
Murine 
cancer,
C6 glioma
Farokhzad et al. 2004, 
2006, 2008, 2012 [242, 
243, 249, 256]
Wang et al. 2014 [257]
Lu et al. 2013 [239]
Kumar et al. 2012, 2013 
[258-260]
Cai et al. 2014 [261]
Zhang et al. 2014 [262]
Qu et al. 2012 [254]
Huang et al. 2014 [263]
Chen et al. 2011 [246]
DNA
aptamer
MUC1 PTX, 
Epi, 
DOX
PLGA NPs, 
SPION, 
MSNs
Breast cancer, 
Colon cancer
Yang et al. 2011 [264]
Abnous et al. 2013 [250]
Santos-Oliveira et al. 
2013 [255]
DNA
aptamer 
CCRF-
CEM
DOX Nanoassembly 
system, DNA 
nanotrains
T-cell ALL Tan et al. 2013a [265];
Tan et al. 2013b [266]
ALL: acute lymphoblastic leukemia; AuMP, mesoporous silica-encapsulated Au nanorod; CUR, 
curcumin; Dtxl, docetaxel; DOX, doxorubicin; EGFR, epidermal growth factor receptor; Epi, 
Epirubicin; GEM, gemcitabine; MSN, Mesoporous silica nanoparticle; PSMA, prostate-specific 
membrane antigen; PTX, paclitaxel; SPION, super paramagnetic iron oxide nanoparticle. 
1.1.5.6 Aptamer-mediated nucleic acid therapy for cancer therapy
1.1.5.6.1 Aptamer-guided nucleic acid therapy
In contrast to antibodies that can be easily inactivated due to the increased acidity in 
cellular organelles, aptamers generated with chemical modifications maintain stability 
after endocytosis [209, 212, 214, 216, 267, 268]. Aptamers have been exploited as 
guiding moieties for both drug delivery and nucleic acid transport vehicles such as 
small interfering RNA (siRNA), micro RNA (miRNA) and short hairpin RNA 
(shRNA) [185, 269-271] (Fig. 1-8). Aptamers can mediate nucleic acid therapy by 
increasing nucleic acid targeting efficacy for oncogenes and suppressing 
overexpressed signaling or regulatory nucleic acids in cancer [242, 272, 273]. Intense 
effort has been devoted to exploring aptamers as an effective nucleic acid therapy 
modality for cancer therapeutics.    
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Figure 1-8. Schematic illustration of aptamer-guided cancer nucleic acid therapy.
Exogenous therapeutic small RNAs (siRNA, miRNA and anti-miRNA) can be directly 
conjugated with aptamers or encapsulated within nanoparticles functionalized with an 
aptamer. As targeted-delivery modalities, aptamers bind to cell surface targets on 
cancer cells, followed by internalization via receptor-mediated endocytosis. Through 
unknown mechanisms, small RNAs escape endosomes and engage cytoplasmic 
RNAi/miRNA protein machinery. The mature siRNA/shRNA/miRNA interact with 
their cytoplasmic or nucleic target sequences, leading to mRNA degradation, 
translation promotion or repression or modulation of gene expression. (Adapted from 
[169])
1.1.5.6.2 Aptamer-siRNA chimera for targeted cancer nucleic acid therapy
Small interfering RNA (siRNA) can be integrated into RNA-induced silencing 
complex (RISC), leading to the degradation of target mRNA by RNA interference 
(RNAi) [274]. Despite the potential of efficiently inhibiting nucleic acid expression of 
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unlimited targets, the insufficient dose delivery of siRNA to target tissues in vivo 
hampers the translation of this technology from bench to bedside. Generating a 
chimera by linking siRNA with an aptamer, aptamer-guided siRNA delivery via 
receptor-mediated endocytosis serves as a promising approach for cancer-targeted 
RNAi therapy. After transportation to the cytoplasm by an elucidated route or 
mechanism, the therapeutic siRNA can be recognized and processed by Dicer to 
produce the mature siRNA followed by the target mRNA degradation [275].
In order to clarify the importance of memory T cells in mediating protective immunity 
against cancer, Berezhnoy et al. used a siRNA to downregulate intracellular mediators 
of CD8+ T cell effector differentiation [276]. To reduce the undesirable 
immunosuppressive effects that could result from the downregulation of siRNA in 
inactivated cells, they conjugated the siRNA targeting the mTORC1 component raptor 
to an oligonucleotide aptamer specific for 4-1BB (Kd = ~40 nM), a co-stimulatory 
molecule that is expressed on CD8+ T cells. To build up a B16/F10 melanoma tumor 
models, C57Bl/6 mice were firstly immunized with 106 irradiated B16 melanoma cells 
(GVAX), and one day later mice were treated with aptamer-siRNA conjugates (0.25 
nmol/mouse) administered i.v. RUZLWKȝJRIUDSDP\FLQLQMHFWHGLSWKUHHWLPHV
daily. On day 50, the mice were xenotransplanted s.c. with 106 B16/F10 tumor cells. 
In this study, systemic administration of the 4-1BB aptamer-raptor siRNA to mice 
downregulated mTOR complex 1 (mTORC1) activity in CD8+ T cells, leading to the 
enhancement of antigen-activated CD8+ T cell function and enhanced vaccine-induced 
protective immunity in tumor-bearing mice. Mice treated only with rapamycin, but not 
with 4-1BB aptamer-conjugated siRNA, failed to reject a subsequent tumor challenge. 
This study indicated that aptamer-targeted siRNA downregulation of mTORC1 in 
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CD8+ T cells can enhance their differentiation into memory T cells and promote 
antitumor immunity more effectively than the pharmacologic inhibitor rapamycin. In 
addition, Lai et al. utilised two nucleolin aptamer-siRNA chimeras (aptNCL-
SLUGsiR and aptNCL-NRP1siR) to evaluate the synergistic effect in blocking key 
signaling pathways involved in tumor invasion and angiogenesis [277]. After 
establishment of an in vivo lung cancer model in NOD-SCID mice by subcutaneously 
inoculating 2 × 106 CL1-5 cells, Lai and co-workers administered single chimera (2 
mM of aptNCL-ControlsiR, aptNCL-SLUGsiR, or aptNCL-NRP1siR) and combined 
chimera (1 mM of each chimera-aptNCL-SLUGsiR and aptNCLNRP1siR) in 50 μL 
PBS intratumorly three times per week until day 42. The tumor growth rate in the 
chimera-treated groups (aptNCL-SLUGsiR, aptNCL-NRP1siR, and combined 
treatment) was found to be 3-fold (with single chimera treatment) to 4-fold (with 
combined chimera treatment) lower than the group treated with saline. Furthermore, 
the combined-chimera treatment synergistically suppressed tumor invasion (1.2-fold 
suppression vs. control chimera) even at half-dose administration. These data indicate 
that aptamer-siRNA chimera holds promise for targeted cancer nucleic acid therapy. 
1.1.5.6.3 Aptamer-miRNA active targeting system 
MicroRNA (miRNA), a small non-coding RNA with 20-22 nucleotides, regulates 
transcriptional and post-transcriptional nucleic acid expression and modulates normal 
cell functions such as proliferation, apoptosis and tumor destruction [278, 279]. The 
manipulation of miRNA function constitutes a promising approach for anti-cancer 
therapy [280, 281]. However, interaction with target nucleic acids requires the specific 
delivery of miRNAs to their targets, minimizing side effects [280]. After conjugation 
of a miRNA with an aptamer, the miRNA can be specifically delivered to their targets 
expressing proteins recognized by the aptamer. Following internalization into cancer 
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cells via ATP-dependent endocytosis, miRNA is processed by Dicer followed by the 
loading of such miRNA duplexes into an Argonaut protein in the miRNA-induced 
silencing complex (Fig. 5). Esposito et al engineered a multifunctional aptamer-
miRNA conjugate by linking a tumor suppressor let-7g miRNA to the GL21.T 
aptamer specifically recognizing the oncogenic receptor tyrosine kinase Axl [282].
The results indicated that the functional let-7g miRNA was delivered by this conjugate 
to Axl-expressing A549 lung cancer cells and let-7g target nucleic acids could be 
effectively silenced both in vitro and in vivo (1.6 nmol/mouse, three injections a week 
for 3 weeks), contributing to the prevention of tumor cell proliferation and migration 
in vitro and the tumor growth inhibition in a lung adenocarcinoma model.    
1.1.5.6.4 Aptamer-mediated shRNA delivery for cancer therapy 
As an alternative approach to RNAi, shRNA can be produced by various DNA 
constructs such as DNA plasmid, linear template, or packaged viral vectors [283, 284].
Being produced in host cells, shRNA elicits a more durable gene silencing compared 
to siRNA that are normally degraded around 48 h in vivo [285]. However, the 
requirement of using gene transfection or viral vectors hinders shRNA application in 
the clinic. To explore vector-free RNAi using shRNA, Ni et al explored a chimera 
linking RNA A10-3 aptamer (56 nucleotides) targeting PSMA to a shRNA (50 
nucleotides) against DNA-activated protein kinase catalytic polypeptide (DNAPK), a 
target protein for radio-sensitization [271]. After incubating LNCaP cells with 
aptamer-shRNA chimera (400 nM) for 2 days, the chimera significantly reduced levels 
of BRCA2, DNAPK and ATM mRNA.  The in vivo efficacy of such treatment was 
evaluated in a xenograft LNCaP mouse model in which the mice were treated with 
radiation plus two intratumoral injections of 200 pmol A10-3 aptamer-shRNA. The 
time for reaching quadruple tumor volume was dramatically extended from one week 
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(for mice treated with control) to ~10 weeks. This aptamer-guided delivery of shRNA 
resulted in an effective knockdown of DNAPK and significantly improved tumor 
response to ionizing radiation.   
1.1.5.7 Aptamer-mediated co-delivery system 
Compared to a single agent delivery system, co-delivery of two or more therapeutic 
agents, such as chemotherapeutic agents and small RNAs, represents a more powerful 
approach to cancer treatment [286-289] (Fig. 1-9).  Such a combinatorial treatment 
strategy may 1) provide synergistic or addictive effects beyond one single drug therapy; 
2) circumvent multiple drug resistance of cancer cells by targeted delivery of 
anticancer agents intracellularly; and 3) afford lower doses of individual drugs thus 
minimising systematic side effects of individual agents. A physical conjugate of DOX 
and A10 RNA aptamer was linked to Dtxl-encapsulated PLGA-PEG NPs to generate 
a targeted co-delivery of both hydrophobic and hydrophilic drugs to tumors [229].
Both Dtxl and DOX were selectively delivered by LNCaP cells with high PSMA 
expression while limited DOX was internalized to the control PSMA-negative PC3 
cells. In addition, anti-proliferation assays indicated that relative cell viability of 
LNCaP cells treated by NP (Dtxl)–Apt (DOX) was 54%, compared with that of 58 %, 
86%, and 100%, respectively, for cells treated with NP (Dtxl)–Apt, NP–Apt (DOX), 
and NP–Apt. These results suggest that the co-delivery of DOX-loaded aptamer with 
Dtxl-encapsulated polymeric NPs exhibit more efficient killing of target cancer cells 
compared with the same amount of individual drugs. 
The combination of chemotherapeutic agents with small RNAs, i.e., siRNA, miRNA, 
anti-miRNA and shRNAs, has emerged as a potential strategy for achieving 
synergistic efficacies for targeted cancer therapy [290]. For example, a co-drug 
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delivery system that combines PTX and the chimera comprising of MUC1 aptamer 
and let-7i miRNA specifically delivered let-7i miRNA and PTX to target ovarian 
cancer cells for circumventing PTX-induced chemoresistance [291]. Furthermore, 
Kim and colleagues synthesized PSMA aptamer-conjugated polyplexes (APs) that 
selectively targeted co-delivered shRNA against the anti-apoptotic gene Bcl-xL and 
DOX to prostate cancer cells by aptamer-mediated interaction [292]. This system 
efficiently activated intrinsic apoptosis of cancer cells and resulted in a 17-fold 
improvement in IC50 compared with the simple mixture of shRNA/Lipofectamine with 
DOX. These results suggest that aptamer-mediated co-delivery of anticancer drugs 
with shRNA could broaden the therapeutic window for selective eradication of cancer 
cells. 
Figure 1-9. Schematic illustration of co-delivery of therapeutic drugs and 
therapeutic small RNA using free aptamer or aptamer-conjugated nanoparticles.
The choice of drugs and small RNA is based on rational design and subject to 
extensive in vivo testing.  Therapeutic agents can be directly conjugated with aptamers 
without further encapsulated into a nanoparticle, while aptamers can either be grafted 
on to the surface of nanoparticles as a targeting agent, and/or conjugated with a drug. 
(Adapted from [169])
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1.1.6 Future perspective: aptamer-mediated chemotherapy for targeting CSCs
Based on current studies, CSCs are attractive targets for anticancer therapies. 
Limitations, such as only a small population of CSC, overlapping of CSC-correlated 
surface markers and signal transduction circuits (e.g. Wnt and Notch pathway) with 
normal stem cells, hamper the effective targeting of CSCs [293]. However, cell surface
markers and/or signal transduction routes that underline tumor clonogenicity and 
tumor resistance could still provide promising therapeutic targets for developing 
effective anticancer drugs [294]. One of the challenges facing effective anti-CSC 
therapy is the elevated expression of drug efflux pumps and intracellular detoxification 
capacities [63, 95-100]. Active targeting of CSCs might hold the answer for 
circumventing chemoresistance [101]. Emerging data indicate that sensitizing CSCs 
to current chemotherapy using a CSC-targeting strategy could eliminate CSCs and 
minimize cancer recurrence [295]. For example, McAuliffe et al have shown that 
targeting CSC-DVVRFLDWHG 1RWFK SDWKZD\ ZLWK D Ȗ-secretase inhibitor and Notch3 
siRNA knockdown can increase tumor sensitivity to platinum treatment in both cancer 
cell lines and patient-derived xenograft ovarian cancer models [144]. In addition, 
following the isolation of CSCs from non-small-cell lung carcinoma (NSCLC) sphere 
cells and blocking the stem cell factor (SCF) c-kit signaling that modulates self-
renewal and proliferation of lung CSCs, the anti-SCF antibody conjugated cisplatin 
could target both non-CSCs and CSCs, enhancing the anti-tumor efficacy in human 
NSCLC [296]. Instead of developing new drugs, these studies explored a potential 
effective strategy that utilizes a CSC-targeting moiety to deliver existing 
chemotherapeutic agents to eradicate both non-CSCs and CSCs. Most recently, RNA 
aptamers for targeting CSC markers (EpCAM and CD133) have been isolated [173, 
184, 297]. Upon binding to cancer cells expressing these CSC markers, these CSC-
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targeting aptamers efficiently internalized via receptor-mediated endocytosis, an 
important mechanism capable of bypassing ATP-binding cassette transporters (ABC 
transporters) that are responsible for multiple drug resistance in CSC [184, 223].
1.1.7 Conclusion 
The CSC model continues to evolve.  In addition to leukemia stem cells, recent lineage 
tracing experiments have demonstrated the existence and roles of CSCs in the 
development of solid tumors. Challenges remain on how to effectively target CSCs in 
vivo and overcome chemoresistance. Recent evidence indicates that clonal evolution 
and CSC models are not mutually exclusive but rather co-exist and complement each 
other in tumorigenesis. Therefore, future elucidation of molecular and cellular 
mechanism underlying CSC biology should lead to the development of efficacious 
novel treatment strategies that eliminate both the bulk of the tumor cells as well as the 
CSCs. Aptamers as chemical antibodies possess attractive physicochemical and cell 
biological attributes for clinical applications both in cancer diagnosis and targeted 
cancer therapy. In particular, aptamers have been exploited as active targeting moieties 
for targeted delivery of therapeutic agents for cancer therapy. Through either direct 
physical conjugation or chemical conjugation onto nanoparticles, aptamers can guide 
drugs to tumor sites efficiently with superior tumor penetration than antibodies. The 
co-delivery of classic anticancer reagents coupled with single or multiple small RNA 
therapeutics may offer more efficacious cancer treatment regimens than either of these 
anticancer tactics alone. Further engineering of aptamers with shorter sequences but 
extended blood residence time and superior tumor penetration will facilitate the 
development of aptamer-guided cancer therapeutics with significantly improved 
clinical outcome and better quality of life for patients with cancer.
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1.2 Hypothesis and specific aims
1.2.1 Study hypothesis
The following are working hypotheses:
1) That aptamers, which are small single-stranded oligonucleotides, possess 
several superior characteristics over antibodies in terms of tumor penetration, 
accumulation and retention. 
2) That direct conjugation of a conventional anticancer drug, doxorubicin, into an
RNA EpCAM aptamer would be able to effectively target EpCAM-expressing 
cancer stem cells with enhanced cellular internalization, delivering drugs deep 
inside cancer stem cells. 
3) That the conjugation of aptamer-doxorubicin would lead to a new modality
capable of effectively targeting and eradicating cancer stem cells in vivo, 
resulting in the inhibition of tumor growth and prolong of survival rate in mice-
bearing xenograft tumors.  
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1.2.2 Study aims
The specific aims of this thesis are:
1) To investigate the superior properties of aptamers to antibodies in terms of 
penetrating into tumors, accumulation and retention in tumor sites.  
2) To establish a reliable system for cancer stem cell-targeting study.
3) To develop a strategy of direct conjugation of doxorubicin with a cancer stem 
cell-targeting RNA EpCAM aptamer that could target and release drugs inside 
cancer stem cells for effective anticancer treatment in vitro and ex vivo.
4) To evaluate the cancer stem cell targeting ability of aptamer-doxorubicin
conjugates in vivo using a model of xenogarft colorectal tumor-bearing 
NOD/SCID mice. 
5) To evaluate the efficacies of aptamer-doxorubicin conjugate in inhibiting 
tumor growth and prolonging the survival of mice-bearing xenograft tumors.  
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CHAPTER 2
MATERIALS AND METHODS
2.1 Ethics Statement
The Deakin University Animal Welfare Committee has approved all animal protocols 
used in this research.
2.2 Materials and equipment
2.2.1 Chemicals and reagents 
1% acid alcohol (Amber Scientific, Cat No: 100305)
10% Neutral buffered formalin (Sigma, Cat No: HT5014-ICS) 
2-Mercaptoethanol (Merck, Cat No: 8.05740.0250)
3M sodium acetate (pH 5.2) (Invitrogen, Cat No: 46-0236)
40 μm cell Strainers (BD Falcon, Cat No: 352340) 
8- chamber cover glass slides (Lab-Tek, Cat No: 155409) 
Acetonitrile (Merck, Cat No: UN1648)
Acetic acid (Merck, Cat No: 1.00063.2500)
Acrylamide (Bio-Rad, Cat No: 161-0156)
ALDEFLUOR kit (STEMCELL technologies, Cat No: 01700)
Alkaline phosphatase solution (Vector, Cat No: SK-5100)
ApopTag Red In Situ Apoptosis Detection Kit (Millipore, Cat No: SK-4105) 
ATP (Invitrogen, Cat No: 46-0223)
Avidin (Sigma, Cat No: A9275)
B27 (Gibco, Cat No: 10889-038)
Bisbenzimide Hoechst 33342 (Sigma, Cat No: 14533)
47
 
Biotin (Sigma, Cat No: B4501)
Bovine serum albumin (BSA, Sigma, Cat No: A4503)
Bromophenol Blue (Bio-Rad, Cat No: 161-0404)
CaCl2 (Merck, Cat No: 172570)
Chloroform (Sigma, Cat No: 366927)
Collagenase II (Sigma, Cat No: C6885) 
Costar Ultralow attachment surface 6-well plates (Corning, Cat No: 3471) 
Costar Ultralow attachment surface 96-well plates (Corning, Cat No: 30913022)
DAB peroxidase substrate solution (Vector Laboratories, Cat No: SK-4105) 
DAPI (Sigma, Cat No: D9642)
DAS 2.0 software (Mathematical Pharmacology Professional Committee of China). 
DEPC-treated water (Santa Cruz, Cat No: sc-204391A)
Dimethyl Sulfoxide (DMSO, Merck, Cat No: 1.02952.1000)
DMEM medium (Invitrogen, Cat No: 12800-017)
DMEM/F-12 media (Invitrogen, Cat No: 12500-096) 
Doxorubicin (Sigma, Cat No: 44583)
DPX (Sigma, Cat No: 317616)
Eosin (Amber Scientific, Cat No: 110543)
Epidermal growth factor (EGF, Sapphire Bioscience, Cat No: 701-02360) 
Ethanol (Merck, Cat No: 1434543)
Ethylenediaminetetraacetic acid (EDTA, Scharlau, Cat No: AC0965)
Fibroblast growth factor (FGF, Sapphire Bioscience, Cat No: 701-23300)
Foetal bovine serum (FBS, Invitro Technologies, Cat No: A50111-5039)
Giesma (Sigma, GS500)
Glucose (Sigma, Cat No: 50-99-7)
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Glutamax (Life Technologies, Cat No: 35050-061) 
Glycerol (Ajax Finechem, Cat No: 0810081)
Glycine (MP Biomedical, Cat No: 808831)
Goat serum (Abcam, Cat No: ab7481)
Ham’s F12 medium (Invitrogen, Australia, Cat No: 11765-054) 
HCL (Merck, Cat No: K37835117 737)
Hematoxylin (Amber Scientific, Cat No: 111207)
HEPES (Applichem, Cat No: A3724, 0100)
HhaI enzyme (Katara, Cat No: 1056A) 
Histolene (Grale Scientific, Cat No: Z60809)
Human transferrin conjugate Alexa Fluor 488 (Life technologies, Cat No: T13342) 
Hydrogen peroxide (Selby-Biolab, Cat No: FOC171)
Insulin (Sigma, Cat No: 19278) 
Isopropyl alcohol (Fluka, Cat No: 59304)
KCl (Sigma, Cat No: P9541)
KH2PO4 ( Sigma, Cat No:  P0662)
Ligase buffer (Invitrogen, Cat No: 46-0226)
Lipofectamine 2000 (Life Technologies, Cat No: 11668-030)
LysoTraker Green (Life technologies, Cat No: L-7526) 
Matrigel™ Basement Membrane Matrix (BD Biosciences, Cat No: 354234) 
Methanol (Merck, Cat No: 6.10158.2511)
MgCl2 (Ajax Finechem, Cat No: A296)
Na2HPO4 (Riedel-de Haen, Cat No: 30435 )
NaCl (Merck, Cat No: K37303004)
NaHCO3 (Sigma, Cat No: 30435)
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OptEIA (Human TNF ELISA Set) ELISA sets (BD Biosciences, Cat No: 555212 and
558874)
Penicillin /Streptomycin (InvitrogenTM, Australia, Cat No: 15070-063) 
Phenol: Chloroform (Invitrogen, Cat No: 46-0374)
Phosphate saline buffer (PBS, Medicago, Cat No: 09-7400-100) 
Pierce High Sensitivity Streptavidin HRP conjugate (Thermo Scientific, Cat No: 21140) 
Protease inhibitor cocktails (Roche, Cat No: 11697498001). 
Proteinase K (Merck, Cat No: VL700168) 
Quanta Blu fluorogenic Peroxidase substrate system (Thermo scientific, Cat No: 15169) 
RPMI 1640 plus l-glutamine medium (Invitrogen Life Technologies, Cat No: 11875) 
Salmon sperm DNA (Sigma, Cat No: D1626) 
Scott’s tap water substitute (Amber Scientific, Cat No: 111226)
Skim milk powder (Diploma, Cat No 28510001)
Sodium dodecyl sulfate (SDS, Medicago, Cat No: 09-2026-1000)
Stripping buffer (Thermo Scientifics, Cat No: 21059)
Super Signal West Dura substrate (Thermo Sciences, Cat No: 34075)
SuperBlock Blocking buffer (Thermo Scientific, Cat No: 37537) 
TdT enzyme (Millipore, Cat No: 90418)
TEMED (Invitrogen, Cat No: 15524-010)
Tetramethyl benzidine substrate (Sigma-Aldrich, Cat No: T0440) 
Tris Base (Sigma, Cat No: T6066)
Triton X-100 (Merck, Cat No: 1.08603.2500)
Trizol (Invitrogen, Cat No: 15596-026) 
Trypan Blue (Sigma, Cat No: T8154)
Trypsin-EDTA (Gibco, Australia, Cat No: 15400-054) 
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Tryptone (Sigma, Cat No: T7293)
Tween 20 (MP Biomedicals, Cat No: Tween201)
VECTASHIELD® Mounting medium (Vector Laboratories, Cat No: H-1000) 
All the organic reagents, including methanol and chloroform, used in this study were 
analytical or high-performance liquid chromatography (HPLC) grade. All other 
chemicals were of the highest grade available
2.2.2 Equipment, services and consumables
0.22 mm syringe driven filter (Millipore, Cat No: SLGP033RS)
15 mL centrifuge tube (Corning, Cat No: 430791) 
5 ml polystyrene round bottom tube with strainer (BD Falcon, Cat No: 352235)
ABX Micros ESV60 haematology analysing system (Horiba Medical).
Australian Genome Research Facility (AGRF) 
BD FACSDiva software (v6.0) 
BD ultrafine insulin syringe (BD, Cat No: 326769)
CellBank Australia
Cellstar 24 well plates (Greiner Bio One, Cat No: 662160)
Cellstar 6-well plate (Greiner Bio One, Cat No: 657160)
Cellstar 96-well plates (Greiner Bio One, Cat No: 657185)
Cellstar Cell culture dish (Greiner Bio One, Cat No: 664160)
CLD MIAN WORKBWENCH software 7.0.3 (Qiagen).
Electrical homogenizer (Glas-Col, S/N CTM0500082) 
FACS Canto II flow cytometer (Becton Dickinson) 
FACSAria II flow cytometer (BD Biosciences)  
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Flowjo 7.6.1 (Tree star)
Fluostar OPTIMA plate reader (BMG Labtech)
FluoView FV10i confocal microscope (Olympus , Japan)
FrameStrip 8 Clear Tubes & Caps (Integrated Sciences, Cat No: 4ti-0751)
Goat anti-mouse lgG pre-coated wells (Sapphire Bioscience, Cat No: 600-11050)
HERA cell 150i CO2 incubator (Thermo Scientific)
Heparin coated Microtainer, (BD, Cat No: 015576N)
Hitachi CT15RE Bench-top Refrigerated Centrifuge (Japan, Cat No: 90560701)
HPLC (Waters, Cat No: e2695)
Image-Pro software (Media Cybernetics)
ImageQuant LAS-4000 Chemiluminescence & Fluorescence Imaging System
(Fujitsu Life Sciences)
LAS-4000 Imaging software (GE Healthcare Life Sciences). 
Living Image Software V2.50 (Xenogen) Electrical homogenizer (Glas-Col) 
Microtome (Leica, Cat No: RM 2125RT)
Milli-Q® Advantage A10 Water System (Millipore)
NC membrane (Whatman, Cat No: 10401196)
Olympus SC20 camera (B & B Microscopes, USA)
Orbital Shaking Incubator (Ratex, Cat No: OM15)
Paraffin embedding machine (Leica, Cat No: TP 1020)
Petri Dish (Global Science, Cat No: 031604-000110)
pH metre (HANNA, Cat No: pH211) 
Poly-l-lysine coated glass slides (Sigma, Cat No: S9027-1PAK)
PVDF membrane (Thermo Scientific, Cat No: 77010)
Semi-Micro Analytical Balances (A&D, Cat No: GR-200)
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Sephadex®G-10 medium column (SIGMA-ALDRICH, Cat No: 11814427001)
Slid-A-Lyzer Dialysis Cassette (MW cut off 3.5 kDa, Thermo SCIENTIFIC, ,Cat No: 66333)
Spectrophotometers and Fluorospectrometers (Thermo Scientific, NanoDrop 2000c)
T75 flask (CELLSTAR, Cat No: 658170).
TECNIPLAST SealsafeTM Individually Ventilated Cages (UK)
The limiting dilution formula on the website of Walter and Eliza Hall Institute of 
Medical Research (http://bioinf.wehi.edu.au/software/elda/index.html).   
VICTOR TM X5 Plate Reader (PerkinElmer Life and Analytical Sciences). 
Xenogen IVIS Lumina II imaging system (Caliper life sciences) 
Zetasizer Nano ZS Particle Characterisation System from Malver Instruments
(Malvern, UK).
2.2.3 Antibodies 
Anti-Biotin secondary antibody (Vector, Cat No: SP-3020)
FITC conjugated mouse anti-human EpCAM antibody (BD Biosciences, Cat No: 347197) 
FITC conjugated mouse anti-human EpCAM antibody (Fitzgerald, Cat No: 10R-2376)
Goat anti-mouse HRP-conjugated secondary antibody (Thermo Fisher, Cat No: 31430) 
Goat anti-mouse anti-fluorescein HRP secondary antibody (Abcam, Cat No: AB6656) 
Goat anti-rabbit HRP-conjugated antibody (Pierce, Cat No: 31460)
Monoclonal Anti-FITC antibody (mouse IgG1 isotype) (Sigma, Cat No: F5636)
Mouse anti-human Anti-phospho-Histone H2A.X (Ser139) clone JBW301
(Millipore, Cat No: 05-636)
PE conjugated mouse anti-human CD24 antibody (BD Biosciences, Cat No: 555428)
Percp.cy5.5 conjugated mouse anti-human CD44 antibody (BD Biosciences, Cat No: 560531) 
Polyclonal anti-human Ki67 antibody  (mouse IgG isotype) (Abcam, Cat No: ab15580)
53
 
Rabbit anti-CD31/PECAM-1 with Biotin conjugated (Bioss, Cat No: 0195R)
Rabbit anti-human Anti-Histone H2A.X (Millipore, Cat No: 07-627)
Rhodamine conjugated anti-digoxigenin antibody (Millipore, Cat No: 90429)
V450 mouse anti-human CD44 (BD Biosciences, Cat No: 561292)
2.2.4 Animals used in this study
All animals were purchased from The Animal Resources Centre (Perth, Australia). Six 
to eight weeks old NOD-SCID female mice were used for HT29 tumor xenograft 
establishment. The mice were housed in TECNIPLAST SealsafeTM Individually 
Ventilated Cages, which were placed in a temperature-controlled room (25 ± 1 °C)
with a 12-h light-dark cycle. Mice were fed ad libitum with a standard diet. Beddings, 
cages and water were autoclaved at 121 °C for 30 min while the fodder was sterilised 
by ultraviolet irradiation before use. Male Sprague-Dawley rats (200 to 250 g) were
housed in a temperature-controlled room (25 ± 1 °C) with a 12-h light-dark cycle. Rats 
were fed ad libitum with a standard diet and were fasted overnight before treatments
administration.
2.2.5 Aptamers used in this study
Aptamers were synthesised by IBA GmbH (Rudolf-Wissell-Straße 28, 37079 
Göttingen, Germany) followed by HPLC purification.
RNA EpCAM aptamer: 5’- (DY647) - A (2’-F-C) G (2’-F-U) A (2’-F-U) (2’-F-C) 
(2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) G (2’-F-
U) -3’
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Negative control  RNA EpCAM aptamer: 5’- (DY647) - A (2’-O-Me-C) G (2’-O-
Me-U) A (2’-O-Me-U) (2’-O-Me-C) (2’-O-Me-C) (2’-O-Me-C) (2’-O-Me-U) (2’-O-
Me-U) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-C) G (2’-O-Me-C) G (2’-O-Me-U) -3’
Hybrid RNA EpCAM aptamer: 5’- (DY647) - c g c g c g c c g c A (2’-F-C) G (2’-
F-U) A (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-
F-C) G (2’-F-C) G (2’-F-U) c g g c g c g c g -3’ 
Negative control Hybrid RNA EpCAM aptamer: 5’- (DY647) - c g c g c g c c g c 
A (2’-O-Me-C) G (2’-O-Me-U) A (2’-O-Me-U) (2’-O-Me-C) (2’-O-Me-C) (2’-O-Me-
C) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-C) G (2’-O-Me-
C) G (2’-O-Me-U) c g g c g c g c g -3’
PEGylated RNA EpCAM aptamer: 5’-(20 kDa PEG-FITC)- c g c g c g c c g c A
(2’-F-C) G (2’-F-U) A (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-
U) (2’-F-U) (2’-F-C) G (2’-F-C) G (2’-F-U) c g g c g c g c g - (Biotin or DY647) -3’
Negative control PEGylated RNA EpCAM aptamer: 5’-(20 kDa PEG-FITC)- c g 
c g c g c c g c A (2’-O-Me-C) G (2’-O-Me-U) A (2’-O-Me-U) (2’-O-Me-C) (2’-O-
Me-C) (2’-O-Me-C) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) (2’-O-
Me-C) G (2’-O-Me-C) G (2’-O-Me-U) c g g c g c g c g - (Biotin or DY647) -3’
2’-F represents 2’-fluoropyrimidine, 2’-O-Me indicates 2’-O-methyl modification). 
Lowercase letters indicate DNAs which are modified with5’-Methyl-deoxyCytidine
(5-Methyl-dC). The negative control aptamer is an aptamer of the same sequence as 
EpCAM targeting aptamer but with a different side-chain modification that could 
affect the 3-dimensional structure of aptamer [298]. As a result, this control aptamer 
is not able to bind to EpCAM and does not specifically target the cancer cells with 
high expression of EpCAM. For engineering an effective DOX loading segment. 5’-
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Methyl-deoxyCytidine (dC) was deployed in the newly engineered DNA stem as 5-
Methyl dC when substituted for dC will increase the Tm by as much as 0.5°C per 
insertion. In addition, the presence of 5’-Methyl dC in CpG motifs can prevent or limit 
unwanted immune responses that otherwise occur if oligonucleotides are administered 
in vivo, which is of particular importance in in vivo applications (Fig. 5-2a) [299-301].
Prior to conducting all the experiments using aptamers, the aptamers are prepared in 
PBS containing 5 mM MgCl2 DQG WKHQ IROGHGE\GHQDWXUDWLRQ DW Û& IRUPLQ
followed by 10 min incubation DWURRPWHPSHUDWXUHDQGUHIROGLQJDWÛ&IRUDWOHDVW
15 min.
2.3 Methods
2.3.1 Cells culture 
HT-29 (human colorectal adenocarcinoma, ATCC® HTB38™) cell line, SKOV-3
(human ovary adenocarcinoma, ATCC® HTB77™) cell line and HEK-293T (human 
embryonic kidney, ATCC ® CRL-11268™) cell line were purchased from American 
Type Culture Collection (ATCC, Manassas, VA). Huh-7 (human hepatocarcinoma) 
cell line and PLC/PRF/7 (human liver hepatoma) cell line were kindly denoted from 
Dr. Liang Qiao, Sydney University. All the above cells were cultured in DMEM 
(Invitrogen, Australia) medium supplemented with 10% fetal bovine serum (FBS, 
Hyclone, Canada), penicillin (50 U/mL, Invitrogen, Australia), and streptomycin (50 
μg/mL, Invitrogen, Australia) and 1× Glutamax (Life Technologies) in a humidified 
atmosphere containing 5% CO2 at 37 °C. For subculturing cells from monolayer, cell 
culture medium was removed and cells were rinsed gently with sterilized phosphate 
saline buffer (PBS) twice, followed by detachment with 0.05% trypsin-EDTA 
(Invitrogen, Australia) at 37 °C until cells were rounded up and detached from the 
surface of flasks. Then, complete medium was used to inactivate the trypsin. Cells 
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were centrifuged and collected at room temperature, followed by resuspension with 
appropriate buffer or medium. 
2.3.2 Tumor implantation and evaluation
All animals were purchased from The Animal Resources Centre (Perth, Australia). Six 
to eight week old NOD-SCID female mice were kept under pathogen-free conditions 
in the TECNIPLAST SealsafeTM Individually Ventilated Cages at 25 ± 1 °C and a 12 
h light/12 h dark cycle and allowed a 7-day acclimatization period after arrival. They 
were fed ad libitum with a standard diet. Beddings, cages and water were autoclaved 
at 121 °C for 30 min while the fodder was sterilized by ultraviolet irradiation before 
use. To establish xenograft tumors, single suspension HT29 cells were harvested after 
trypsinization. The cells (1 × 105) were mixed and resuspended with DMEM (serum 
free) and Matrigel (50:50 = V:V) followed by transplantion into the flank of each 
mouse with a 0.5 mL syringe and 26-gauge needle. Once tumors arose, mice were 
randomized into treatment groups of 4 mice per group. Treatment was initiated when 
the tumor volume reached 50 mm3. Mice were euthanized two days after the last 
treatments or in the cases of in vivo LDA and survival assays, monitored over 3 months. 
Tumor weight and tumor size were monitored every other day after implantation and 
approximate tumor burden (mm3) was calculated as Length × Width2/2, where length 
and width are the longest and shortest axis in millimeters. The endpoints were defined 
as either diameter of the tumor reached 17 mm, consistent or rapid body weight loss 
of 20%, or other health deteriorations impacting on the welfare of the animal. Tumor 
fragments were archived in neutral buffered formalin for further analysis. Slides of 
sections were processed for TUNEL using the ApopTag Red In Situ Apoptosis 
Detection Kit (Millipore) or Ki-67 analysis.
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2.3.3 Determination of particle size of aptamer and antibody
$ȝ/DOLTXRWRI(S&$0DSWDPHURU(S&$0DQWLERG\),7&)LW]JHUDOG5-2376) 
Q0ZDVGLOXWHGLQȝ/3%6DQGPL[HGJHQWO\7KHYHVLFOHVL]HZDVPHDVXUHG
using a Zetasizer Nano ZS Particle Characterization System (Malvern, UK) following 
the manufacturer’s instruction. In addition, the shape of EpCAM aptamer, PEGylated 
EpCAM aptamer and EpCAM antibody at a concentration of (10 pM) were analyzed 
by an atomic force microscopy (AFM).  
2.3.4 Development of aptamer-drug conjugate 
EpCAM aptamer was designed for conjugation with a chemotherapy agent 
doxorubicin (DOX) (SIGMA-ALDRICH) which was prepared at concentrations of 2 
mg/ml and stored at 4 °C. DOX was mixed well with folded aptamer in conjugation 
buffer containing 0.1 M sodium acetate, 0.05 M NaCl, and 5 mM MgCl2 and incubated 
in orbital mixer/incubator (RATEK) for 30 min - 1 hour at 75 RPM. The conjugate 
mixture was then passed through Sephadex®G-10 medium column (SIGMA-
ALDRICH) to separate the conjugates from free DOX. After conjugation, the amount 
of DOX loaded onto aptamers was evaluated as following. Thirty micro-liters of Apt-
DOX conjugate was added into 90 μL of acetonitrile and vortex for 1 min. This 
solution was then centrifuged for 5 min at 21 000 x gDQGȝ/RIWKHVXSHUQDWDQW
was diluted in 150 μL PBS and mixed well prior to another centrifugation for 5 min 
at 21 000 x g. Sixty to one hundred micro-liters of supernatant was analyzed in a 
fluorescence VICTOR TM X5 Plate Reader (PerkinElmer Life) for determination of 
DOX concentrations at an excitation and emission wavelength of 470 nm and 585 nm, 
respectively. A standard curve of free DOX was also prepared in parallel.
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2.3.5 Evaluation of conjugate molar ratio and DOX loading efficiency
The natural fluorescence of DOX and its subsequent quenching after intercalating into 
the aptamer allowed efficient measuring of conjugate molar ratio and DOX loading 
efficiency via Plate Reader. Conjugation stability and molar ratio was determined with
different aptamer to DOX molar ratios (0, 0.01, 0.02, 0.04, 0.08, 0.1, 0.2, 0.4, 0.6, and 
DQGDQDO\]HGWKURXJKLQMHFWLRQRIȝ/PL[WXUHVLQWR3ODWH5HDGHU$VWDQGDUG
curve of free DOX was also prepared in parallel. The efficient loading of DOX into
aptamers was further verified using the VICTOR TM X5 Plate Reader (PerkinElmer 
Life) at a wavelength from 520 nm to 700 nm with a fixed concentration of DOX 
incubated with increasing amount of aptamer.  
2.3.6 Stability of Apt-DOX conjugates
The stability and release of DOX from Apt-DOX conjugates in vitro were studied by 
monitoring the release of DOX from the conjugates using a dialysis method with a 
Slide-A-Lyzer Dialysis Cassette. For determination of the stability, Apt-DOX and 
control Apt-DOX (Ctrl-Apt-DOX) at an equivalent DOX concentration of 1μg/mL 
were dialyzed in conjugation buffer under conditions that simulate the physiologic 
conditions (pH 7.4) at 37 °C. Four hundred microliters of each sample outside the 
dialysis cassette were collected at various time intervals (10 min, 2 h, 4 h, 6 h and 8 
h), and free DOX dialyzed in a similar way was served as a control. The concentration 
of free DOX in the dialysis buffer which represents those that had dissociated from 
the Apt-DOX conjugates was determined as described in Section 2.3.4. In addition, 
the same dialysis cassette containing Apt-DOX conjugates (400 μL, equivalent to 1 
μg/mL DOX) was dialyzed against PBS at pH 8, 7.4 or 5.0 at 37°C, with gentle 
agitation in the dark. At various time points (10 min, 0.5 h, 1 h, 2h, 4 h, 6h, 8 h, 24 h, 
26 h, 30 h, 32 h, 48 h, 50 h, 54 h and 72 h), thirty microliter aliquots of the medium 
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were withdrawn from external buffer for release kinetics analysis, and replaced with 
30 μL of fresh medium. The DOX concentration was determined as described in 
Section 2.3.4 by converting the fluorescence intensity to mass of DOX according to a 
standard curve of DOX concentration vs. its fluorescence intensity. Accumulative 
release of DOX from Apt-DOX was expressed as a percentage of the released DOX 
and plotted as a function of time.
2.3.7 Analysis of cellular uptake and retention of Apt-DOX 
Cells were seeded at a density of 75,000 cells per cm2 in an 8-chamber slide (Lab-Tek 
II, Nunc) and allowed to adhere overnight. Following the removal of media, cells were 
incubated in blocking buffer (PBS supplemented with 5 mM MgCl2, 0.1 mg/mL tRNA, 
PJ»P/VDOPRQVSHUP'1$DQG)%6DWURRPWHPSHUDWXUHIRUPLQZDVKHG
twice with PBS prior to incubation with full DMEM medium (phenol red free) for 
another 2 h with 50 nM LysoTracker (Life technologies) in the first 90 min, followed 
by the incubation  with 100 nM folded EpCAM aptamer or 100 nM EpCAM antibody 
(FITC) for 30 min. Bisbenzimide Hoechst 33342 (3 ng/mL) (Sigma) was added to the 
cells during the final 15 min of incubation. Cells were then washed three times with 
PBS and allowed to stay in phenol red free medium for imaging using a FluoView 
FV10i laser scanning confocal microscope (Olympus). Specific binding of aptamer or 
antibody on HT29 cells was carried out as the above process without the incubation 
with LysoTracker. The co-localization of aptamer or antibody was quantified using 
Image-Pro software (Media Cybernetics). 
To determine the internalization of Apt-DOX, cells were prepared and blocked as 
described above prior to incubation with free DOX and Apt-DOX at an equivalent 
'2;FRQFHQWUDWLRQRI0IRUPLQDQGKDWÛ&%LVEHQ]LPLGH+RHFKVW
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(3 ng/mL) (Sigma) was added to the cells during the final 15 min of incubation. 
Following each time point, free DOX, Apt-DOX or Ctrl-Apt-DOX solution was 
removed and the cells were washed three times with PBS prior to visualization using 
a FluoView FV10i laser scanning confocal microscope (Olympus). Similarly, to 
determine the internalization of Apt-DOX in tumorspheres, HT29 monolayer cells 
were replaced by tumorspheres and all the processes were performed as described 
above. As for evaluating the retention of Apt-DOX within tumor cells, HT-29 tumor 
cells were incubated with phenol red free DMEM for further 2 h and 24 h incubation 
before being imaged via confocal microscopy. The co-localization of DOX in nucleus 
was quantified using Image-Pro software.
To quantitatively determine the accumulation of Apt-DOX inside cancer cells, cellular 
uptake and retention of Apt-DOX compared to that of free DOX was determined. After 
10 and 30 min incubation of HT29 sphere cells with free DOX, Apt-DOX and Ctrl-
Apt-DOX (at an equivalent concentration of 1.5 μM DOX), cells were washed with 
PBS and incubated with culture media without phenol red for a further 2 and 24 h 
respectively. In addition, a dose-dependent analysis was performed by incubating cells 
with DOX, Apt-DOX and Ctrl-Apt-DOX at concentrations equivalent to 0.5, 1 and 2 
μM DOX. Blank cells were used as a control (n = 5 in each group). The cellular uptake 
of DOX was measured as described in Section 2.3.4. 
2.3.8 Determination of binding affinity 
The equilibrium dissociation constant (K’d) of 2’-F RNA aptamer species to EpCAM 
proteins expressed on the cell surface was determined using flow cytometry. HT29 or 
HEK293T cells (5 u 105) were first incubated with blocking buffer (PBS supplemented 
with 5 mM MgCl2PJP/W51$PJ»P/VDOPRQVSHUP'1$DQG)%6
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for 20 min at room temperature followed by two washes with PBS prior to incubation 
at serial concentrations (0 nM, 10 nM, 20 nM, 40 nM, 60 nM, 80 nM, 100 nM, 150 
nM and 200 nM) of DY647-labelled EpCAM aptamer, control aptamer or FITC-
ODEHOOHG(S&$0DQWLERG\LQDȝ/EORFNLQJEXIIHUDW&IRUPLQ7KHFHOOV
ZHUHZDVKHGWKUHHWLPHVUHVXVSHQGHGLQȝ/DVVD\EXIIHr containing 5 mM MgCl2
and subjected to flow cytometric analyses. The binding affinity was calculated after 
subtracting the mean fluorescence intensity (MFI) obtained from target cells to that of 
negative control cells according to a method described by Ellington and colleagues 
[302]. Fluorescent histograms were recorded by BD FACS-CantoTM II flow cytometer 
and analysed using BD FACSDiva software (v6.0). For determining the binding 
affinity of Apt-DOX, all the processes were performed as described above following 
the preparation of Apt-DOX as described in Section 2.3.4. Following conjugation of 
Apt-DOX, the conjugates were purified by passing through a Sephadex®G-50 column 
(SIGMA-ALDRICH) to remove free DOX.
2.3.9 Confocal microscopy analysis of tumorsphere preparation of aptamer and 
antibody
Two thousand HT29, Huh-7 and HEK293T cells were plated out in ultralow 
attachment wells and allowed to form spheres for 3-5 days in DMEM/F12 media 
(Invitrogen Life Technologies) supplemented with B27 (100 units/mL), Insulin (10 
μg/mL), EGF (20 ng/mL) and bFGF (20 ng/mL). The spheres were washed three times 
in PBS containing 5 mM MgCl2 and blocked for 20 min using blocking buffer. The 
spheres were then incubated with 100 nM of aptamer or antibody for 30 min, 60 min, 
120 min, or 240 min. Following each time point, the spheres were washed three times 
with PBS prior to visualisation using the FluoView FV10i confocal microscope. To 
determine the retention of aptamers within tumor spheres, HT-29 tumor spheres were 
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incubated with EpCAM aptamers or EpCAM antibody (FITC)  for a total of 4 h, 
washed three times in PBS, followed by incubation in sphere medium for a further 24 
h before being imaged.  
2.3.10 Chromatographic instrumentation and system
Chromatographic instrumentation was used based on a previously published method 
with some modifications [303]. Briefly, the high performance liquid chromatography 
(HPLC) system (Milford, MA, USA) used in this study consists of a Waters e2695 
6HSDUDWLRQ0RGXOHDQGD:DWHUV0XOWLȜ)OXRUHVFHQFH'HWHFWRU7KHH[FLWDWLRQ
and emission wavelengths were set at the 470 nm and 585 nm, respectively. 
Chromatographic separation was performed using a Nova-Pak® C18 column (3.9 × 
PPLGȝP:DWHUV86$ZLWKD1RYD-Pak® C18 guard column (3.9 × 20 mm 
LGȝP:DWHUV86$$PL[WXUHYYRIPHWKDQRODQGP0SKRVSKDWH
buffer (pH = 3.0, Fluka, Cat No: 71500) was used as the mobile phase. The flow-rate 
used in the assay was 1 mL/min and the column was maintained at 40 ± 5 °C 
throughout the chromatographic process. All solvents for HPLC procedures were 
SUHSDUHGIUHVKO\DQGILOWHUHGZLWKȝPPHPEUDQHEHIRUHXVLQJ
2.3.11 Establishing standard curves of DOX in plasma
Free DOX was dissolved in methanol to a stock concentration of 1 mg/mL. For each 
concentration (1, 5, 10, 50, 100, 200, 500, 1000, 4000 and 8000 ng/mL), stock was 
WKHQGLOXWHGZLWKȝ/EODQNSODVPDDQGPHWKDQROSKRVphate buffer mixture (55:45, 
v/v) to a final volume of 1 mL. Samples were vortexed for 1 min, and centrifuged at 
21,000 × g for 10 min at 4 qC. The supernatant was transferred to another tube 
IROORZHGE\WKHDGGLWLRQRIȝ/RIIUHVKO\SUHSDUHGSHUFKORULFDFLGYY7KHQ
samples were vortexed for another 1 min and centrifuged at 21,000 × g for 10 min at 
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4 °C. The supernatant was collected into vials, followed by measuring of DOX via 
HPLC. Calibration curves were constructed by plotting peak area of fluorescence 
derived from DOX vs. DOX concentrations. A linear regression was used for 
quantitation. The standard formulas were determined by linear regression as y = mx + 
b, where y is the peak area of DOX and x is the DOX concentration. 
2.3.12 Pharmacokinetics (PK) study
To investigate the PK properties of free DOX, PEGylated Apt-DOX and control 
PEGylated Apt-DOX in vivo, healthy male Sprague-Dawley rats (200 to 250 g, n=3) 
were injected intravenously with agents at an equivalent dose of DOX 5 mg/kg. After 
injection, blood was serially collected from animals in heparinised tubes from the tail 
at time points of 10 min, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h and 24 h. 
%ORRGVDPSOHVȝ/ZHUHFHQWULIXJHGDW× g at 4 °C for 10 min to separate 
the plasma.  The supernatant was stored at -20 °C until determination of DOX by the 
HPLC as described in Section 2.3.11. The pharmacokinetic parameters were analyzed 
using the DAS 2.0 software (Mathematical Pharmacology Professional Committee of 
China).
2.3.14 Establishing standard curves of DOX in tissues
7RHVWDEOLVKD VWDQGDUG FXUYHRI'2;LQ WLVVXHVȝJRI WLVVXHZDVSODFHG LQa
tightly sealed 2-mL screw-capped tube. Then, 1 mL methanol/phosphate buffer 
mixture (55:45, v/v) with different free DOX concentrations (50, 100, 500, 1000 and 
5000 ng/mL) was added into the tubes. Samples were pulverized via vortexing for 1 
min using FastPrep®-24 tissue and cell homogenizer (MP Biomedicals, US) and 
centrifuged at 21,000 × g at 4 °C for 10 min. The supernatant was transferred to a fresh 
tube, followed by measurement of DOX concentration under the conditions as 
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described in Section 2.3.4. Calibration curves were constructed as described in Section 
2.3.4.
2.3.15 Bio-distribution assay 
For determination of DOX distribution in vivo, HT29 tumor bearing NOD/SCID mice 
were randomly divided into three groups as indicated in PK assay: free DOX, 
PEGylated Apt-DOX and control PEGylated Apt-DOX (3 mice per group, termed 3 
h, 6 h and 24 h time point groups) once tumors reached an average volume of 150 
mm3. Agents were delivered via tail vein injection with an equivalent dose of DOX 5 
mg/kg. Organs including heart, liver, spleen, kidney, lung and tumor were collected 3 
h and 24 h after aptamer injection and then lightly washed in cold physiological saline 
to remove any excess blood, blot-dried using filter paper and thoroughly homogenized 
in PBS (tissue: PBS weight ratio 1:3) using the FastPrep®-24 tissue and cell 
homogenizer. The tissue homogenate was centrifuged at 21,000 × g for 10 min at 4 °C. 
The supernatant was transferred to another tube and extracted with the addition of 2 
ȝ/IUHVKO\SUHSDUHGSHrchloric acid (35%, v/v), vortexed for 1 min, and centrifuged at 
21,000 × g for 10 min at 4 °C. The supernatant was stored at -20 °C until determination 
of DOX by the HPLC as described in Section 2.3.11. As for bio-distribution of 
PEGylated aptamer in vivo, the supernatants of homogenate were collected and the 
aptamer concentration was quantified by ELISA.  
2.3.16 ELISA
Fifty microliters of the 10 μg/mL anti-FITC antibody (Sigma) in washing buffer (PBS 
containing 0.1 mg/mL tRNA and 1 mg/mL BSA) was added to 96-wells that had been 
pre-coated with the goat anti-mouse lgG (Sapphire Bioscience). After 1 h incubation 
at room temperature, anti-FITC antibody was removed followed by thorough washes 
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with PBS. The treated wells were blocked with 50 μL 1× SuperBlock Blocking buffer 
(Thermo Scientific) at room temperature for 1 h, followed by 3 washes with PBS, 3 
min per time. Tissue or serum samples containing aptamer (100 μL/well) were added 
and incubated for 1 h at room temperature. After extensive washing, 50 μL of 1:5000 
diluted Pierce High Sensitivity Streptavidin HRP conjugate (Thermo Scientific) was 
added to each well to bind biotin-conjugated aptamer. After 1 h incubation at room 
temperature and extensive washing, the bound aptamer was detected with a Quanta 
Blu fluorogenic Peroxidase substrate system (Thermo scientific) and measured at a 
wavelength of 325/420 nm using the VICTOR TM X5 Plate Reader (PerkinElmer Life).
2.3.17 In vivo imaging 
Non-PEGylated aptamer, PEGylated aptamer and antibody were administrated into 
mice-bearing HT29 xenograft tumors via i.v. injection at a dose of 0.75 nmol/mouse 
when the tumor volume reached around 150 mm3. The live animal imaging was 
conducted at 5 min interval using a Xenogen IVIS Lumina II imaging system (Caliper 
life Sciences). A circular region of interest (ROI) around the tumor site of each mouse 
was made and the total flux in this region was quantified using Living Image Software 
V2.50 (Xenogen) with the units of photons/s/cm2/sr. The data were used for semi-
quantification of fluorescence signal in tumors and other tissues.
2.3.18 Tumor dissociation   
All operations were performed using sterile techniques. HT29 tumor tissues were 
washed thoroughly with Hank’s buffer (containing 1% penicillin/strep) to remove 
blood and any extraneous material.  The full strength Hank's Buffered Salt Solution 
includes 0.137 M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 1 mg/mL glucose, 0.44 
mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4 and 4.2 mM NaHCO3.Tumor tissues 
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were placed in a Petri dish and minced into approximately 2 - 4 mm3 pieces with a 
scalpel. The chopped tissues were collected in a 50 mL centrifuge tube in Hank’s 
buffer and rinsed 3 times. A collagenase solution was prepared in DMEM medium 
supplemented with 1% penicillin/strep, 20% FBS, B27, Insulin (10 μg/mL), EGF (20 
ng/mL), bFGF (20 ng/mL).The small pieces of tissues were then resuspended in 50 
U/mL collagenase II (Sigma, Cat No: C6885) medium with the ratio of 6 mL/gram 
tumor at 37 °C overnight, with the tubes kept rotating in orbit mixer incubator at 60 
r.p.m. After overnight digestion, samples were pipetted 10 times and filtered through 
40 μm cell strainers. Cells were then collected through centrifugation at 1000 × g for 
5 min. The pellets were resuspended and washed in PBS twice (centrifuge at 250 × g)
to remove the debris. The cell viability was determined by Trypan blue staining. In the 
case of tumor dissociation prepared for cell sorting, tumors were minced and incubated 
in 100 U/mL collagenase II medium with the ratio of 6 mL/gram tumor supplemented 
with 1% penicillin/strep, at 37°C for 3 h and followed the same procedure as described 
above. 
2.3.19 Flow cytometry analysis of cell surface markers and aldehyde 
dehydrogenase (ALDH) activity  
To evaluate the in vivo capability of targeting CSCs by Apt-DOX, NOD/SCID mice-
bearing colorectal tumors (50 mm3) were randomized into six groups (saline, free 
aptamer, control free aptamer, free DOX, Apt-DOX and control Apt-DOX) (n=4), 
each receiving an i.v. injection of  an agent that is equivalent to 2.5 mg/kg (first two 
injections) and 1.0 mg/kg (last two injections) DOX, at a two-day interval. The treated 
tumors were harvested on the day after the last treatment and single-cell suspension of 
the tumor were prepared. The change in the abundance of putative CSC (as defined by 
ALDH+) were quantified by flow cytometry analysis. For identification of ALDH+
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cells, ALDEFLUOR kit (Stem Cell Technologies, Cat No: 01700), which detects 
ALDH expression in cells, were used. Methodological details were followed as 
described in a previous report [304]. Specific ALDH activity is based on the difference 
between the presence/absence of the Aldefluor inhibitor diethylaminobenzaldehyde 
(DEAB). Cells obtained from treated HT29 tumor xenografts were suspended in 
$/'()/825DVVD\EXIIHUFRQWDLQLQJ$/'+VXEVWUDWH%$$$ȝPROSHUî6
cells) and incubated 30-40 minutes at 37° C. As a negative control, for each sample of 
cells, an aliquot was treated with 1.5 mM DEAB. The brightly fluorescent ALDH-
expressing cells were recorded by BD FACS-CantoTM II flow cytometer operating at 
488ௗnm excitation and 520 nm emission and analyzed using BD FACSDiva software 
(v6.0). 
2.3.20 Fluorescence-activated cell sorting
For cell surface marker analysis and cell sorting, cells from cell culture or tumors were 
dissociated into single cells, washed with PBS containing 0.1% BSA and stained with 
human-specific antibodies to PE conjugated CD24 (1:25 dilution) (BD Biosciences, 
Cat No: 555428), V450 mouse anti-human CD44 (1:100 dilution) (BD Biosciences, 
Cat No: 561292) and FITC conjugated EpCAM (1:10 dilution) (BD Biosciences, Cat 
No: 347197) for 30 min at 4 °C. After thorough washing with PBS, the population of 
CSCs (defined as EpCAM+CD44+CD24+) were analyzed using FACS-Canto II 
(Becton Dickinson) or sorted using the FACSAria flow cytometer (BD Biosciences) 
for further analysis. Cells were routinely sorted twice, and the cells (1 × 105) were 
reanalyzed for purity, which typically was > 95%. For surface marker analysis, a
minimum of 10,000 events were analyzed for each sample from three independent 
experiments. 
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2.3.21 In vitro tumorsphere formation assay and ex vivo limiting dilution 
combined with tumorigenicity assay (LDA)
The colonosphere assay was conducted according to previously reported protocols 
[305]. Briefly, cells were harvested at 80% confluence with trypsin digestion and 
resuspended as single cells in DMEM/F12 serum-free media supplemented with B27 
(100 units/mL), Insulin (10 μg/mL), EGF (20 ng/mL), bFGF (20 ng/mL) following 
centrifugation (200 x g for 5 min). Cells were plated into round-bottom 96-well 
ultralow attachment plates at a density of 1, 5, 10, 100, and 200 cells per well,  or at 
8000 cells /well in 6-well flat-bottom ultralow attachment plates for tumorsphere 
formation at 37 °C. Six experiment groups were used: saline, free aptamer, free DOX 
treatment (1 μM), Ctrl-Apt-DOX and Apt-DOX treatment (equivalent to 1 μM free 
DOX) and Salinomycin (5 μM). Tumorsphere formation frequency were recorded 5-
7 days after seeding. The frequency of CSCs was calculated using the ELDA website 
(http://bioinf.wehi.edu.au/software/elda/index.html). The tumorsphere formation 
frequency in 6-well plates was calculated according to the formula F= Numbers of 
forming tumorspheres / Number of single cells plated (F is the tumorsphere formation 
frequency). For secondary and tertiary tumorsphere formation, the first-generation 
tumorspheres from 6-well plate were counted and digested using trypsin for 5 min at 
37 °C followed by gentle dispersing. The tubes containing the mixture of spheres and 
trypsin were placed back in the incubator followed by 5 min incubation and gentle 
dispersing. This process was repeated for 3-5 cycles more until the spheres were 
sufficiently digested when observed under a light microscopy. The single cell 
suspension was pelleted and re-plated under the same conditions as the first generation. 
The sphere numbers were counted 5-7 days after the plating and only spheres with a 
size larger than 50 μm in diameter were counted.  
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Limiting dilution assay is designed to define an unknown frequency of effector cells 
in a population. For ex vivo LDA, HT29 cells were cultured in ultra-low attachment 
plate and maintained in DMEM/F12 serum free medium supplemented with B27, 
Insulin (10 μg/mL), EGF (20 ng/mL), bFGF (20 ng/mL). Following 5 - 7 days 
treatment with free Aptamer, free DOX and Apt-DOX (2 μM), single cell preparation 
of HT29 sphere-forming cells were injected subcutaneously (s.c.) into NOD/SCID 
mice at two cell concentrations (1x 105 and 1 x 104) in serum-free DMEM/Matrigel 
(V:V = 1:1). Tumor diameters were measured using a digital caliper every day after 
tumor cell inoculation and tumor volume was calculated as the formula of Length × 
Width2/2 (V=LW2/2), as well as the survival rate of mice treated with various groups. 
2.3.22 In vivo tumorigenicity assay
HT29 tumor-bearing NOD/SCID mice (60 mm3) were randomly assigned to six 
groups (n=4) and underwent treatments same as described in Section 2.3.19.  One day 
after the last treatment, tumors were removed and single cell suspensions prepared and 
were used for in vitro LDA plus xenotransplantation as described in Section 2.3.21. 
Specifically, viable single cell suspensions dissociated from each tumor were 
inoculated into three sub-groups of mice using cell doses of 1 × 105, 1 × 104, 1 × 103
and 1 × 102/mouse, 4 mice per sub-group. The growth of tumor was evaluated daily 
during a 3-month period. The endpoint was defined as described in Section 2.3.2. The 
CSC frequency was derived using the limiting dilution software package on the 
website of Walter and Eliza Hall Institute of Medical Research 
(http://bioinf.wehi.edu.au/software/elda/index.html).
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2.3.23 Immunohistochemistry (double staining of CD31 and aptamer or 
antibody)
All xenograft tumors were obtained from our laboratory under the approval and 
guidance of the Institutional Animal Care and Use Committee, School of Medicine, 
Deakin University. The tumor tissues dissected from tumor-bearing mice were fixed 
at 10% neutral buffered formalin, processed and embedded in paraffin in order to 
retain their shape and architecture, as well as for their long term storage. Paraffin 
embedded sections were deparaffinized with Histoclear and rehydrated through 
graded ethanol. Heat induced antigen retrieval was performed in a microwave oven 
using sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for 20 
min and the slides were allowed to cool prior to blocking with endogenous peroxidase 
using 0.3% hydrogen peroxide in PBST (PBS containing 0.1% Tween 20) for 20 
minutes at room temperature. Additional blocking with 0.1 mg/mL tRNA, and 1 
mg/mL bovine serum albumin (BSA) or 10% goat serum in phosphate buffered saline 
(PBS) for 20 min was carried out before avidin-biotin blocking. Following serial 
incubation with 100 μL avidin (0.1 mg/mL) and 100 μL biotin (0.5 mg/mL) per slide 
for 15mins of each, the slide was washed with PBST twice and incubated with 1:100 
dilution of rabbit anti-CD31/PECAM-1 (platelet endothelial cell adhesion molecule-
1) conjugated with biotin for 2 h at 37°C. The chromogenic alkaline phosphatase 
solution (SK-5100) was prepared according to the manufacturer’s instruction and 
added to the slides following the 1 h staining of secondary anti-biotin (SP-3020) (1:
250 dilution). Upon completion of the staining of blood vessels with CD31 antibody 
and washing with PBST twice for 5 min each, the sections were incubated with anti-
FITC secondary antibody (1: 100 dilution) for 2 h at room temperature. The slides 
were then washed in PBST for 5 min for three times prior to be treated with 100 μL 
DAB peroxidase substrate solution (Vector Laboratories, Burlingame, CA) for 5-10 
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mins at room temperature for color development, followed by a single wash under 
running tap water. Counterstaining of tissue sections was performed by immersion in 
haematoxylin solution for 5 mins followed by washing under running tap water for 3-
5 min. Slides were then differentiated in 1% acid alcohol for 30 sec and washed under 
running water for 1 min prior to bluing with Scott’s solution for 1 min. Slides were 
washed under running water for 5 min and then dehydrated with 95% and 100 % 
alcohol serially. Finally, slides were cleared using two changes of histolene for 5 min 
each, and then mounted using DPX (Sigma, Cat No: 317616). Stained sections were 
examined under a light microscope equipped with an Olympus SC20 camera (Victoria, 
Australia).
To investigate the distribution of aptamer or antibody in tumor sections, their pixel 
intensity in relation to distance from the blood vessel within the selected region of 
interest was quantified by Image Pro software, according to the protocol reported by 
Lee and Tannock [306]. Briefly, images displaying anti-CD31 staining and aptamer 
or antibody staining were converted to black and white binary images: each image was 
overlaid with the corresponding field of view displaying the intensity of the agent of 
interest, resulting in an 8-bit black and white image with blood vessels identified by 
an intensity of 255 (gray scale) and agent intensity ranging from 0-254 (gray scale). 
Areas of interest were selected from each tissue section and were on average 1600 × 
ȝPȝP2/pixel). The intensity of aptamer/antibody signal was represented as 
mean ± SEM for all pixels at a given distance to the nearest vessel and plotted as a 
function of that distance.
72
 
2.3.24 Immunohistochemistry (Ki-67 staining)
Following the same deparaffinization, rehydration and antigen retrieval steps as in 
Section 2.3.23, once the solution was cooled down, sections were taken out and 
washed in PBST for 2 changes for 2 min each. The sections were then blocked with 
0.3% hydrogen peroxide for 30 min followed by 2 times washing in PBST, 2 min each 
time. The sections were then blocked in 10% goat serum for 30 min followed by PBST 
wash, 2 changes and 2 min each. The washing buffer was removed and sections were 
incubated with 1:100 mouse anti-human Ki-67 antibody (Abcam, Cat No: ab15580) 
for 2 h at room temperature. After thoroughly washing with 0.1% Tween 20 PBS, 
sections were incubated with 1:400 diluted goat anti-mouse HRP-labelled secondary 
antibody (Thermo Fisher, Cat No: 31430) for 30 min at room temperature. Sections 
were washed and treated with DAB peroxidase substrate solution (Vector Laboratories,
Burlingame, CA) for 5-10 min at room temperature for color development, followed 
by a single wash under running tap water for 1 min. Counterstaining of tissue sections 
was performed as in Section 2.3.23. 
2.3.25 TUNEL assay 
The processes of tissue fixation, dehydration, embedding and deparaffinization were 
the same as described in Section 2.3.23. After deparaffinization, sections were washed 
in one change of PBS for 5 min and protein digestion was performed with freshly 
diluted proteinase K (20 μg/mL in PBS) for 15 min at room temperature plus 5 min 
treatment with 0.5% Triton X100. The sections were then washed in 2 changes of PBS 
for 2 min each wash. After gently taping off excess liquid and carefully blotting or 
aspirating the remaining fluid off the section, equilibration buffer was applied directly 
on the specimen and incubated for 1 min at room temperature. Then, the sections were 
incubated with 55 μL/5 cm2 of working strength TdT enzyme at 37 °C for 1 h. One 
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hour later, the reaction was stopped by washing with stop/wash buffer at room 
temperature for 10 min. After thoroughly washing in PBS, the sections were then 
incubated with rhodamine-conjugated anti-digoxigenin antibody (1:50) at room 
temperature in a darkened humidified chamber for 30 min. After another round of 
thorough wash with PBS, the sections were counterstained with mounting medium 
(Vectashield, Vector Laboratories, Burlingame, CA) containing 0.5-1 μg/mL DAPI 
before visualization under a Fluoview FV10i laser scanning confocal microscope 
(Olympus, NSW, Australia).
When conducting TUNEL assay on cell culture, cell suspensions were prepared and 
washed with PBS and then fixed in 1% paraformaldehyde in PBS for 10 min at room 
temperature followed by thorough washing with PBS. Post-fix was performed in 
precooled ethanol: acetic acid 2:1 for 5 min at -20°C in a Coplin jar. Cells were then 
resuspended in PBS medium with concentration of 2 × 106 cells/mL and dried on a 
microscopy slide. The subsequent treatments were conducted as described above. 
2.3.26 Evaluation of antitumor efficacy and survival rate
HT29 tumor (50 mm3) bearing mice were grouped and treated the same as that for in 
vivo tumorigenicity assay. The mice were evaluated daily for disease-free survival and 
disease-related events. The tumor growth was measured as in Section 2.3.2. The 
endpoints are detailed as in Section 2.3.2. The Kaplan-Meier Survival Curves were 
derived using a Log-Rank test with a 95% confidence interval.   
2.3.27 Protein extraction and immunoblotting assay
Cells from cell culture or tumors were lysed with lysis buffer (20 mM Tris HCL, 135 
mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100 and 10% Glycerol) 
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containing 1 × protease inhibitor cocktails (Roche). Briefly, cells were trypsinized and 
collected into a 1.5 mL Eppendorf tube. Lysis buffer was then mixed with cells at a 
ratio of 0.2 mL/1 ×106 cells. Following 10 min incubation on ice, the contents were 
subjected to centrifuge at 21,500 × g at 4 °C for 30 min. The supernatants were finally 
collected and quantification was conducted using a Nanodrop (Thermo Scientific 
NanoDrop 2000c). For protein extraction from tissues, fresh tissues were washed with 
PBS and minced in a Petri dish. The collected tissue pieces were then briefly 
homogenized with an electrical homogenizer (Glas-Col) with tissue: PBS weight ratio 
at 1:3. After washing with PBS, the pellets were mixed with lysis buffer and subjected 
to the same procedure as with extracting protein from cultured cells. Lysates (50 
ȝJODQH ZHUH VHSDUDWHG ZLWK 6'6-PAGE gel and protein was transferred onto a 
nitrocellulose membrane (Whatman) or PVDF membrane (Thermo Scientific). 
Following sufficient blocking with 5% skim milk (overnight at 4°C), primary 
antibodies were incubated according to the manufacturers’ suggestions. Specific anti-
human antibodies to H2A.X (rabbit anti-human, Millipore, Cat No: 07-627) and 
H2A.X Ser139 (mouse anti-human, Millipore, Cat No: 05-636) were detected using 
goat anti-rabbit and goat anti-mouse HRP conjugated IgG respectively and visualized 
using the Super Signal West Dura substrate (Thermo Sciences). Relative 
quantification was conducted using a LAS-4000 Imaging System (GE Healthcare Life 
Sciences) with ȕ-actin as an internal control.
2.3.28 Statistical analysis
All statistical analyses were performed using GraphPad Prism 6.0 (San Diego, CA). 
An unpaired t test was used for comparisons between two experimental groups, and 
ANOVA was used for comparisons of more than two groups. Unless otherwise 
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indicated, all results were averaged from biological triplicates and values are reported 
as means ± SEM. P < 0.05 was considered statistically significant. 
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CHAPTER 3
SUPERIOR PERFORMANCE OF APTAMER IN 
TUMOR PENETRATION OVER ANTIBODY: 
IMPLICATION OF APTAMER-BASED 
THERANOSTICS IN SOLID TUMORS
3.1 Introduction
In order to achieve a curable outcome of cancer treatment, anticancer agents should 
effectively penetrate the extravascular space and gain access to all viable cancer cells 
with a sufficient concentration [1, 307-309]. However, the properties of abnormal 
tumor niche, including disorganized vascular system, dysfunctional lymphatics, 
increased interstitial fluid pressure, the presence of extracellular matrix, and resultant 
hypoxia with insufficient oxygen and nutrients, limit the penetration and diffusion of 
molecular medicines into tumor cells [308-315]. This insufficient and heterogeneous 
drug distribution can significantly reduce therapeutic efficacy by leaving a portion of 
viable cells, in turn leading to the increase of systematic drug resistance and the failure 
of cancer treatment [316]. Therefore, there is an urgent need to develop effective 
anticancer therapeutics that could effectively penetrate tumor tissues and accumulate 
inside tumor cells. 
Even though therapeutic antibodies have been routinely used for targeting cancers to 
overcome the insufficient specificity of traditional anticancer drugs [317-319], their 
efficacy of in vivo anticancer treatment is restricted due to 1) immunogenicity, 2) 
limited tumor penetration and distribution [316, 320-322], and 3) less accessible for 
chemical modification [323]. To overcome these challenges, new therapeutics that are 
tumor-specific, non-immunogenic and ease of conjugation with various agents to 
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improve tumor penetration are desirable. Aptamers are small single-stranded DNA or 
RNA oligonucleotides that could bind to their targets with high affinity and specificity 
[169]. The limitations of nucleic acid aptamers used in vivo are the reduced circulatory 
half-life and nucleic acid degradation, which can be alleviated by conjugation of 
polyethylene glycol (PEG) to alter the pharmacokinetics, and by introducing site-
specific chemical modification to minimize the susceptibility to attack from 
endonucleases and exonucleases [169, 324, 325]. Aptamers can be modified and 
conjugated with functional molecules for cancer diagnostic or therapeutic purposes 
[169, 326, 327]. In contrast to protein antibodies, aptamers possess little to no 
immunogenicity and low systemic toxicity in vivo [169, 328, 329].
Because aptamers have a size between antibodies (150 kDa) and small peptides (1–5
kDa) [324], we hypothesized that aptamers with a smaller size and suitable affinity 
might be advantageous over antibodies in not only effectively penetrating into tumors 
but also maintaining a durable retention in tumor tissues. The in vitro multicellular 
tumorsphere possesses several properties of the solid tumor niche in vivo [310, 330-
332] and is a simple and practicable method for evaluating drug penetration. To 
evaluate the tumor penetration performance of aptamers, we systematically evaluated 
the tumor penetration and retention by aptamer and antibodies in 3D tumorsphere 
model in vitro and tumor tissues in vivo.
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3.2 Results
3.2.1 EpCAM aptamers internalize into target cells more efficiently than 
antibody
Efficient delivery of a therapeutic ligand to a tumor requires a sufficient amounts of 
the agent to reach tumors, associated with accompanied rapid elimination from healthy 
tissues.  Such effective tumor delivery is dictated by a number of factors including a 
suitable binding affinity of the ligand to its targets, the expression of the target antigen 
at the tumor and the size of the therapeutic ligand [319, 321, 333]. The EpCAM 
antibody to be used in this study has high molecular weight (150 kDa) with a size of 
around 15 nm, while the EpCAM aptamer to be used has a smaller size of around 2.09 
nm (Fig. 3-1a). The equilibrium dissociation constant of EpCAM aptamer or the 
EpCAM antibody to HT29 cells was determined to be 39.42 nM and 5.18 nM, 
respectively (Fig. 3-1b). Adams et al. reported that for a tumor-targeting ligand, the 
K’d value lower than 1 nM does not necessarily improve tumor penetration but rather 
limits their further transport and perfusion in the tumor site [321, 333]. This 
phenomena was explained by the “binding site barrier” model which postulated that 
monoclonal antibodies with very high affinity (K’d < 1 nM)  stably bind to the first 
interacted tumor antigens with a slow rate of dissociation, resulting in a reduction of
further diffusion and thus poor penetration into tumors [334, 335]. The K’ds for both 
the EpCAM aptamer and the antibody used in this study are well above the 1 nM 
threshold for “binding site barrier”.  Therefore, it is extremely unlikely that the K’d of 
either the aptamer or the antibody used will have a profound negative influence on 
tumor penetration.  Here, we sought to investigate the tumor penetration and retention 
of an aptamer with a 7-fold lower binding affinity than its antibody counterpart.
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Binding of targeting moieties to the cell surface molecules often results in the uptake 
and trafficking of the ligand-target complex through endocytic pathways that 
internalize the targeting molecules into various cellular organelles. To investigate the 
efficiency in cell internalization and trafficking of the aptamer and antibody after cell 
binding, we examined their presence in late endosomes and lysosomes using a 
LysoTracker® Green DND-22 dye that stains acidic compartments in live cells. 
Confocal imaging of live cells was conducted on HT29 cells incubated with the same 
concentration of aptamers or antibodies (100 nM). At 15 min the aptamers were 
transported to and predominantly localized at late endosomes or lysosomes as evident 
from the colocalization of the blue (for aptamers) and red (for all acidic vesicles) 
fluorescence (Fig. 3-1c). In contrast, at least 8-fold less antibodies (green) were 
observed in these acidic vesicles (red) compared to that of aptamers (Fig. 3-1d). The 
ligand (EpCAM)-dependent internalization of the aptamer was assessed by using a 
control aptamer that has the same nucleic acid sequence as the EpCAM aptamer but 
with a 2’OMe modification of the pyrimidines instead of 2’-fluoro modification thus 
abolishing its binding to EpCAM proteins. As shown in Fig. 3-1c and d, very limited 
negative control aptamers (blue) were found in the late endosome-lysosome 
compartments; those inside the cells might enter the cells via non receptor-mediated 
endocytosis.
To be an effective cancer theranostic agent, an aptamer should be ideally internalized 
following binding to its target expressed on the cell surface of various types of tumors
[173, 336, 337]. To study if the efficient endocytosis of the aptamer is a general rather 
than a cell type-specific phenomenon, HT29 cells and two different types of 
hepatocarcimona cells (Huh-7 and PLC/PRF/5) were employed and incubated with 
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aptamers at 37 °C for 30 min followed by confocal microscopy. The EpCAM aptamer 
efficiently internalized to these three different EpCAM-positive human cancer cell 
lines with a specific red fluorescence compared to the control aptamer (Fig. 3-1e). 
Such internalization was specific as there was no binding of the aptamer to the 
negative control that HEK293T cells does not express EpCAM proteins. The cell 
binding and internalization of the EpCAM aptamer in hepatocarcinoma cells were 
further quantified (Fig. 3-1f). After 30 min incubation, there was at least 40-fold 
enhancement in binding and/or internalization of aptamer to EpCAM-positive cell 
lines compared with that in the EpCAM-negative cell line. These results are consistent 
with our previous observation that the EpCAM aptamer is able to specifically enter to 
a variety of EpCAM-positive tumor cells via receptor-mediated endocytosis [173, 
184].
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Figure 3-1. Cell binding and internalisation of EpCAM aptamer and antibody in 
vitro.
(a) Particle size of EpCAM aptamer and EpCAM antibody as determined by dynamic 
light scattering. (b) Determination of the equilibrium dissociation constants (K’d) of 
EpCAM aptamer and EpCAM antibody to HT29 cells using flow cytometry by 
incubating cells at varying concentrations of aptamer and antibody (1–200 nmol/L). 
K’d was derived using GraphPad Prism program 6.0. (c) Localization of EpCAM 
aptamer, control EpCAM aptamer or EpCAM antibody in acidic organelles (late 
endosome and lysosomes). Following incubation with 100 nM EpCAM aptamer or 
EpCAM antibody at 37 °C for 15 min and three time washes, HT29 cells were 
incubated with LysoTracker® Green in the first 90 min of a further 2 h incubation 
followed by confocal microscopy imaging. (d) Quantification of fluorescence signals 
from localized aptamer or antibody in acidic organelles (late endosome and 
lysosomes) as in (c). (e) Specificity of EpCAM aptamer binding and internalization. 
Three EpCAM-expression cell lines (HT29, Huh-7 and PLC/PRF/5) and control 
EpCAM-negative HEK293T cells were incubated with 100 nM EpCAM aptamer or 
control EpCAM aptamer at 37 °C for 15 min, followed by washing and confocal 
microscopy imaging. (f) Quantification of fluorescence signals from internalized 
aptamers in various cell lines (HT29, Huh-7, PLC/PRF/5 and HEK293T) as in (e).
'DWDDUHPHDQV6(0Q 6FDOHEDUȝP
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3.2.2 Aptamer is superior to antibody for tumorsphere penetration   
Having established that the EpCAM aptamer internalized more efficiently than 
antibody into monolayer cell culture, we proceeded to investigate the ability of our 
aptamers to penetrate an in vitro 3D cell structure. For this purpose, we used 
tumorsphere as a 3D cell model, as it is ideal for in vitro evaluation of penetrating 
ability of targeting molecules due to the ease of establishment and the similar 
microenvironment to in vivo tumors such as high inner pressure, low oxygen and low 
pH situation [338, 339]. We generated both EpCAM-positive (HT29) and EpCAM-
negative (HEK293T) tumorspheres in low adherence culture conditions. Upon 
reaching 200 Pm in size, these spheres were incubated with 100 nM EpCAM aptamer 
or the same concentration of EpCAM antibody for the indicated time, washed 3 times 
with PBS and subjected to confocal microscopy. The laser scanning confocal 
microscope recorded images of a serial z-stack optical sections of 500 nm thickness
from the periphery to the center of spheres. The images of the middle of z-stack
sections were used for the comparison of tumorsphere penetration (Fig. 3-2a). As 
shown in Fig. 3-2b, the EpCAM aptamer penetrated into the center of the tumorsphere 
as early as 30 min, and achieved excellent penetration throughout the center of HT29 
tumorspheres between 60 min to 240 min. In sharp contrast, limited tumor penetration 
into the center of the tumorsphere was observed at 30 min for EpCAM antibody and 
there was a patchy antibody presence in the center of the tumorsphere of the antibody 
even after 4 h incubation. The extremely limited penetration by the negative control 
aptamer throughout entire assay period (up to 6 h) suggests the specific interaction 
between EpCAM aptamer and its ligand, rather than a passive diffusion of any nucleic 
acid molecule, is required for the efficient penetration into the center of the 
tumorsphere. Furthermore, after 240 min incubation, only a weak signal for EpCAM 
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aptamer was discernable with the HEK293T spheres that does not express EpCAM 
(Fig. 3-2c).  
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Figure 3-2. EpCAM aptamer penetrates tumorsphere more effectively than 
EpCAM antibody. 
EpCAM aptamer, control aptamer, or EpCAM antibody of the same concentration 
(100 nM) were incubated with HT29 tumorsphere for up to 240 min at 37 °C. The 
tumorspheres were then washed three times in PBS and imaged using laser scanning 
confocal microscopy. (a) The images of the middle of z-stack sections (yellow 
bounded) were used for the comparison of tumorsphere penetration. (b) Aptamer and 
antibody staining of HT29 tumorspheres. (c) Aptamer and antibody staining of 
+(.7WXPRUVSKHUHVDIWHUPLQLQFXEDWLRQ6FDOHEDUȝP
In order to confirm the observed superior tumorsphere penetration by the EpCAM 
aptamer was not limited to the 3-D model of HT29 colorectal cancer cells, a liver 
cancer model, Huh-7 tumorsphere which expresses high level of EpCAM was also 
included in our studies. As shown in Fig. 3-3a, EpCAM aptamer effective penetrated
into the center of Huh-7 tumorspheres between 30 min and 240 min, while the signal 
of antibody that penetrated into tumorspheres were hardly detectable. Importantly, the 
fluorescence signals of EpCAM aptamers in tumorspheres were clearly detectable 
after extensive washing followed by further incubation in sphere medium for 24 h (Fig. 
3-3b), in contrast to the signals from antibodies in HEK293T tumorspheres that was 
hardly detectable after 4 h further incubation (Fig. 3-3c). These data indicated that the 
EpCAM aptamers can not only penetrate into the core of the tumorsphere derived from 
both colorectal and hepatocellular carcinoma but also were adequately retained by the 
tumor cells in the center of the tumorsphere for at least 24 h in vitro.
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Figure 3-3. EpCAM aptamer is retained much longer inside tumorsphere than 
EpCAM antibody. 
EpCAM aptamer, control aptamer, or EpCAM antibody of the same concentration 
(100 nM) were incubated with HT29 and Huh-7 tumorsphere for up to 240 min at 
37 °C. The tumorspheres were then washed three times in PBS and either imaged using 
laser scanning confocal microscopy or incubated for further 4 h and 24 h incubation 
in phenol red free culture medium. (a) Aptamer and antibody staining of Huh-7
tumorspheres. (b-c) Following a 4 h incubation with EpCAM aptamer and EpCAM 
antibody, the HT-29 and Huh-7 tumorspheres were washed with PBS and incubated 
for 24 h (b) or 4 h (c), and imaged using laser scanning confocal microscopy. Scale 
bar = 200 μm. 
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3.2.3 Aptamer is superior to antibody for in vivo tumor imaging
Given that the EpCAM RNA aptamer penetrated the tumorsphere much better than 
antibody in vitro, we next compared the performance in in vivo imaging between 
aptamer and antibody. A  DY647 fluorophore were conjugated to the 5’-end of the 
EpCAM aptamer to facilitate molecular imaging. As for the imaging study, 
NOD/SCID mice-bearing HT29 xenograft tumors with a tumor volume of ~150 mm3
received a bolus intravenous (i.v.) injection of 0.75 nmole of DY647-labelled aptamers
or FITC-labeled EpCAM antibodies. The whole body imaging was performed using 
the IVIS Live Imaging System. Fluorescence signals obtained from aptamers or 
antibodies at the regions of interest (ROIs) of tumor sites were recorded at a 5 min 
interval until the signal disappeared. The signal of aptamer on HT29 tumors appeared 
immediately and the maximum uptake was observed at around 10 min after i.v.
injection and lasted for approximately 80 min (Fig. 3-4a and b). In sharp contrast, the 
signal for antibody observed in tumor sites had a slow onset, with the maximum uptake 
reached at 3 h.  The signal in the tumor receiving EpCAM antibody lasted for at least 
6 h. Thus, the aptamer achieved highest concentration in the tumor within 10 min and 
the signal in the tumor diminished at least 4.5-times faster than that of the antibody. 
Such quick onset of the maximum signal at the site of the tumor followed by rapid 
disappearance confers aptamer with highly desirable characteristics for function as a 
promising molecular imaging probe which outperform antibodies [340, 341].
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Figure 3-4. Outstanding in vivo imaging properties of EpCAM aptamer over 
EpCAM antibody. 
(a) Representative live animal images of aptamers and antibody. NOD-SCID mice 
bearing HT29 tumor (150 mm3) received a single i.v. injection of 0.75 nmol of 
EpCAM aptamer and EpCAM antibody. (b) The fluorescence-time curve of EpCAM
aptamer and EpCAM antibody in tumors as indicated in Fig. 3-4a was determined by 
Living Imaging Software v2.50 (Xenogen) with the units of photons/s/cm2/sr. Log-
scale heat map (middle) of photon flux applies to all panels. p/s/cm2/sr: photons per 
second per cm2 per steradian. Arrow depicts the position of the subcutaneous HT29 
tumor.
3.2.4 PEGylated-aptamer is superior to antibody for in vivo drug delivery 
Next, the in vivo performance of aptamer and antibody was studied. In order to confer 
sufficient serum half-life, the EpCAM aptamer was further engineered by conjugating 
a terminal 20 kDa polyethylene glycol (PEG) (Fig. 3-5a). The PEGylation of aptamer 
increased the size of aptamer from 2.09 nm (non-PEGylated version) to approximately 
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12 nm, exceeding the 10 nm threshold of glomerular filtration (Fig. 3-5b) [342]. The 
PEGylation of the aptamer did not introduce adverse effects to the binding affinity. As 
illustrated in Figure 3-5c, the K’d of the PEGylated aptamer corresponded well to the 
reported K’d of the parental EpCAM aptamer against target cell lines [173]. In the 
case of HT29, the PEGylated EpCAM aptamer had a K’d of 51.79 nM to HT29, 
compared with that of 39.42 nM for the original EpCAM aptamer (Fig. 3-5c). In 
addition, the PEGylated aptamer maintained its binding ability to EpCAM-positive 
cancer cells (Fig. 3-5d). To study tumor delivery and retention, 0.75 nmole of DY647-
labelled PEGylated aptamers, control DY647-labelled PEGylated aptamers or FITC-
labeled EpCAM antibodies was injected i.v. into NOD/SCID mice-bearing HT29 
xenograft tumors.  The signal from the ROIs of HT29 tumors from mice receiving
PEGylated aptamer gradually increased to a plateau at 5 h followed by a slow and 
prolonged decrease until 26 h or later. However, signals from either control PEGylated 
aptamer or antibody disappeared at around 6 h (Fig. 3-5e and f), suggesting that the 
prolonged tumor residence of PEGylated EpCAM aptamer was not a non-specific 
accumulation due to EPR effect but rather resulted from the combined EPR effect and 
specific ligand interaction. The duration of the antibody signal at the tumor, which is 
indicative of its tumor volume of distribution, was 4.3-fold shorter than the tumor 
residence time of the PEGylated aptamer. Taken together, the PEGylated aptamers 
achieved longer tumor retention than the antibody counterpart, paving the way for the 
development of aptamers as effective targeted drug delivery vehicles. 
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Figure 3-5. Advanced tumor accumulation and retention of PEGylated aptamer 
than that of antibody to HT29 xenograft tumors. 
(a) PEGylated aptamer was developed by attaching a 20 kDa PEG-FITC to the 3’-end 
and a biotin and DY647 dye to the 5’- end of the DNA strand. (b) Particle size of 
PEGylated aptamer and antibody as determined by dynamic light scattering. (c)
Determination of the equilibrium dissociation constants (K’d) of PEGylated aptamer 
to HT29 cells using flow cytometry by incubating cells at varying concentrations (1–
200 nmol/L). K’d was derived using GraphPad Prism program 6.0. (d) Sustained 
binding and internalization property of PEGylated aptamer to HT29 cells which were 
incubated with 100 nM EpCAM aptamer at 37 °C for 30 min, followed by washing 
DQGFRQIRFDOPLFURVFRS\LPDJLQJ6FDOHEDULVȝP(e) Representative live animal 
images of antibodies and aptamers. NOD-SCID mice bearing HT29 tumor (150 mm3)
received a single intravenous injection of 0.75 nmol of control PEGylated aptamer, 
PEGylated aptamer and antibody followed by live imaging at the indicated time points.
(f) The fluorescence-time curve of PEGylated aptamer in tumors as indicated in Fig. 
3-5e was determined by Living Imaging Software v2.50 (Xenogen) with the units of 
photons/s/cm2/sr. Log-scale heat map (middle) of photon flux applies to all panels. 
p/s/cm2/sr: photons per second per cm2 per steradian. Data are means ± SEM, n=3.
3.2.5 Comparison of penetration of aptamer and antibody in tumors
The efficacy of drug transport inside tumors was highly restricted because of limited 
penetration, due to the abnormal and complication of tumor microenvironment, 
including poorly organized vascular system, increased interstitial fluid pressure as 
well as the presence of extracellular matrixes. Thus, next generation of anticancer 
therapeutics must penetrate into tumor tissues efficiently and gain access to all cancer 
cells in a sufficient concentration to exert effective treatment of solid tumors [308, 310, 
320, 343]. To further determine the penetration ability of aptamer in comparison with 
antibody in vivo, NOD/SCID mice bearing xenograft colorectal tumous with a tumor 
volume of 150 mm3 received a bolus i.v. injection of 2 nmol mouse of PEGylated-
aptamer or antibody. At 3 h or 24 h post injection, the mice were sacrificed and the 
formalin fixed paraffin embedded tumor sections were prepared for double staining of 
blood vessels and aptamer or antibody. To evaluate tumor penetration in vivo, the 
FITC-labeled aptamer or antibody were detected with an anti-FITC antibody and 
visualized with the aid of chromogenic substrates 3.3' diaminobenzidine (DAB); while 
the blood vessels were marked by anti-mouse CD31 antibody and visualized using 
91
 
chromogenic alkaline phosphatase solution. The distribution of aptamer or antibody 
in tumor sections was assessed by quantification of pixel intensity of aptamer or 
antibody in relation to distances from the blood vessels within the selected region of 
interest using Image Pro software. Shown in Fig. 3-6a are representative images of 
time-dependent distribution of PEGylated aptamers or antibodies (brown, marked by 
green arrows) in relation to blood vessels (red, marked by red arrows) in HT29 
xenografts sections. These images show that the majority of brown staining for 
antibodies was localized near blood vessels, whereas regions away from vessels of the 
tumors show ample red staining for aptamers. The quantification of intensity of 
aptamer or antibody in relation to distances from blood vessels at 3 h after intravenous 
injection revealed that there were significant differences in the intensity of signals 
between aptamers and aQWLERGLHV WKURXJKRXW WKH HQWLUH ȝPGLVWDQFHV IURP WKH
blood vessels (Fig. 3-6b).  In fact, aptamer achieved at least 4-time better tumor 
penetration than that of the antibody throughout the tumor space studied after 3 h i.v.
injection. Importantly, 24 h after administration, intratumoral antibody was hardly 
discernable even in the close range (20 μm) of the blood vessels. In contrast, the 
aptamer remained detectable even at regions as far as 200 μm away from the blood 
vessels (Fig. 3-5c). These data indicate that aptamers, even after PEGylation, can 
penetrate tumors much more extensively and efficiently than antibodies. Therefore, 
there is a great potential for aptamers to become effective modalities for targeted tumor 
therapeutics and imaging. 
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Figure 3-6. Time-dependent penetration of PEGylated aptamer and antibody in 
relation to blood vessels in HT29 xenograft tumors. 
(a) Representative images of double staining of aptamer or antibody and blood vessels 
in tumor sections dissected from treated mice-bearing HT29 xenografts 3 h and 24 h 
after i.v. administration of aptamer or antibody at a dose of 2 nmol/mouse. Red arrow: 
blood vessel; green arrow: aptamer or antibody. Scale bar ȝP (b-c) Quantitative 
determination of staining intensity against distance to the blood vessels at 3 h. (b) and 
24 h (c) after i.v. injection of aptamer/antibody. Data are means ± SEM (n=8). 
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3.3 Discussion
Recently, increasing data suggest that the size of nanomedicines is critically important 
for the deep penetration and efficacy of therapeutic agents to be transported into tumor 
tissues in vivo, which is vital for achieving a curable outcome [344-346]. Therapeutic 
antibodies are important agents used in clinics, though there have been mixed results 
in clinic as tumor immunotherapy [173, 182, 347, 348]. Monoclonal antibodies with 
large molecule weight have been reported to possess limited penetration into solid 
tumors, as evidenced from a steep concentration gradient inside a tumor [349, 350].
The mixed outcome of antibody-based therapeutics has been attributed, at least partly, 
to the large size and binding affinity of the immunoglobulin, as well as 
immunogenicity [348, 349, 351, 352]. Aptamers, as “chemical antibodies”, have a 
molecule weight and size of around 30-fold smaller than that of monoclonal antibodies. 
And are thus superior to antibodies for in vivo application due to the lack of the Fc 
fragment and thus devoid of immune response [315]. Despite 24 years of research into 
aptamers, however, there is a paucity in our knowledge in terms of difference in the 
ability of aptamer and antibody in tumor penetration. To our knowledge, this study is 
the first thorough investigation that compares tumor accumulation and penetration 
between aptamer and antibody both in vitro and in vivo.
Tumor-targeting efficacy of monoclonal antibodies requires sufficient binding affinity 
for durable tumor internalization and retention, which does not mean that an antibody 
has to possess extremely high affinity to be therapeutically relevant [333]. Adams et 
al. revealed that for a tumor-targeting ligand, a K’d value lower than 1 nM has a 
detrimental effect on its tumor penetration, and in fact limits further transport and 
perfusion into tumors [321, 333]. This phenomena was known as the “binding site 
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barrier”, which is caused by high-affinity binding of the antibody to the first few layers 
of tumor cells that the antibodies encountered after extravasation, resulting in a 
reduction of the amounts of available free antibodies for further penetration into 
tumors and leaving many viable tumor cells untargeted [307, 316, 329, 334, 335].
Accordingly, targeting ligands with moderate affinity would contribute to the 
development of optimal therapeutics as they could effectively perfuse and penetrate 
into tumors with a durable retention, especially when a therapeutic efficacy mostly 
relies on uniform drug delivery to tumor cells [335, 353]. Of note, the moderate 
binding affinity of both the EpCAM aptamer (K’d = 39.42 nM) and antibody (K’d = 
5.18 nM) used in this study are well above the 1 nM threshold for triggering the 
“binding site barrier” effect. Therefore, the K’d of the EpCAM aptamer and EpCAM 
antibody employed in this study is unlikely to impose adverse effects on the diffusion 
process given the extensive literature on the triggering K’d for binding site barrier 
being lower than 1 nM.  Previous work by others has shown the importance of the size 
of a molecule in tumor penetration [319, 321, 333], For example, despite being only 
2-fold larger in size than the scFv, Fab fragments display a 16 h delay to move a 
distance of 1 mm into a solid tumor [321].  Thus, the observed difference in tumor 
penetration and retention between the aptamer and the antibody is likely derived from 
the differences in the molecular weight and size. 
We started our comparison of tumor targeting by aptamer and antibody by the 
examination of cellular internalization upon binding.  As shown in Fig. 3-1a and d, 
aptamers exhibited at least 8-fold increase in entrance into endosomes and lysosomes 
than antibodies during a 15 min incubation. The efficient transport into acidic cellular 
organelles is critically important for a cancer-targeting modality to be used as a 
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theranostic agent as this will facilitate the release of chemotherapy drugs and imaging 
reporter molecules for PET SPECT, CT and MRI [186]. The observed marked 
difference in endocytosis is unlikely the result of the antibody or aptamer engaging 
different receptor-mediated endocytic pathways in a cell-line specific manner, as 
similar differences in the efficiency of endocytosis were observed in three different 
types of cancer cells.  However, in the absence of the exact knowledge of the epitope(s) 
on the EpCAM protein that the aptamer and the antibody binds, one cannot entirely 
exclude the possibility of the influence from the binding to different epitopes of the 
target on  the efficiency of endocytosis revealed for the EpCAM  antibody and aptamer, 
although it is unlikely.  
The 3D tumorsphere culture model has been proven to possess unique advantages over 
the monolayer culture system for cancer research [331, 332]. In the sphere model, cells 
are shaped tightly with lack of cell interactions, which is similar to the condition of 
tumor tissue in vivo, providing an ideal model for determining the penetration 
behavior of aptamer and antibody.  For example, cells in the outer region of the 
spheroid were exposure to sufficient oxygen and nutrients that corresponded to the 
tumor sites close to the blood vessel. Moreover cells located in the inner core were 
quiescent and more drug resistant due to the decreased supply of oxygen and nutrients, 
similar to tumor tissues far from blood vessels [320, 332, 354]. Our study in comparing 
the tumorsphere penetration by aptamer and antibody revealed the aptamer was 
capable of not only penetrating a tumorsphere efficiently, but were also retained for at 
least 24 h (Fig. 3-2b and Fig. 3-3b). In contrast, the EpCAM antibody barely reached 
the core of tumorsphere after 6 h, and had poor retention as it almost disappeared from 
the core of the tumorsphere after 4 h (Fig 3-2b, Fig. 3-3a and c). The superior ability 
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of aptamer to antibody in penetrating and being retained in the core of the tumorsphere 
revealed in this study highlights the invaluable attribute of aptamers for molecular 
imaging and targeted therapy.
To be clinically useful as in vivo molecular imaging agents in oncology, an imaging 
probe/ligand should display a rapid uptake in target sites with a maximum tumor 
uptake at 15 min followed by a rapid blood clearance [324]. Our in vivo imaging data 
demonstrate that the EpCAM aptamer showed a quick uptake in the tumor, reaching 
peak signal at around 10 min followed by swift decline of the signal in tumor until 80 
min (Fig. 3-4a and b). In addition, the aptamer displayed a durable accumulation and 
retention in the tumor area within the window of imaging as it had approximately 50% 
of signal retained within 30 min. Taken together, these parameters suggest a potential 
match with short half-life radiotracer species such as typical isotopes (carbon-11 and 
nitrogen-13) used in PET scanning [324, 355]. In contrast, the EpCAM antibody took 
3 h to a maximum uptake after i.v. injection and showed a slow blood clearance of 
over a 6 h period, these data suggest that the EpCAM aptamer would produce a much 
better clinically viable signal-to-background ratio than the EpCAM antibody for
molecular imaging applications.
An effective anticancer agent should target tumors with not only sufficient 
concentrations but also for a durable retention time. In order to facilitate in vivo
therapeutic delivery, the aptamer was further engineered by the conjugation of a 20 
kDa PEG to prolong serum retention and minimize systemic clearance. The 
PEGylation has increased the size of non-PEGylated aptamer and maintained not only 
its binding affinity but also the binding ability as well (Fig. 3-5b, c and d). In our live 
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animal imaging study for therapeutic application, the signal of PEGylated aptamer in 
the tumor persisted more than 24 h, which is consistent with the period of aptamer 
retention in the tumorsphere model. In contrast, the antibody produced only a short-
lasting signal for up to 6 h (Fig. 3-5e and f). The 4.3-fold increase of tumor persistence 
of aptamer than that of antibody indicates that aptamer is a valuable class of targeting 
ligand for targeted drug delivery.
The distribution of monoclonal antibody (trastuzumab) in HER2 overexpressing 
xenografts (MDA-435/LCC6HER2) was found to display considerable intervessel 
heterogeneity following a single i.p. injection of 20 mg/kg trastuzumab. The functional 
distance of trastuzumab, derived from average intensity, from nearest microvessel was 
XSWRȝPWKURXJKRXWWKHWXPRUFRUG[356]. This is consistent with the distribution 
profile of the EpCAM antibody we observed within the tumor in that distribution was 
hardly discernable at 150 – ȝPDZD\IURPWKHEORRGYHVVHO)LJ-6).  In contrast, 
the EpCAM aptamer displayed at least 4-fold better tumor penetration than that of the 
antibody at all distances (20 – ȝPIURPWKHEORRGYHVVHOVVWXGLHGDIWHUKi.v.
injection. Work from several independent laboratories have revealed the 
heterogeneous distribution of monoclonal antibodies at various times after their 
administration [321, 356, 357]. Dennis et al. used intravital microscopy to detect 
perivascular localization of trastuzumab conjugated to FITC, at 24 hours after i.v.
injection of 10 mg/kg (about 0.25 mg/mouse) to mice bearing allograft mammary 
tumors [322]. Compared to the deep and even penetration of Fab4D5 (a 52 kDa 
antibody fragment) and AB.Fab4D5 (a 120 kDa antibody albumin-binding fragment), 
limited penetration and heterogeneous distribution of trastuzumab (only 3-4 cell 
layers) were observed 24 h post-treatment. It has been appreciated that size plays a 
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role in affecting a targeting agent to penetrate tissues. Intact antibodies tend to localize 
besides to blood vessels and are less uniform in distribution throughout tumors, while 
smaller agents possess the ability to penetrate depths of 8 to 10 cell layers [350, 358].
This is consistent with our findings that the EpCAM aptamer established a 2-fold 
higher and more uniform distribution than that of antibody in tumors 24 h after i.v.
injection even there was less amount of aptamers present at 24 h compared with that 
at 3 h (Fig. 3-5). Furthermore, assuming the average size of a cancer cell being 15 μm, 
at the distance of 200 μm away from the blood vessels, the EpCAM aptamers would 
have travelled a distance that is well beyond 10 cell layers from the blood vessels at 
both 3 h and 24 h. Therefore, our results suggest that aptamers have superior ability 
of tumor penetration and thus possessing great potential as a targeting moiety for 
targeted therapeutics as well as in molecular imaging in which deep and uniform tumor 
penetration is desirable.  
In summary, aptamers, as chemical antibodies, possess a number of superior attributes 
over monoclonal antibodies in terms of tumor penetration, accumulation and retention. 
Consistent with the criteria of an ideal in vivo imaging agent [340, 341], the EpCAM 
aptamer displays a rapid tumor uptake at around 10 min followed by a rapid clearance. 
This parameter suggests that aptamers could be used as an attractive alternative to 
monoclonal antibodies for in vivo imaging for imaging tumors using radioactive 
tracers. The EpCAM aptamer can also be chemically modified including PEGylation 
to achieve a better pharmacokinetic performance for targeted drug delivery. 
Incomplete penetration of therapeutic antibodies or agents inside tumor tissues is one 
of the known factors contributing to drug resistance. In addition to the desirable 
properties for in vivo imaging and targeted drug delivery, the superior tumor 
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penetration ability demonstrated for aptamers to antibodies make aptamers ideal escort 
modalities for the development of active targeting-based theranostics for both cancer 
therapy and in vivo imaging without the side effects associated with conventional 
immunotherapy. 
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CHAPTER 4
DEVELOPMENT OF APTAMER-DOX CONJUGATE 
FOR TARGETING CSCs IN VITRO AND EX VIVO
4.1 Introduction
Current approaches including chemotherapy and radiotherapy are widely used for 
cancer treatment, but their lack of specificity to cancer cells often results in increased 
side effects and limited therapeutic efficacy [359, 360]. The dose-limiting toxicity of 
free drugs used in clinic limits the possibility to treat a patient at a planned dose or to 
timely start a new cycle of treatment, thereby underlying the failure of chemotherapy 
[361, 362]. To overcome these problems, several strategies such as immune-
conjugates, peptide or protein conjugates have been used for specific targeting of 
cancer cells [363-365]. However, these methods have drawbacks as conjugation with 
antibodies or proteins is tedious and the cross-reactivity of the drug can significantly 
lower the selectivity. Furthermore, the current failure of cancer treatment is largely 
attributed to our inability in eradicate CSCs [1, 366]. In the CSC model, cancer is 
considered as a hierarchical organization, in which only a small population of cancer 
cells possess the ability to extensively proliferate, self-renew, differentiate to multiple 
lineages and generate a tumor [366, 367]. CSCs, as ‘roots of cancer’, are defined by 
their abilities to form new tumors that histologically resembles the original tumor 
when transplanted into immunodeficient mice. They are resistant to traditional 
therapies such as chemo- and/or radio-therapy [368-370]. As CSCs are more drug 
resistant, more aggressive, more invasive with higher metastatic potential than their 
non-CSC counterparts, CSCs must be effectively targeted in order to improve the 
survival of patients with cancer [366].
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To achieve this goal, tumor active targeting systems have been intensively explored 
as they have the tumor-targeting potential that delivers therapeutic agents more 
selectively to cancer cells, thereby enhancing the therapeutic efficacy while 
minimizing non-specific toxicity to healthy cells [189, 371].  Active targeting entails 
the guidance of therapeutic agents, with the aid of targeting ligands, to tumor cells and 
promotes their subsequent cellular entry through receptor-mediated endocytosis [194-
196]. Aptamers, as chemical antibodies, are a novel ligands for drug targeting and 
offer significant advantages over antibodies in terms of smaller size, low 
immunogenicity and high stability, as well as the  high reproducibility and ease for 
chemical modification [181, 200, 204, 205]. Aptamer-guided active targeting enables 
the increased delivery of therapeutic agents to tumors as well as a reduction of side 
effects by minimizing the exposure of normal tissues to the therapeutic agent.   
Instead of developing new drugs to target CSCs, this project aims to explore a novel 
strategy that utilizes a CSC-targeting moiety to deliver existing chemotherapeutic 
agents to target CSCs. We have developed RNA aptamers against CSC surface 
markers (EpCAM and CD133) [173, 184]. Upon binding to cancer cells expressing 
these CSC markers, these CSC-targeting aptamers are efficiently internalized via 
receptor-mediated endocytosis, an important mechanism capable of bypassing ATP-
binding cassette transporters (ABC transporters) that are responsible for multidrug 
resistance in CSC [372, 373]. Doxorubicin (DOX), also known as Adriamycin, is 
widely used for treating a spectrum of cancers including hematological malignancies 
and solid cancers of breast, ovarian, lung and others. DOX functions by intercalating 
double-stranded G-C sequences of DNA and inhibit the synthesis of nuclei acids, 
resulting in DNA damage, epigenome and transcriptome deregulation [374]. Another 
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main anticancer action of DOX is to induce apoptosis via increasing the mitochondrial 
membrane permeability [375-377]. However, dose-limiting toxicity due to nonspecific 
targeting and the increased emergence of drug resistance following DOX 
administration limit its success in anticancer treatment [374]. By directly conjugating 
DOX to a CSC-targeting RNA aptamer (EpCAM) without any chemical modification 
of the drug, we reasoned that this strategy may be able to effectively target EpCAM-
expressing CSCs followed by enhanced cellular internalization, followed by releasing 
the drug deep inside of CSCs. To test this hypothesis, a colorectal cancer model 
(derived from HT29 cells) was established and a set of in vitro and ex vivo studies 
were conducted, including cellular uptake, in vitro colonosphere formation, and ex 
vivo limiting dilution assay, to evaluate the potential of the CSC-targeting aptamer as 
a promising drug targeting vehicle for effective  CSC therapy.  
Figure 4-1. Schematic illustration of a new paradigm for CSC-targeted therapy 
by aptamer-guided drug delivery. 
(a) Traditional strategy for cancer chemotherapy that mostly kills the bulk of tumor 
cells but leaves CSCs behind, resulting in a tumor relapse and the failure of cancer 
treatment. (b) A new therapeutic paradigm by directly conjugating a cytotoxic agent 
into a CSC-targeting aptamer is able to effectively seek the roots of cancer (CSCs) and 
release the drug deep inside of CSCs. I, receptor binding; II, internalization; III, 
endocytic pathway; IV, endosome or lysosome release; V, DOX accumulation in 
nucleus; VI, cancer cell eradication.
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4.2 Results 
4.2.1 Engineering aptamer for effective conjugation of DOX  
To generate a self-assembled targeted drug carrier, a traditional anticancer agent, DOX, 
was conjugated with an RNA EpCAM aptamer. The well-known mechanism of DOX 
action is to intercalate into double-stranded DNA G-C base pairs and inhibit the 
synthesis of nucleic acids, resulting in the failure of DNA replication [374]. The 
fluorescence property of DOX can be quenched after intercalation into double-
stranded DNA structures. We have developed and optimized the world first shortest 
RNA aptamer (18-nucleotides) that targets a CSC marker EpCAM [173, 184]. Recent 
work in our laboratory, showed that it is the loop of this RNA aptamer that determines 
its target binding and modifications made to the stem portion of the aptamer have no 
discernible impact on target interaction [173, 184]. As DOX bind RNA poorly, the 
stem of the original RNA aptamer was replaced with a 10-bp DNA G-C stem. In 
addition, 5’-Methyl-deoxyCytidine (dC) was deployed in the newly engineered DNA 
stem for this aptamer as 5-Methyl dC when substituted for dC will increase the Tm by 
as much as 0.5°C per insertion. In addition, the presence of 5’-Methyl dC in the CpG 
motifs can prevent or limit nonspecific immune responses that otherwise occur if 
oligonucleotides are administered in vivo, which is of particular importance in in vivo 
applications (Fig. 4-2a) [299-301]. Thus, a self-assembled drug transport vehicle, Apt-
DOX conjugate, was created by conjugation of DOX with chemically modified DNA-
RNA hybrid EpCAM aptamer. The successful conjugation of DOX to the aptamer was 
verified using Atomic force microscopy (AFM) (Fig. 4-2b). A negative control 
aptamer, which has the same nucleic acid sequence as EpCAM aptamer but using 2’-
O-methyl (2’-O-Me) instead of 2’-fluoropyrimidine modifications in the loop of the 
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RNA aptamer thus abolishing its binding to EpCAM proteins, was used throughout 
the study as indicated in Chapter 2.   
Figure 4-2. Schematic diagram of the predicted intercalation of DOX to 
engineered EpCAM aptamer. 
(a) Schematic illustration of the hybrid RNA-DNAEpCAM aptamer. A 10-bp DNA 
G-C stem was engineered to the original 18-nt RNA EpCAM aptamer, along with 2’-
fluoropyrimidine modification of all RNA nucleotides, 5’-Methyl-dC in the stem and 
a DY647 fluorophore conjugation to the 5’-end. (b) AFM images of intercalation 
between the aptamer and DOX due to the drug interacting with double stranded G-C
pairing. 
In order to determine the optimal molar ratio for DOX loading into the aptamer, a 
conjugation assay with sequential increases of molar ratio of aptamer to DOX was 
performed. For this study, a quantitative assessment of intrinsic fluorescence and auto-
quenching properties of DOX at various concentrations was carried out using 
fluorescence spectrometry. The fluorescence intensity measured provides a correlation 
between the fluorescence and the actual concentration of free DOX (Fig. 4-3a). The 
correlation coefficients (R2) for the calibration curves for fluorescence quenching was 
0.9998, suggesting a good linear regression within the tested ranges. As shown in Fig. 
4-3b, the signal of DOX natural fluorescence was gradually quenched upon 
intercalation with increasing molar ratio of aptamer to DOX. The loading of DOX to 
aptamer increased with increasing concentrations of aptamer as evident from the 
quenching of DOX fluorescence. The quenching of the DOX fluorescence reached a 
plateau around 92% at the molar ratio of Apt: DOX being 0.4 after 30 min incubation. 
At an Apt/DOX molar ratio of 0.2, the fluorescence for DOX was dramatically 
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quenched at about 79.1%. The efficient loading of DOX into aptamer was further 
verified at scanning wavelengths from 520 nm to 700 nm when a fixed concentration 
of DOX was incubated with increasing amounts of aptamer (Fig. 4-3c).  
Figure 4-3. Determination of successful intercalation of DOX to aptamers. 
(a) Establishment of a standard curve via fluorescence spectroscopy to determine the 
relationship between fluorescence intensity and the DOX concentration. R2 = 0.9998. 
(b) The fluorescenFHTXHQFKLQJRI'2;DWDIL[HGFRQFHQWUDWLRQȝ0DIWHUPLQ
incubation with an increasing aptamer to DOX molar ratio (0.001, 0.002, 0.004, 0.006, 
0.1, 0.6 and 1). (c) Fluorescence quenching of DOX solution (10 μM) with increasing 
molar ratios of the aptamer (from top to bottom: 0, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 
0.2, 0.4, 0.6, 1 and buffer) indicates the loading of DOX to aptamer. Data shown are 
means ± SEM. (n=3).
4.2.2 In vitro stability of Apt-DOX
As controlled and sustained drug release plays key roles in an effective drug delivery 
system [378], the stability of Apt-DOX complex was next studied by determining the 
free DOX concentrations dissociated from the Apt-DOX complex and released into 
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the buffer using a dialysis system. As shown in Fig. 4-4a, approximately 17.6 % of 
DOX diffused from both Apt-DOX and Ctrl-Apt-DOX at 8 h in PBS buffer at pH 7.4. 
This was in sharp contrast to fast diffusion of free DOX (about 80.1 %) under the same 
experimental conditions, demonstrating a high stability of the Apt-DOX complex (Fig. 
4-4a). Researchers have previously shown that upon binding to cell surface target 
proteins, aptamers are internalized via endocytosis, possibly into the endosome and 
lysosome compartments that have a pH of 6.0 to 5.0 [379]. To study the effects of pH-
dependent drug release, the in vitro release profile of DOX from Apt-DOX was 
investigated under various pHs (pH 5.0, 7.4 and 8.0) at 37 °C. As shown in Fig. 4-4b, 
at acidic conditions (pH 5.0), there was a 3.1-fold to 4.8-fold increase of release of 
DOX from Apt-DOX conjugates compared with that in the neutral or slightly basic 
pH. Notably, the release of DOX from Apt-DOX exhibited a steady and continued 
release pattern with an initial burst release at pH 5.0. Specifically, approximately 89.2 % 
of the intercalated DOX was released after 72 h at pH 5.0; while 27.6 % and 18.4 % 
of the DOX were released after 72 h at pH 7.4 and pH 8.0 respectively. Such a pH-
dependent drug release behavior is desirable as an ideal drug delivery system should
reduce the systemic exposure of DOX to sensitive organs under physiological 
conditions (pH 7.4) in vivo, but allow the trigger of a swift release of DOX after Apt-
DOX complex internalize into target cancer cells where the pH of the endosomes and 
lysosomes have a pH ranging from 4.5 to 6.5. Therefore, the pH-sensitive drug release 
of Apt-DOX complex is an invaluable attribute for targeted cancer therapy as it can 
greatly enhance the level of drugs inside cancer cells and minimize the non-specific 
systemic toxicity. 
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Figure 4-4. DOX release profile from conjugate. 
(a) In vitro time-dependent comparison of DOX release from Apt-DOX, Ctrl-Apt-
DOX conjugates and free DOX. (b) In vitro pH-dependent DOX release from Apt-
DOX conjugates at pH of 5.0, 7.4 and 8.0. Data shown are means ± SEM. (n=3).
4.2.3 Retention of functionality of Apt-DOX conjugate 
Having confirmed the successful conjugation of DOX to aptamer, we proceeded to 
determine whether the conjugation of DOX impedes binding affinity and specificity 
of the aptamer to target EpCAM proteins. To this end, the fluorescently labelled 
DY647 Apt-DOX conjugate was incubated with HT29 and EpCAM-negative 
HEK293T cells and the equilibrium dissociation constant (K’d) was determined via 
flow cytometric analysis. As shown in Figure 4-5a, the Apt-DOX conjugate had 
negligible affinity to the negative control HEK293T cells since it displayed a K’d
of >1000 nM. To ascertain that aptamer binds to EpCAM via specific molecular 
interaction rather than a non-specific binding between a nucleic acid and EpCAM, the 
experiments were repeated with a negative control Apt-DOX conjugate, as this 
negative control aptamer has identical nucleotide sequence as the targeting aptamer 
but with an altered 3-D structure that abolishes its binding to EpCAM. As shown in 
Fig. 4-5b, the negative control Apt-DOX (Ctrl-Apt-DOX) also showed minimal 
binding to the HT29 cell line with a K’d of 871.6 ± 211.5 nM. In contrast, the Apt-
DOX conjugate bound to HT29 cells with high affinity with a K’d being 16.08 ± 4.83 
nM, suggesting a retention in affinity (Fig. 4-5b). The slightly improved binding 
108
 
affinity of Apt-DOX conjugate over aptamer alone could be derived from a more 
stable 3-D structure of the Apt-DOX conferred by the 10-bp GC stem and the 
conjugation of the DOX which in turn facilitate stronger interaction of the engineered 
Apt-DOX and the target cells. 
Figure 4-5. Determination of dissociation constant of Apt-DOX conjugate. 
The binding affinity was evaluated on fluorescence labelled Apt-DOX conjugates with 
concentrations ranging from 0 to 200 nM. (a) Binding affinity of Apt-DOX on 
EpCAM-negative cell line HEK293T and Ctrl-Apt-DOX on HT29 cells. (b) Binding 
affinity of the free aptamer and Apt-DOX on HT29 cells. RFI: relative fluorescence 
intensity. Data shown are means ± SEM. (n=3).
4.2.4 Characterization of the cellular internalization and retention of the Apt-
DOX conjugate 
ABC transporters present on the plasma membrane that efflux free drugs is one of the 
key mechanisms underlying chemoresistance in cancer cells [380, 381]. One way to 
overcome such defenses is to deliver the cytotoxic drugs via endocytosis, thus 
bypassing the plasma membrane-based drug efflux pumps [382, 383]. Therefore, this 
project utilized EpCAM aptamer mediated endocytosis to deliver DOX to bypass ABC 
transporters. To confirm the hypothesis that the Apt-DOX conjugate can efficiently 
deliver the drug intracellularly and prevent/minimize drug from being pumped outside 
cells, internalization of the Apt-DOX conjugate was analyzed qualitatively via 
confocal microscopy followed by quantification using Image Pro software. Following 
30 min incubation, a large amount of Apt-DOX was located inside of cells especially 
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within the nucleus as evident from the overlapping of red (for DOX) and blue (for 
nuclei) fluorescence (Fig. 4-6a). After 2 h incubation, the cells were then thoroughly 
washed and incubated further with drug-free media and re-imaged. After 2 h and 24 h 
drug washout period, the red fluorescence signal for DOX in cells treated with Apt-
DOX was clearly detectable, most likely due to the fact Apt-DOX enters into the cells 
via endocytosis. In contrast, after 2 h of drug washout, there was little fluorescence in 
the nuclei of cells incubated with free DOX for 2 h.  Furthermore, after 24 h of drug 
washout, there was only residual DOX fluorescence found in the cytoplasm of cells 
incubated with free DOX for 2 h, suggesting most free DOX might be pumped out of 
cells during the 2 h or 24 period after the initial 2 h treatment (Fig. 4-6b and c). After 
30 min and 2 h incubation, there was a weak fluorescence in HEK293T cells treated 
with either free aptamer or DOX, suggesting low background non-specific uptake of 
free aptamer and less uptake of DOX by HEK293T cells (Fig. 4-6d). Taken together, 
these data suggested that Apt-DOX internalization resulted in a more effective DOX 
accumulation in HT29 cells. To investigate whether the conjugate could specifically 
enter target cells in vitro in a 3-D architecture in addition to the monolayer cell culture 
system used above, both HT29 and HEK293T tumorspheres were generated to mimic 
in vivo tumors. As shown in Fig. 4-6e, the Apt-DOX internalized efficiently into the 
3-D HT29 tumorspheres, but not the negative control (HEK293T) counterparts, after 
incubating for 30 min at 37 °C. Taken together, these data strongly indicated that Apt-
DOX could discriminate between target and non-target cells in both a monolayer and 
3-D model of cell culture. 
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Figure 4-6. Specific drug delivery and retention of Apt-DOX. 
(a) HT29 cells were incubated with Apt-'2;ȝ0RI'2;HTXLYDOHQWDW&
for 30 min or 2 h, followed by washing and further 2 h or 24 h incubation with fresh 
medium after removal of excess Apt-'2;FRQMXJDWHV6FDOHEDU LVȝP (b) Poor 
retention of free DOX. The assay conditions were as described in (a). Scale bar is 5 
ȝP (c) Quantification analysis of aptamer-guided DOX intracellular delivery and 
retention in nucleus of HT29 cells as in (a) and (b). (d) Low drug internalization into 
HEK293T cells that were incubated with Apt-DOX at 37 °C for 30 min and 2 h. Scale 
EDULVȝP (e) Both HT29 and HEK293T tumorspheres were incubated with Apt-
DOX at 37 °C for 30 min followed by determination of the drug penetration using 
FRQIRFDOPLFURVFRS\6FDOHEDULVȝP
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Having established that aptamer-guided DOX could specifically internalize into 
EpCAM-positive tumor cells, we sought to evaluate whether Apt-DOX enters cells in 
a time- and dose-dependent manner. In a 10-min time course study with a DOX or 
equivalent DOX concentration of 1.5 μM, the cumulative cellular uptake of Apt-DOX 
was found to be 37.11 ng DOX per 1 x 106 cells, showing a 2-fold and 2.5-fold increase 
compared with that of free DOX and Ctrl-Apt-DOX, respectively (P < 0.01) (Fig. 4-
7a). Upon 30 min incubation, the cumulative cellular uptake of DOX delivered by Apt-
DOX increased to 57.26 ng DOX per 1 x 106 cells that was 1.6-time and 1.8-time 
higher than that of free DOX and Ctrl-Apt-DOX, respectively (P < 0.01). For studying 
drug retention, cells were first incubated with 1.5 μM free DOX, Ctrl-Apt-DOX and 
Apt-DOX for 10 min and 30 min, thoroughly washed and incubated with phenol red 
free fresh medium for further 2 h or 24 h.  At the 2 h retention after 10 min retention, 
the HT29 cells treated with Apt-DOX retained 16.34 ng DOX per 1 x 106 cells, while 
only 0.12 ng and 4.79 ng DOX per 1 x 106 cells were retained in cells treated with free 
DOX and Ctrl-Apt-DOX, respectively (Fig. 4-7b). After 24 h retention, the retention 
of free DOX and Ctrl-Apt-DOX were hardly detectable, while Apt-DOX treated cells 
still remained 5.16 ng DOX per 1 x 106 cells. Similar trends of DOX concentration 
was observed after 30 min incubation followed by 2 and 24 h retention, even at the 
end point of 24 retention, the DOX concentration in Apt-DOX group was still as high 
as 23.71 ng per 1 x 106 cells, demonstrating that Apt-DOX can not only be internalized 
effectively, but can also be retained by the tumor sphere cells for at least 24 h. Similar 
results were also observed, after 30 min incubation, at a dose-dependent approach with 
cells treated with three equivalent DOX concentrations of 0.5 μM, 1 μM and 2 μM in 
which cellular uptake of Apt-DOX were statistically significantly higher than that of 
free DOX and Ctrl-Apt-DOX incubated cells (Fig. 4-7c).  Taken together, these results 
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suggest that Apt-DOX is capable of efficiently targeting HT29 cells and enhancing the 
intracellular delivery of DOX both in a time- and dose-dependent manner.
Figure 4-7. Cellular uptake and retention of Apt-DOX.
(a) Evaluation of time-dependent intracellular delivery and retention of Apt-DOX (1.5 
ȝ0RI'2;HTXLYDOHQWLQWRWDO+7FHOOVDV described in (a). (b) Dose-dependent 
intracellular delivery and retention of Apt-DOX in total HT29 cells after 30 min 
incubation at 37 °C. Data shown are means ± SEM. (n=3).
4.2.5 Evaluation of the capability of Apt-DOX conjugate in eliminating self-
renewal cells in vitro
Having established that Apt-DOX can deliver a large and persistent dose of DOX into 
colorectal cancer cells, it is important to evaluate if this translates into effective 
pharmacological outcome of eliminating CSCs.  For this purpose, it is critical to 
analyze the functional capacity of CSCs.  This is because, while the phenotypic 
characteristics of CSCs may vary according to different types of cancer, tumor 
progression stage and heterogeneity of a population, the capacities of CSCs to self-
renew and sustain a tumor still remain [47-49, 54, 65, 67, 71]. The gold standard for 
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determining the frequency of CSCs is to perform the in vivo limiting dilution assay 
after xenotransplanting single cell suspensions of tumor cells into mice. By selecting 
cells under conditions that promote self-renewal (a key property of CSCs) and 
eliminating terminally differentiated cells, the in vitro colonosphere formation assay 
is a valid surrogate of in vivo limiting dilution assay and can be utilized as a good 
indicator of self-renewal potential [384, 385]. To evaluate if the Apt-DOX could 
improve the cytotoxic capacity of DOX against CSCs, the in vitro tumorsphere 
formation assay was executed. To this end, various doses of HT29 cells were seeded 
in ultra-ORZDWWDFKPHQWSODWHVDQGLQFXEDWHGZLWKȝ0RIIUHH'2;RUHTXLYDOHQW
concentration of Apt-DOX. Salinomycin is an agent known to be able to robustly kill 
cancer stem cells and it was thus included as a positive control to validate the 
sensitivity of the tumorsphere assay system in detecting the elimination of cells with 
self-renewal capacity [386]. Cells treated with free DOX showed no significant 
decrease in the frequency of tumorsphere formation, except for those with a cell 
seeding dose of 10 cells/well or less. In contrast, targeted delivery of DOX via 
aptamer-guided transport was effective at reducing the sphere-initiating ability of 
putative CSCs (Table 4-1). The cells treated with Apt-DOX resulted in a 16.7-fold 
decrease of sphere formation from putative CSCs compared to that of free DOX. In 
order to investigate whether this system, CSC-targeting aptamer-guided drug delivery, 
was not restricted on one particular cancer cell line but rather universally functions in 
other types of cancer as well, two additional carcinoma models (ovarian cancer cell 
line SKOV-3 and breast cancer cell T47D) were used to verify this strategy using the 
96-well ultralow attachment plates under the same experimental conditions used for 
HT29 cells. Using the limiting dilution assay, the CSC frequency of cells were 
determined after 5-7 days treatment of SKOV-3 and T47D cells with free DOX, Apt-
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DOX and other controls as indicated at an equivalent DOX concentration of 0.2 μM 
and 0.1 μM, respectively.  As showed in Table 4-2, Apt-DOX treated groups resulted 
in a 16-fold and 2.6-fold decrease of tumorsphere formation of putative CSCs 
compared to free DOX treated cells in the ovarian and breast cancer respectively, 
indicating that this system could effectively impair the tumorigenicity of CSCs in at 
least 3 key types of solid tumors via aptamer-mediated DOX delivery.      
To further confirm the results obtained with 96-well ultralow attachment plates, a 
second version of tumorsphere assay was used to ensure the results obtained were 
reproducible, as the 6-well assay utilizes a very different principle of enumerating 
CSCs from its 96-well counterpart. Similar to the results obtained from 96-well plate 
assay format, there was a dramatic decrease in tumorsphere formation from HT29 cells 
in 6-well treated plates with Apt-DOX (equivalent to 1 μM free DOX) compared to 
that treated with free DOX or control (Fig. 4-8a). The percentage of tumorsphere 
formation after Apt-DOX treatment, in the first passage, was 8.7 % which was 10.4-
fold decrease than that of free DOX treated tumor cells. This difference in tumorsphere 
formation was more pronounced during the second (12.37-fold decrease) and third 
passage (170-fold decrease) of tumorsphere culture, when cells without true self-
renewal capacities that managed to survive the first-round tumorsphere assay are more 
effectively eliminated (Fig. 4-8b).
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Table 4-1. In vitro limiting dilution assay of colorectal tumor cells.
Groups Cell numbers 
incubated
Tumor sphere
incidence†
CSC frequency 
(95% CI)
Saline 200
100
10
5
1
10/10
10/10
10/10
10/10
0/10
1 in 2.53
(4.40-1.46)
Apt 200
100
10
5
1
10/10
10/10
10/10
10/10
0/10
1 in 2.53
(4.40-1.46)
DOX 200
100
10
5
1
10/10
10/10
9/10
7/10
0/10
1 in 5.04
(8.53-2.98)
Ctrl-Apt-DOX 200
100
10
5
1
10/10
9/10
8/10
8/10
0/10
1 in 12.06
(22.67-6.41)
Apt-DOX 200
100
10
5
1
10/10
6/10
1/10
0/10
0/10
1 in 84.39
(143.07-49.78)
Salinomycin 200
100
10
5
1
10/10
5/10
0/10
0/10
0/10
1 in 104.68
(178.39-61.43)
Table 4-2. CSC frequency of ovarian and breast tumor cells treated by DOX and 
Apt-DOX and other controls in vitro with limiting dilution assay.
Groups Saline Apt DOX Ctrl-Apt-DOX Apt-DOX
CSC frequency   
(95% CI)
SKOV-3 1 in 2.53
(5.53-1.16)
1 in 2.53
(5.53-1.16)
1 in 3.61
(7.58-1.72)
1 in 4.75
(9.98-2.26)
1 in 57.54
(124.50-26.60)
T47D 1 in 2.52
(5.48-1.16)
1 in 2.52
(5.48-1.16)
1 in 4.55
(9.01-2.30)
1 in 4.55
(9.01-2.30)
1 in 11.87
(23.72-5.94)
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Figure 4-8. Impairment of CSC self-renewal capacity by aptamer-guided DOX 
treatment in vitro.
(a) Representative images of tumorsphere formation ability in vitro. HT29 cells (8 × 
103) were treated and plated in a 6-well ultra-low attachment plate with CSC medium.
Six experiment groups were used: saline, free aptamer, free DOX treatment (1 μM), 
Ctrl-Apt-DOX and Apt-DOX treatment (equivalent to 1 μM free DOX) and 
Salinomycin (5 μM). Tumorsphere formation frequency were recorded 5-7 days after 
seeding. ScaOH EDU LV  ȝP (b) The percentage of tumorsphere formation was 
calculated following for 5-7 days incubation. Data shown are means ± SEM. (n=3). 
***P < 0.001 compared with groups receiving free DOX or Ctrl-Apt-DOX (two-tailed 
Student’s t-test).
4.2.6 Apt-DOX reduced tumor growth and eradicates CSCs ex vivo
To further determine if treatment of these cells with Apt-DOX would affect the activity 
of CSCs and reduce their ability to form tumors in immunocompromised mice, HT29 
cells were treated in vitro for 5 days with either saline, free aptamer, free DOX or Apt-
DOX, and then injected subcutaneously (i.v.) into NOD/SCID mice at two cell doses 
of 1 × 105 and 1 × 104. The results from ex vivo limiting dilution assay indicated that 
Apt-DOX treatment resulted in an approximately 3.9 × 105-fold lower CSC frequency 
than that of cells treated by free DOX (Table 4-3). In addition, after treatment with 
Apt-DOX, no mouse formed a tumor at the inoculating cell dose of 1 × 104, in contrast 
to those cells treated with free drug or a control that all formed tumors, suggesting that 
Apt-DOX conjugate treatment eliminated all CSCs at this cell dose (Fig. 4-9a and b). 
Tumor latency was monitored after injection of in vitro treated cells into mice and was 
defined by the period of time during which the mice remained tumor-free. 
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Implantation of 1 × 105 cells treated by Apt-DOX exhibited a significantly longer 
tumor-free period that was around 6 weeks, compared to the 2 weeks latent period of 
free DOX treated cells. Accordingly, the mice-bearing HT-29 cells treated with Apt-
DOX survived more than 3 weeks longer than the mice-bearing cells treated with free 
DOX at the inoculating cell dose of 1 × 105 (Fig. 4-9c and d). These results strongly
suggest that the aptamer-guided DOX delivery successfully targeted the CSCs in vitro
and therefore the suppressed tumor growth, prolonged tumor-free tendency and 
extended survival were most likely derived from the eradication of CSCs in xenograft 
colorectal cancer.
Table 4-3. Ex vivo limiting dilution assay of single suspension cells after in vitro
treatment.
Groups Cell numbers 
injected
Tumor 
incidence†
Latency 
(days)‡
CSC frequency 
(95% CI)
Saline 1 x 105
1 x 104
4/4
4/4
8
16 – 18
1 in 1
(15582-1)
Apt 1 x 105
1 x 104
4/4
4/4
10
18 – 19
1 in 1
(15582-1)
DOX 1 x 105
1 x 104
4/4
4/4
13
31 – 32
1 in 1
(15582-1)
Apt-DOX 1 x 105
1 x 104
1/4
0/4
40
--
1 in 387857
(2737697-54949)
†The number of tumors detected/number of mice received xenotransplantation.
‡Approximate number of days from tumor cell injection to the appearance of a tumor.
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Figure 4-9. Apt-DOX reduced tumor growth and eradicates CSCs ex vivo.
Tumor growth of colorectal tumors that were transplanted with 1 × 104 (a) and 1 × 105 
(b) cells/mouse following treatment with various groups as indicated. Error bars 
indicate SEM. (n=3). (c) and (d) Survival curves of NOD/SCID mice-bearing 
xenograft tumors treated as described (n=3).
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4.3 Discussion
Current anticancer strategies that mainly focus on the elimination of the bulk cancer 
cells fail to cure cancers as the remaining population of CSCs may cause tumor 
recurrence due to their characteristics of treatment resistance, aggressiveness and 
metastatic potential. EpCAM is expressed at low levels in normal epithelial cells and 
become overexpressed in most solid tumors. EpCAM is widely acceptable as a stem 
cell marker in a number of solid tumors, including colon, breast, pancreas, liver, and 
prostate tumors [173, 184, 387, 388]. The presence of EpCAM+ tumor cells have been 
shown to correlate with CSC’s phenotype and properties [173, 388, 389].  Therefore,  
EpCAM is a valid target for CSC-targeted therapy as this molecule is 800~1000-fold 
overexpressed in cancer cells than normal epithelial cells [390]. As indicated in 
Chapter 4 and the data presented here [173], the EpCAM aptamer we have developed 
bound specifically to HT29, MCF-7, T47D and SW480 cells that overexpress 
EpCAM, but not to EpCAM-negative HEK293T cells, indicating the highly specific
nature of EpCAM-based cellular interaction of  the aptamer. Here the RNA EpCAM 
aptamer was utilised to develop a novel therapeutic strategy to transform a traditional 
chemotherapeutic drug to an agent to target the self-renewal capacity of CSCs.  
Despite being a robust anticancer drug, abundant clinical and preclinical studies have 
revealed that DOX is largely ineffective in eliminating CSCs [391-393]. Here an RNA 
aptamer was engineered with a binding loop specific to EpCAM receptor, a marker 
highly expressed on colon CSCs, and a docking DNA stem for loading DOX [113, 
394]. Promising data obtained in this study provide the indication that an Apt-DOX
conjugate is capable of targeting colorectal CSCs.  
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In this study, the EpCAM aptamer was engineered to contain a stem of 10 base-pairs 
of G-C sequence, specifically designed to allow efficient intercalation of DOX. As 
presented in Fig. 4-3, as more aptamer was added to DOX, more quenching of 
fluorescence was observed. Other studies have shown similar results with different 
aptamers that are able to intercalate with DOX [378, 395]. The differences in molar 
ratio achieved for the conjugation of aptamer with DOX could derive from the 
differences in molecular structure of the aptamers. This investigation has used a 10 
3’G-C 5’ DNA sequence in the stem, therefore allowing the loading of 2 to 3 
molecules of DOX to each EpCAM aptamer.  
Having confirmed the initial intercalation of the drug to the EpCAM aptamer, it is 
important to assess the stability, or the extent of DOX release from the aptamer at 
various pH. This is because the conjugate must be stable at physiological pH when it 
circulates in the body. Upon entering target cancer cells, DOX should be released from 
the aptamer to enter nucleus if the conjugate is to exert its cytotoxic effect. Our 
previous studies have shown that the EpCAM aptamer is internalized to the target cells 
via endocytosis [173, 184]. Therefore, aptamer-guided drug delivery would initially 
involve the aptamer entering from the circulatory system via intravenous injection (pH 
7.4), whereby it would be able to bind cells with a high level of EpCAM, and 
internalize via endocytosis. The retention of DOX with the aptamer at neutral pH and 
the release of DOX at acidic pH are critical to the success of targeted cancer therapy. 
A recent study by Gong et al., utilized an aptamer specifically binding to prostate 
specific membrane antigen (PSMA) and showed that DOX was released at a high rate 
at pH 5.3, compared to that at pH of 7.4, which is consistent with the results in this 
investigation for the Apt-DOX conjugate despite differences in the aptamers used (Fig. 
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4-4). While largely retained within the Apt-DOX conjugate at pH of 7.4, DOX was 
released efficiently from the conjugate at pH 5.0. This data suggest that DOX would 
remain stable conjugated with the EpCAM aptamer in conditions of pH 7.4, such as 
the circulatory system and tissue interstitium, but would be released from the aptamer 
after being delivered intracellularly in the endosome-lysosome compartment, allowing 
DOX to mainly exert its cytotoxic effect after entering the target cells. This could 
potentially enhance the therapeutic index of the Apt-DOX conjugate. 
Next we determined the actual binding affinity and specificity of Apt-DOX conjugate
to their target cells via flow cytometric analysis. Careful analyses of these results 
indicated no or very little binding of the negative-control Apt-DOX or the binding of 
the Apt-DOX to the negative control cell line (Fig. 4-5a). As shown in Chapter 3 Fig. 
3-1b, EpCAM aptamer without DOX intercalation produced a high affinity for HT29 
cells that expressed the EpCAM marker. Interestingly, the Apt-DOX conjugates had 
a higher affinity (lower K’d value) to HT29 cells compared to that of free aptamer 
alone (Fig. 4-5b).  This improved affinity could be attributed to the intercalation of 
DOX to the engineered tail consisting of 10-GC pairs, which might result in an 
increased structural stability of the aptamer. Earlier studies revealed the loop in the 
aptamer is responsible for the interaction with its partner protein [396-401]. Therefore, 
an important question derived is, does the intercalation of DOX into the stem of the 
aptamer affect its ability to interact with its target? It is possible that intercalation of
DOX could be changing the 3-D conformation of the aptamer which may impact on 
target binding. Results obtained in this study demonstrated that not only did the Apt-
DOX retain its specificity but also have improved affinity for EpCAM-expressing 
colon cancer cells. This has laid a solid foundation for a  possible solution to the 
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insufficient cytotoxicity of DOX when targeting  CSCs, given that  colon CSCs 
express EpCAM at a level that is 1000-fold higher than normal colon cells [390].
As mentioned above, previous studies have alluded to the cellular mechanisms of how 
aptamers are internalized via endocytosis. Furthermore, the pH-dependent release of 
DOX from the Apt-DOX confirmed in this investigation, suggest that DOX can be 
effectively released after endocytosis. This intracellular release could circumvent the 
efflux by ABC transporters, allowing delivery of the DOX to the site of action, the 
nucleus. To confirm this, laser confocal microscopy was used to qualitatively identify 
whether the DOX in the conjugate could in fact be delivered into the nuclei.  Treatment 
of cells with Apt-DOX resulted in a selective and more effective uptake of DOX and 
accumulation in the nuclei by EpCAM-positive cells but not the EpCAM-negative 
cells (Fig. 4-6a and Fig. 4-7a). This is a strong indication that Apt-DOX could 
discriminate between target and non-target cells. This indicates that the Apt-DOX 
conjugate can successfully deliver the payload into the target cell followed by the 
release of DOX from the aptamer to ensure that DOX enters the nucleus to elicit its 
cytotoxic effect. In addition to the in vitro evidence of releasing DOX at acidic pH, 
the confocal microscopy analysis confirmed DOX did diffuse into the nuclei. 
Furthermore, 2 h after incubation of HT29 cells with free DOX, there was a much 
lower DOX fluorescence inside the cells, with hardly discernible DOX in the nuclei 
(Fig. 4-6b). In contrast, cells treated with Apt-DOX equivalent to the free DOX was 
found to retain DOX in the nuclei for at least 24 h. This suggests that free DOX that 
enters cells via random diffusion is rapid efflux or metabolized, but DOX delivered 
by Apt-DOX can maintain high concentration in the nucleus. To complement the 
initial results achieved from confocal microscopy, the cellular uptake of free DOX, 
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control Apt-DOX and Apt-DOX in HT29 cells was further quantitatively evaluated to 
verify the enhancement uptake of Apt-DOX by colon cancer cells. The data 
demonstrated that the average cellular uptake of DOX in Apt-DOX by HT29 cells was 
statistically significantly higher than that of all control groups (Fig. 4-6d and e). These 
results confirmed that targeted drug delivery by Apt-DOX affords enhanced cellular 
DOX uptake.  
The gold standard analysis of CSCs is to xenotransplant single cell suspension of 
tumor cells into immunodeficient mice with limiting dilution assay. Here, an in vitro
surrogate of the gold standard CSC assay, tumorsphere formation assay, was 
employed to provide initial assessment of the CSC-targeting ability of Apt-DOX
conjugates. The tumorsphere formation assay allows researchers to functionally test a 
key property of CSCs, self-renewal [384].  That is, by plating cells in ultralow 
attachment plates in a serum-free medium containing EGF, FGF, insulin and B27, the 
procedure selectively eliminates cells without self-renewal capacities, and generates 
tumorspheres from cells that do possess self-renewal capacity. This assay has been 
widely utilized to tests drugs, both conventional and novel, to examine their cytotoxic 
effect on putative CSCs in vitro [402, 403]. Careful analysis at serial seeding doses of 
cells confirmed the ability of the Apt-DOX conjugates in inhibiting sphere-initiating 
frequency (Table 4-1).  In addition to the colorectal cancer HT29 cells, an additional 
two cancer cell lines from different types of solid tumor (ovarian and breast cancers) 
were tested as well using the same CSC incubation conditions with limiting dilution 
assay. The results indicated that the aptamer-guided DOX delivery to EpCAM-
specific cells could be a universal approach for CSC-targeted therapy (Table 4-2). In 
addition to the 96-well format of tumorsphere assay, an alternative 6-well assay that 
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utilizes a different cell enumerating strategy, was employed to verify the capacity of 
CSC targeting (Fig. 4-8). Again, results from these two different format of 
tumorsphere assays confirmed that aptamer-DOX conjugates, but not the free DOX, 
has the potential for effectively targeting and eliminating CSCs. 
To functionally verify the anticancer efficacy and CSC-targeting ability of Apt-DOX, 
an ex vivo limiting dilution assay was conducted by xenotransplanting single cell 
preparations of tumors cells that were previously treated with Apt-DOX and other 
controls in vitro into NOD/SCID mice. Consistent with the in vitro results from 
tumorsphere assays, the treatment of cells with Apt-DOX resulted in a significant 
reduction of tumor growth and a longer latency, compared to free DOX and any 
control treatment (Table 4-3, Fig. 4-9a and b). Most importantly, the Apt-DOX 
treatment remarkably prolonged the survival of mice-bearing HT29 tumors, indicating 
that the subpopulation of CSCs was effectively eliminated in vitro before they were 
xenotransplanted into mice (Fig. 4-9c and d). Nevertheless, the in vivo CSC-targeting 
ability of EpCAM aptamer-DOX still needs to be verified in preclinical animal models 
in follow-up studies. 
While recent literature has focused on using aptamers for targeted specificity, the data 
obtained in this chapter presents evidence for a targeted aptamer therapy towards 
CSCs. Furthermore, while others have also focused on inhibition of signaling 
pathways that has been associated with CSCs, the combined CSC-targeting  and  
DOX-induced DNA impairment afforded by this conjugate provide a viable 
alternative to eradicate CSCs at the heart of its self-renewal tenacity [115, 143, 149, 
404].
125
 
In summary, a CSC-targeted drug delivery carrier was successfully developed 
composed of a conventional anticancer therapeutic, DOX, conjugated into an EpCAM 
RNA aptamer. This conjugate was found to be stable enough to allow sufficient 
loading of DOX to the aptamer and maintain the stability for delivery of the DOX 
payload inside the EpCAM expressing cancer cells, resulting in a high concentration 
and prolonged drug retention. These results were further supported by evidence of 
effectively targeting and eliminating CSCs through an analysis of tumorsphere 
formation or self-renewal potential both in vitro and ex vivo, paving the way for future 
exploration of this conjugate for in vivo targeting CSCs. 
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CHAPTER 5
APTAMER-GUIDED DOX DELIVERY FOR 
TARGETING CSCs IN VIVO
This Chapter was adapted from part of the published research article:
1. Li L*, Xiang D*, Shigdar S, Yang W, Li Q, Lin J, Liu K, and Duan W. Epithelial 
cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG 
nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int 
J Nanomedicine 2014; 9: 1083-96. (*co-first author)
5.1 Introduction 
As with many other solid tumors, colorectal cancer is composed of phenotypically and 
functionally diverse cell phenotypes, in which CSCs are capable of extensive self-
renewal and initiating a tumor [405-408]. CSCs are resistant to conventional 
chemotherapy and radiation through their elevated drug efflux function, amplified 
FKHFNSRLQWDFWLYDWLRQDQG'1$GDPDJHUHSDLUDVZHOODVLQFUHDVHG:QWȕ-catenin and 
Notch signaling,  and therefore are responsible for sustaining tumor progression and 
recurrence [366, 368, 409-412]. Thus, therapies that are able to eradicate CSCs may 
eventually contribute to cancer cures [413-415]. CD133+/CD44+/ EpCAM+ cells, as 
well as ALDH+ populations from colorectal cancer cell lines and/or biopsies have been 
identified as CSCs [416-423]. Antibody-based targeted cancer therapies by targeting 
the surface markers of CSCs, such as DLL4, CD123, and CD133, have shown 
promising therapeutic effects in a number of cancers with increasing commercial 
success for combating cancers [65, 113, 424, 425]. As indicated in Chapter 3, aptamers 
are superior to antibodies in biodistribution and tumor penetration. This led to the 
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hypothesis that CSC-targeting aptamers can lead to a preclinical development of a 
novel CSC-targeted therapy.
In previous chapters, the Apt-DOX conjugate was developed and its specific targeting 
and internalization into EpCAM expressing cancer cells were characterized. 
Subsequently, the efficacy of eliminating CSCs by Apt-DOX both in vitro and ex vivo 
was confirmed. The focus of this chapter is to examine the ability of targeting and 
eradicating CSC by Apt-DOX conjugates in vivo.  To achieve this goal, the aptamer 
was firstly engineered with a terminal 20 kDa PEG to prolong the circulation half-life. 
Next, mice-bearing HT29 xenograft tumors were treated by Apt-DOX or controls.  
After the in vivo treatment, the CSC-enriched subpopulations was isolated based on 
the expression of well-characterized cell surface markers of CSC [72, 406, 426, 427].
These FACS sorted cells isolated from the treated xenograft tumor were used to 
evaluate whether the Apt-DOX was able to physically deliver DOX to colorectal 
CSCs.  Finally, the efficacy of aptamer-targeted delivery in inhibiting tumor growth 
and enhancing survival rate of mice-bearing tumors was determined. 
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5.2 Results
5.2.1 PEGylation improves pharmaceutical profile and tumor delivery of Apt-
DOX in vivo
For in vivo therapy, an optimal treatment schedule including ideal doses and 
administration intervals is essential, which mostly relies on the pharmaceutical profile 
of the administrated agent. To study the in vivo performance of the Apt-DOX system, 
the pharmacokinetics and bio-distribution of Apt-DOX was evaluated in healthy 
Sprague Dawley rats and NOD/SCID mice-bearing xenograft tumors, respectively.
The EpCAM aptamer was further engineered by conjugating a terminal 20 kDa 
polyethylene glycol (PEG) to increase its blood retention (Fig. 5-1a). The PEGylation 
of aptamer increased the size of aptamer from 2.09 nm (non-PEGylated version) to 
approximately 12 nm, exceeding the 10 nm renal filtration threshold (Fig. 5-1b) [342].
Following a single intravenous (i.v.) injection of free DOX, PEGylated Apt-DOX and 
control PEGylated Apt-DOX at an equivalent dose of 5 mg/kg, the DOX concentration 
was measured at a time-dependent manner in the bloodstream of rats. The fluorescence 
intensity for DOX measured provides a correlation between the fluorescence and the 
actual concentration of free DOX in the plasma of the animals. The correlation 
coefficients (R2) for the calibration curves for fluorescence intensity was 0.9973, 
suggesting a good linear regression within the tested ranges (Fig. 5-1c). Free DOX 
was rapidly cleared from plasma circulation within 2 h due to its short half-life (t1/2:
0.87 h). In contrast, both PEGylated Apt-DOX and control PEGylated Apt-DOX 
showed higher DOX concentrations than that of free DOX during circulation, with a 
half-life of 7.13 h and 7.73 h respectively (Fig. 5-1d and Table 5-1). The PEGylation 
of aptamer significantly increased the mean residence time (MRT; 16.25 h) of DOX 
during its blood circulation compared with free DOX (MRT; 2.48 h). The area under 
the curve (AUC) of PEGylated Apt-DOX was around 7-fold higher than those of free 
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DOX, while the clearance (CL) of Apt-DOX was 10-fold lower than that of free DOX. 
These results revealed that the DOX intercalated to PEGylated aptamer enjoyed a 
much improved pharmacokinetic profile than free DOX in vivo. Therefore, in this 
chapter, all aptamers described for the in vivo study were PEGylated.
Figure 5-1. Pharmaceutical profile of PEGylated Apt-DOX.
(a) Thematic illustration of PEGylated aptamer with a 20 kDa PEG-FITC conjugated 
to the 3’-end and a biotin or Dy647 to the 5’-end. (b) Particle size of EpCAM aptamer 
and PEGylated EpCAM aptamer as determined by dynamic light scattering. (c)
Establishment of a standard curve via HPLC to determine the relationship between 
fluorescence intensity and the DOX concentration in the serum. R2 = 0.9973. (d)
Pharmacokinetic profiles of DOX after a single i.v. injection of free DOX, PEGylated 
Apt-DOX and control PEGylated Apt-DOX conjugate into SD rats at an equivalent 
dosage of 5 mg/kg DOX followed by quantification of DOX in blood plasma. Data 
shown are means ± SEM. (n=3).
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Table 5-1. Pharmacokinetic parameters of free DOX, PEGylated Apt-DOX and 
control PEGylated Apt-DOX after i.v. administration at a dose of equivalent to 5 
mg/kg DOX.
Pharmacokinetic 
parameters
Free DOX Ctrl-Apt-DOX Apt-DOX
Cmax (μg/mL) 2.53 ± 0.78 23.02 ± 3.16 25.67 ± 4.58
t1/2ĮK 0.07 ± 0.02 0.71 ± 0.15* 0.87 ± 0.11*
t1/2ȕK 0.87 ± 0.25 7.13 ± 3.16* 7.73 ± 2.35*
MRT (h) 2.48 ± 1.39 15.49 ± 2.55* 16.25 ± 2.42*
AUC (h*h*μg/mL) 428.358 ± 156.32 2836.54 ± 1032.41** 3118.64 ±1537.72**
CL (mL/h/kg) 331.33 ± 87.54 37.07 ± 3.65* 30.36 ± 3.44*
Vss (mL/kg) 9404.75 ± 1578.32 470.31 ± 112.38** 372.92 ± 98.65**
Cmax, maximum plasma concentration; t1/2ȕ, elimination half-life; MRT, mean retention time; AUC, 
area under the plasma concentration-time curves; CL, total body clearance; Vss, steady state volume of 
distribution. *, P < 0.01; **, P < 0.001 compared with rats received free DOX (two-tailed Student’s t-
test).
5.2.2 Establishment of standard curves for DOX distribution in various tissues 
For quantification of DOX concentrations in various tissues using HPLC, tissues
(tumor, heart, liver, spleen, lung, kidney, brain, intestine, tail and muscle) spiked with 
a serial dilution of DOX were prepared to obtain calibration curves. The relationship 
between peak areas in the chromatograms and DOX concentrations was assessed over 
a range of 5-8,000 ng/mL. The correlation coefficients (R2) for calibration curves 
being better than 0.996 suggested a good linear regression within the tested ranges 
(Fig. 5-2).
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Figure 5-2. Standard curves for DOX determination in various tissues. 
The calibration curve was made by plotting the peak area of DOX fluorescence against 
DOX concentrations in homogenate. Standard formulas were determined by linear 
UHJUHVVLRQDV< P;EZKHUH<LVWKHSHDNDUHDRI'2;ȝ9îVHFDQG;LVWKH
serial of DOX concentrations (ng/mL).
5.2.3 Biodistribution of Apt-DOX in NOD/SCID mice
To assess the in vivo tissue uptake of Apt-DOX afforded by the PEG incorporation, 
the biodistribution of DOX in various tissues (tumor, heart, liver, spleen, lung, kidney, 
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brain, intestine, tail and muscle) were studied after a single i.v. injection of free DOX, 
Ctrl-Apt-DOX or Apt-DOX at an equivalent DOX concentration of 5 mg/kg (Fig. 5-
3). At 3 h, 6 h and 24 h after the administration, free DOX accumulated rapidly in 
highly perfused organs, such as the liver, kidney, and intestine, followed by a rapid 
decline after reaching a peak concentration at 6 h (Fig. 5-3a). In contrast, the DOX 
profile of the animals receiving Apt-DOX displayed a quite different pattern: DOX 
reached a peak in the tumor at 6 h but slightly decreased to approximately 89% of the 
peak concentration within 24 h (Fig. 5-3b and c). Notably, DOX concentration in the 
mice receiving free DOX exhibited a low peak concentration at 3 h followed by a 
steady decrease of DOX over the 24 h period. On the contrary, the concentration of 
DOX in the tumor of mice receiving Apt-DOX was 100-200% higher than those 
receiving free DOX, reaching a peak concentration of DOX in tumors at 6 h followed 
by a slight decline, to around 73 % of the peak, at 24 h after administration. Ever 24 h 
after the administration of Apt-DOX, the DOX concentration in the tumor was still 
22% higher than that at 3 h after administration (Fig. 5-3d). Interestingly, the levels of 
DOX in the heart, the site of principle dose-liming toxicity of DOX, of the tumor-
bearing mice receiving Apt-DOX treatment were significantly lower (39% to 70% 
lower) than those treated with free DOX at all three time points studied (Fig. 5-3e). 
Taken together, the DOX delivered by tumor-specific aptamer not only improved the 
DOX accumulation in tumors, but also enhanced the safety profile, with reduced 
cardiac exposure.  
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Figure 5-3. Bio-distribution of Apt-DOX in vivo.
(a) Time-dependent biodistribution of DOX in tissues after i.v. injection of free DOX 
into mice-bearing xenograft HT29 tumors. (b) Biodistribution profiles of DOX 
accumulation in tumor and organs 24 h after i.v. injection of agents at an equivalent 
dosage of 5 mg/mL DOX. Data shown are means ± SEM. (n=3). (c) Time-dependent 
biodistribution of DOX in tissues after i.v. injection of Apt-DOX into mice-bearing 
xenograft HT29 tumors. Data shown are means ± SEM. (n=3). (d-e) Biodistribution 
of DOX in the tumor (d) and heart (e) 24 h after i.v. injection. Data shown are means 
± SEM. (n=3). *P < 0.05, **P < 0.01 compared with free DOX administration groups 
(two-tailed Student’s t-test).  
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5.2.4 Apoptosis induction and proliferation inhibition of tumors induced by 
Apt-DOX 
The progression of cancer is controlled by the rate of cancer cell proliferation and 
apoptosis [428].  We next sought to evaluate the effects of Apt-DOX treatment on 
apoptosis and the proliferation of HT29 xenograft tumor cells. When the subcutaneous 
HT29 tumors reached a volume of ~50 mm3, the tumor-bearing mice were randomly 
divided into six groups and intravenously administrated with four serial injections of 
saline, free aptamers, free DOX, Ctrl-Apt-DOX and Apt-DOX. Each tumor-bearing 
mouse received i.v. administrated an agent that is equivalent to 2.5 mg/kg (first two 
injections) and 1.0 mg/kg (last two injections), or saline at a two-day interval. A 
TUNEL assay and Ki-67 staining were employed using formalin-fixed, paraffin-
embedded tissue sections prepared from treated tumors. While single treatment with 
DOX alone induced limited apoptosis in tumors, Apt-DOX treatment elicited a 9.3-
fold and 3.75-fold increase in  apoptotic tumor cells as determined  from the in situ 
TUNEL assay in tumor sections compared with saline and DOX treatment groups, 
respectively (Fig. 5-4a and b). These data indicated that the major inhibition of tumor 
growth was at least partly due to the increased apoptosis effect induced by aptamer-
DOX. Similarly, a statistically significant reduction of Ki-67 antigen expression (0.08 
%) which is indicative of  the potential of tumor proliferation was observed in tumors 
that were treated with Apt-DOX in comparison with the Ki-67 index of 2.0 % and 1.8 
%  in tumors treated with free DOX or Ctrl-Apt-DOX  respectively (Fig. 5-4c and d).
Given the free drug treatment exhibited a 50% reduction on tumor proliferation in Ki-
67 index compared to saline treatment, it is likely that Apt-DOX treatment resulted in 
enhanced specific tumor-targeting of DOX and a reduction in tumor proliferation.
Taken together, these results indicated that the aptamer-guided DOX treatment  not 
only strongly promoted tumor cell apoptosis but also inhibited the proliferation of 
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tumor cells, which are key factors dictating the overall growth and regression of tumor
in response to chemotherapy and radiotherapy [429].
Figure 5-4. Apt-DOX treatment enhanced apoptosis and inhibited proliferation 
of HT29 xenograft tumor. 
(a) Representative images of TUNEL assay on HT29 xenograft tumor sections with 
illustrated treatments. (b) Quantification of apoptotic cells via TUNEL assay as in (a).
Data shown are means ± SEM. (n=3). (c) Ki-67 staining of tumor sections from HT29 
xenograft tumors treated as indicated. (d) Quantification of Ki-67 positive cells as in 
(c). Data shown are means ± SEM. (n=3). ** P < 0.01 compared with that in tumor 
IURPPLFHWUHDWHGZLWKIUHH'2;6FDOHEDULVȝP
5.2.5 Aptamer-guided DOX delivery improved antitumor efficacy in vivo 
Given that aptamer-guided DOX delivery could efficiently target CSCs and impair 
their self-renewal functions, we next studied the antitumor efficacy of Apt-DOX in 
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HT-29 colorectal xenografts in NOD/SCID mice. Following the establishment of the 
xenograft colorectal cancer model, the mice were randomized into six groups and each 
received four injections of DOX, Apt-DOX and other controls as described in Section 
6.2.4. Interestingly, tumor-bearing mice receiving Apt-DOX had a 6.25-fold and 2.3-
fold decrease in tumor weight compared to those receiving saline or free DOX 
treatments, respectively (Fig. 5-5). There was no gross difference in tumor weights 
between mice receiving free aptamer or saline, which is consistent with the results 
presented in Chapter 5, that the aptamer itself had no anticancer activities. 
Figure 5-5. Administration of Apt-DOX inhibits tumor growth in HT29 tumor 
model. 
(a) Images of HT29 xenograft tumors following in vivo treatments. NOD/SCID mice 
bearing HT29 xenograft tumors with a volume of 50 mm3 were treated as indicated. 
Three days after the final injection, the tumors were removed and measured. (b) 
Quantification of tumor weight in mice receiving treatments as indicated. Data shown 
are means ± SEM. (n=4). **, P < 0.01 compared with tumors from mice receiving free 
DOX (two-tailed Student’s t-test). 
The goal of effective anti-cancer therapy is to not only inhibit tumor progression 
temporarily but also to extend survival rates of patients long-term [430]. In order to 
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evaluate the efficacy of Apt-DOX treatment on tumor growth and the overall survival 
of mice-bearing HT29 tumors, a preclinical xenograft mouse model was utilized. As 
shown in Fig. 5-6, saline and free aptamers had no effect on either tumor growth or 
survival rate which is consistent with the previous results both in vitro and ex vivo.
Treatment of tumor-bearing mice with Apt-DOX resulted in a significantly higher 
inhibition efficacy on tumor growth.  This was evident from a  significantly reduced 
rate of tumor growth with an 8-fold and 3-fold smaller tumor size compared with the 
mice received saline or free DOX treatment, respectively (P < 0.01) (Fig. 5-6a). 
Consistent with the observed significant reduction of tumor growth, mice receiving 
free DOX or negative control Apt-DOX succumbed to the tumors at Day 51, while 
mice treated with Apt-DOX had a remarkably prolonged survival rate (Fig. 5-6b). 
Therefore, the novel strategy of aptamer-guided DOX delivery effectively targeted-
CSCs in vivo and thereby significantly inhibited the tumor growth and extended 
overall survival of the tumor-bearing mice. 
Figure 5-6. Aptamer-guided DOX delivery inhibited tumor growth and extended 
survival rate of mice-bearing HT29 tumors. 
NOD/SCID mice-bearing HT29 xenograft tumor were randomized into six groups and 
treated as described in the legend. (a) Tumor volume over time 63 days. Data shown 
are means ± SEM. (n=4). (b) Kaplan-Meier survival curves of mice (n=4) bearing 
HT29 tumor treated as indicated. ** P < 0.01 compared with mice receiving free DOX 
(two-tailed Student’s t-test). 
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5.2.6 Apt-DOX treatment diminished tumorigenicity of colorectal CSCs 
To explore whether the marked suppression of tumor growth and greatly improved 
overall survival observed in Section 5.2.5 were due to the eradication of the non-CSC 
pool of cancer cells only or attributed to the elimination of CSCs, the mechanisms 
underlying the efficacy of Apt-DOX were explored.  The two key characteristics of 
CSCs are their ability for self-renewal and the initiation of tumors. To assess the 
impact of Apt-DOX treatment on the self-renewal capacities of CSCs in vivo, an in 
vitro tumorsphere initiation with limiting dilution assay was carried out on single cell 
suspensions prepared from xenograft tumors after in vivo treatment. As shown in Table 
5-2, there was a 207.8- and 18.1-fold decrease in the frequency of sphere re-initiating 
cells from tumor-bearing mice treated with Apt-DOX compared to those treated with 
saline and free DOX, respectively. 
To further verify the in vivo efficacy of Apt-DOX in targeting CSCs, the self-renewal 
capacity of CSCs in the treated xenograft tumors was studied using the secondary in 
vivo tumor initiation assays at serial limiting cell doses [431-433]. To this end, single 
cell suspensions derived from treated tumors were implanted into naïve NOD/SCID 
mice subcutaneously (s.c.) at cell doses of 1 × 105, 1 × 104, 1 × 103, and 1 × 102. At 
the inoculating cell dose of 1 × 103, tumors formed in all mice receiving cells treated 
with free drug or a control. In contrast, no tumor was detected in mice received 1 × 
103 cells dissociated from the mice treated with Apt-DOX after 3 months, suggesting 
that Apt-DOX conjugate treatment eliminated most, if not all, CSCs at this cell dose 
(Table 5-3). Tumor latency was monitored after injection of cells into mice and was 
defined by the period of time during which the mice remained tumor-free. 
Implantation of 1 × 104 cells treated by Apt-DOX exhibited a significantly longer 
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tumor-free period than those receiving free DOX (7 weeks vs 4 weeks). At higher 
inoculating cell doses of 1 × 105, there were a ~20 days longer tumor-free period in 
mice received Apt-DOX than those treated with free DOX. Furthermore, there was a 
30-fold reduction in the frequency of self-renewing CSCs in naïve mice receiving 
tumor cells from mice that had been treated with Apt-DOX compared with those  
received tumor cells from mice treated with  free DOX  (P < 0.0001) (Table 5-3). 
These results were consistent with the observations by others that in both clinical and 
preclinical settings, free DOX can kill the bulk of non-CSC cancer cells but was 
ineffective in eliminating CSCs [434-436]. However, when DOX was delivered by 
EpCAM aptamer, this classic anti-cancer drug was transformed into a new 
chemotherapeutic that effectively eliminated CSCs, thereby circumventing
chemoresistance and preventing tumor initiation. 
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Table 5-2. In vitro limiting dilution assay of colorectal tumor cells prepared from 
xenograft tumors after in vivo treatment.
Groups Cell numbers 
incubated
Tumor sphere
incidence†
CSC frequency 
(95% CI)
Saline 200
100
10
5
1
10/10
10/10
10/10
10/10
0/10
1 in 2.53
(4.40-1.46)
Ctrl-Apt 200
100
10
5
1
10/10
10/10
10/10
10/10
0/10
1 in 2.53
(4.40-1.46)
Apt 200
100
10
5
1
10/10
10/10
10/10
10/10
0/10
1 in 2.53
(4.40-1.46)
DOX 200
100
10
5
1
10/10
8/10
6/10
4/10
0/10
1 in 28.98
(55.30-15.18)
Ctrl-Apt-DOX 200
100
10
5
1
10/10
8/10
5/10
5/10
0/10
1 in 29.18
(55.60-15.30)
Apt-DOX 200
100
10
5
1
5/10
0/10
0/10
0/10
0/10
1 in 525.67
(1246.2-221.74)
†The number of tumor sphere detected/number of cell seeded.
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Table 5-3. Aptamer-guided DOX delivery increased tumor latency and reduced 
CSC frequency in HT29 xenograft tumors.
Groups Cell numbers 
injected
Tumor 
incidence†
Latency 
(days)‡
CSC frequency 
(95% CI)
Saline 1 x 105
1 x 104
1 x 103
1 x 102
4/4
4/4
4/4
0/4
7 – 9
18 – 23
36 – 42
–
1 in 417
(1259-138)
Ctrl-Apt 1 x 105
1 x 104
1 x 103
1 x 102
4/4
4/4
4/4
0/4
7 - 10
20 – 25
38 – 45
–
1 in 417
(1259-138)
Apt 1 x 105
1 x 104
1 x 103
1 x 102
4/4
4/4
4/4
0/4
8 – 10 
21 – 24
37 – 48
–
1 in 417
(1259-138)
DOX 1 x 105
1 x 104
1 x 103
1 x 102
4/4
3/4
3/4
0/4
13 – 16
27 – 34
50 –
–
1 in 3609
(10942-1190)
Ctrl-Apt-DOX 1 x 105
1 x 104
1 x 103
1 x 102
4/4
3/4
2/4
0/4
12 – 17
26 – 30
50 –
–
1 in 4677
(13769-1589)
Apt-DOX 1 x 105
1 x 104
1 x 103
1 x 102
2/4
1/4
0/4
0/4
30 – 35
47 –
–
–
1 in 108037
(360667-32362)
†The number of tumors detected/number of cell injected.
‡Approximate number of days from tumor cell injection to the appearance of a tumor.
5.2.7 Targeting HT29 colorectal CSCs by Apt-DOX in vivo
Data from Chapter 4 provided strong functional evidence that EpCAM aptamer-
guided DOX delivery was able to target CSCs both in vitro and ex vivo. To evaluate 
the in vivo capability of targeting CSCs by Apt-DOX, NOD/SCID mice bearing 
colorectal tumors were randomized into four groups, each receiving i.v. administrated 
with an agent that is equivalent to 2.5 mg/kg (first two injections) and 1.0 mg/kg (last 
two injections) of DOX, at two-day intervals. On the day after the last treatment, 
treated tumors were removed and single cell suspensions were prepared (Fig. 5-7). 
ALDHs are a group of intracellular enzymes that participate in the process of oxidation 
(detoxification) of exogenously and endogenously generated aldehydes [124-127].
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Increasing evidence supported that ALDH was highly expressed in CSCs.  Therefore, 
either ALDH alone or in combination with other cell surface markers has been used 
to identify CSCs in colon cancers [130-132]. In this study, an ALDEFLUOR® kit was 
used to test the ALDH1 enzymatic activity in the tumor cell suspension dissociated 
from treated colorectal tumor xenografts. Cells, labeled with activated 
ALDEFLUOR® substrate in the presence or absence of the ALDH inhibitor (DEAB), 
were analyzed by flow cytometer. The changes in the abundance of the putative CSCs 
(as defined by ALDH+) were quantified by flow cytometry analysis [416-421, 423].
Consistent with our previous data showing that free aptamers had no effects on CSC 
inhibition, the proportion of ALDH+ cells from tumor-bearing mice that received 
aptamer alone displayed no gross difference in the abundance of ALDH+ compared 
with that of saline treated mice (Fig. 5-8a and b). In contrast, the mean percentage of 
ALDH+ cells in Apt-DOX treated tumors was 7.1 %, showing a statistically 
significantly reduction compared with other groups (P < 0.05). This experiment 
indicates, via an alternative and complementary approach, that the EpCAM aptamer-
guided DOX delivery can indeed effectively target CSCs in HT29 colorectal CSCs in 
vivo, thereby eliminating a significant portion of CSCs. 
Figure 5-7. A representative single suspensions dissociated from treated HT29 
colon tumors. 
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Figure 5-8. Aptamer-guided DOX delivery targeted colorectal CSCs. 
(a) Representative flow cytometric profile of ALDH1+ cells of single suspension cells 
dissociated from xenograft tumors that were treated as indicated. As a negative 
control, cells were incubated with ALDH1 inhibitor DEAB (BAAA denotes activated 
ALDH1 substrate BODIPY-aminoacetaldehyde). (d) Quantification of ALDH1+ cells 
as described in (a). Data shown are means ± SEM. (n=3). **P < 0.01 compared with 
groups receiving free DOX (two-tailed Student’s t-test). 
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5.2.8 Delivery of DOX by EpCAM aptamer targets CSCs 
To further confirm the CSC-targeting ability of Apt-DOX, a more direct evidence was 
sought through experiments conducted directly on the putative CSCs (as defined by 
EpCAM+/CD44+/CD24+) purified from NOD/SCID mice-bearing HT29 tumors that 
had undergone various treatments. Following the establishment of the xenograft 
colorectal cancer model, mice were randomized into five groups and each received 
four injections of DOX, Apt-DOX and other controls as described in Section 5.2.4. 
Single cell suspensions of treated tumors were prepared 3 h after the last treatment. 
Tumorigenic and non-tumorigenic colorectal cancer cells were then sorted via FACS
based on a set of cell surface markers EpCAM+/CD44+/CD24+ and EpCAM-/CD44-
/CD24-. The binding and internalization of the Apt-DOX in FACS-sorted populations 
of CSCs (EpCAM+CD24+CD44+) and non-CSCs (EpCAM-/CD44-/CD24-) were 
examined. The confocal microscopy data confirmed that DY647-labelled Apt-DOX
was indeed internalized into colorectal CSCs (Fig. 5-9a).  No DY647-labelled Apt-
DOX was found in EpCAM-/CD44-/CD24- cells. Importantly, approximately 24 h 
after the last treatment, the intracellular concentration of DOX delivered by Apt-DOX
in sorted putative CSCs was 1.5-fold higher than that in group receiving free DOX (P
= 0.031) (Fig. 5-9b). Consistent with the prolonged intracellular retention of DOX in 
CSCs, 78% of EpCAM+CD24+CD44+ colorectal cancer  cells from mice treated with 
Apt-DOX were apoptotic (TUNEL positive), in sharp contrast to ~19% apoptotic cells  
in the EpCAM+CD24+CD44+ isolated from tumors treated with free DOX s (P <
0.0001) (Fig. 5-9c and d).  
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Figure 5-9. Apt-DOX was delivered into EpCAM+/CD44+/CD24+ cells in treated 
xenograft tumors and eliminates CSCs.  
(a) Representative micrographs showing efficient targeting of Apt-DOX to 
EpCAM+CD24+CD44+ FHOOV LQ +7 [HQRJUDIW WXPRUV 6FDOH EDU LV  ȝP (b)
Retention of DOX in FACS-sorted EpCAM+CD24+CD44+ cells in xenograft tumors 
after four treatments. The tumor-bearing animals were euthanized at 3 h after the last 
treatment. Data shown are means ± SEM. (n=3). P value was obtained by the two-
tailed Student’s t-test. (c) Quantification of apoptotic EpCAM+CD24+CD44+ cells 
after various treatments as described in (d) using TUNEL assay. Data shown are means 
± SEM. (n=4). P value was obtained by the two-tailed Student’s t-test. (d)
Representative of confocal micrographs of TUNEL assay of cells with illustrated 
WUHDWPHQWV6FDOHEDULVȝP
5.2.9 Introduction of DNA double-stranded breaks of Apt-DOX treatment 
To further explore why the conjugation of free DOX to EpCAM aptamer transformed 
a conventional chemotherapy drug that is unable to kill CSCs into an agent that can 
eradicate CSCs, we next sought to determine whether there is any difference in 
pharmacodynamics between free DOX and Apt-DOX by determining the level of 
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SKRVSKRU\ODWLRQRIKLVWRQH+$;DW6Ȗ+$;DQLQGLFDWRURI'1$GRXEOH-
stranded breaks (DBB) and apoptosis [437-440]. Increasing reports have confirmed 
WKDW Ȗ+$; LV D SRWHQWLDO SKDUPDFRG\QDPLF VXUURJDWH ELRPDUNHU IRU PHDVXULQJ
molecular responses to the activity of DOX [441]. Detection of this phosphorylation 
event serves as a highly specific and sensitive molecular marker for monitoring DNA 
damage initiation by DOX. To this end, tumor homogenate was prepared from mice-
bearing HT29 xenograft tumors treated with free DOX, Apt-DOX and other controls, 
as described before. The phosphorylated version of histone H2A.X in the tumors were 
quantified by Western analysis.  As shown in Fig. 5-10, treatment of tumor cells in 
vitro and tumor-bearing mice in vivo with saline or aptamers did not induce the 
phosphorylation of H2A.X protein. On the other hand, the treatment of tumorspheres 
in vitro and tumor-bearing mice in vivo with either free DOX or Apt-DOX elicited a 
robust phosphorylation of the H2A.X protein, indicating that Apt-DOX killed the 
tumor cells via the same mechanism as utilized by free DOX. Close inspection of the 
results from Western analysis revealed that there were quantitative differences 
between the induction of phosphor-H2A.X protein from cells treated by free DOX and 
Apt-DOX.  Specifically,  Apt-DOX  induced an approximately 3.5-fold increase in the 
phosphorylation of H2A.X protein than that by free DOX  (P < 0.05) (Fig. 5-10a and 
b), suggesting that Apt-DOX efficiently induced DNA damage response and cell death 
pathways after DNA damage via the same signaling pathways as the free DOX, albeit 
efficiently or potently. Based on these findings, it is plausible that Apt-DOX elicits 
apoptosis in tumor cells via the same mechanism(s) as the free DOX counterpart. 
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Figure 5-10. Mechanism of Apt-DOX induced cell death. 
(a) Representative immunoblots of phosphorylation of histone H2A.X at Ser139 in 
tumors from mice receiving 4 doses of agents as described in Section 5.2.4 (in vivo)
and in Chapter 4 Section 4.2.5 (in vitro) as indicated. (b) Qualification of 
phosphorylation of histone H2A.X at Ser139 in treated tumors using Western analysis. 
Data shown are means ± SEM. (n=3). 
5.2.10 Reduction of gross toxicity of DOX by Apt-DOX 
One objective of applying the Apt-DOX conjugate in vivo is to reduce adverse effects 
of drugs toward normal tissues. To investigate whether Apt-DOX could reduce side 
effects of DOX, the changes in body weights of mice-bearing xenograft tumors were 
monitored after treatment. HT29 tumor-bearing mice receiving free DOX treatment 
lost 5.7-fold more weight than those treated with Apt-DOX who had received an 
equivalent dose of DOX (P < 0.01), while tumor-bearing mice receiving free aptamer 
and saline displayed an increase in body weight (Fig. 5-11). These data indicate that 
the aptamer itself did not have gross adverse effects on the well-being of the mice and 
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the conjugation of aptamer with DOX significantly reduced the toxicity effects of the 
free DOX.
Figure 5-11. Aptamer-guided DOX delivery reduced gross adverse effects. 
Body weight variation of tumor-bearing mice between day 1 and day 11 were recorded 
after the initiation of the treatment. Data shown are means ± SEM. (n=3). ** P < 0.01 
compared with mice receiving free DOX (two-tailed Student’s t-test).
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5.3 Discussion 
Chemotherapy agents used for cancer therapy have limited efficacy mainly due to their 
low specificity toward cancer cells and poor pharmaco-bioavailability in vivo, which 
are associated with dose-limiting toxicity and side effects [442-444]. To address this 
problem, there is a high demand to explore therapeutic modalities with minimal side 
effects to normal cells. In this case, the study of using targeting molecules for cancer-
specific therapy, solely or linked to drug carriers has been a promising strategy for 
targeted drug delivery and controlled drug release for eradicating cancer [242, 445]. It 
is widely recognized that conventional anticancer agents, such as DOX, are ineffective 
in eliminating CSCs. Furthermore, the clinical applications of DOX are often 
associated with the emergence of drug resistance, and enrichment of CSCs [446-448].
Therefore, empowering conventional anticancer agents with the capability of 
eliminating CSCs would represent a revolution in anticancer drug development [449].
In this Chapter, we conjugated a PEGylated-aptamer with DOX and performed a 
variety of in vivo studies to demonstrate that the Apt-DOX conjugate can efficiently 
target CSCs, to inhibit tumor growth and improve the survival of mice-bearing 
colorectal tumors. 
In order to prolong the blood resident time, DOX was intercalated into the aptamer 
conjugated with a 20 kD PEG (Fig. 5-1). The PEGylated Apt-DOX had a significantly 
increased half-life and MRT compared with that of free DOX (approximately 8.8- and
6.5-fold respectively). The lower level of free DOX after 6 h might be attributable to 
the rapid clearance of the free DOX. The larger size (about 12 nm) of Apt-DOX 
contributed to the prolonged drug circulation in vivo, and thus facilitated the effective
delivery of the drug to tumors due to extended systemic exposure. In addition, there 
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was a significant improvement in biodistribution of Apt-DOX compared to that of free 
DOX (Fig. 5-3). DOX is widely used as an efficient antitumor drug, but its 
cardiotoxicity effect limits its long-term outcomes [450]. Aptamer-guided DOX 
delivery displayed an approximate 4-fold lower DOX concentration in the heart than 
that of free DOX (Fig. 5-3e). Thus, the aptamer-guided DOX delivery system would 
reduce the cardiac toxicity as high DOX accumulation in the heart is closely related to 
the inherent cardiac toxicity. Most importantly, the Apt-DOX delivered a significantly 
higher DOX concentration to tumors than either free DOX or control Apt-DOX at 
least over 24 hours (Fig. 5-3d). This is likely the result of the EPR effect and the 
increased aptamer-mediated active targeting of DOX to EpCAM-expressing tumor 
sites. 
Cancer development is considered to be controlled by the balance between cell 
proliferation and apoptosis [428]. Thus, tumor growth is not simply a result of reduced 
apoptosis but also may due to the enhanced proliferation. TUNEL assay is commonly 
used for detecting cells with DNA fragmentation or that have suffered severe DNA 
damage from apoptotic signaling cascades [451, 452]. Aptamer-guided drug delivery 
based on active targeting, demonstrated remarkably increased apoptosis and reduced 
proliferation of HT29 tumors but not free drug or other controls (Fig. 5-4a and b). 
Antigen Ki-67 is a nuclear protein that is associated with cellular proliferation and 
ribosomal RNA transcription [453]. Accordingly, the Ki-67 protein is an excellent 
marker that is widely used for determining the growth fraction of a given cell 
population [454]. Ki-67 protein is present exclusively during active cell cycles (G1, S, 
G2, and mitosis), excepting the resting G0 phase. The fraction of Ki-67-positive tumor
cells shows the clinical course of cancer development in various types including colon, 
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breast and liver cancers [455-457]. The lower expression of Ki67 index in tumor 
sections following Apt-DOX treatment indicated that aptamer-mediated DOX 
delivery could facilitate the inhibition of tumor proliferation and progression (Fig. 5-
4c and d). These data shown that Apt-DOX treatment not only inhibited the 
proliferation of HT29 cells but also critically promoted apoptosis – two crucial factors 
in defining the overall progression of tumors in response to current anticancer 
therapies [429]. Accordingly, the antitumor efficacy of Apt-DOX was significantly 
higher than that of free DOX or control Apt-DOX when they were administrated at an 
equivalent dose into tumor-bearing mice (Fig. 5-4, Fig. 5-5a). The superior antitumor 
activity of the Apt-DOX was consistent with the higher accumulation of Apt-DOX in 
the tumor (Fig. 5-3c). This result indicated that tumor-specific aptamer-guided drug 
delivery contributed to the enhancement of therapeutic efficacy. The antitumor effect 
of free DOX was nearly the same with control Apt-DOX. In addition, mice-bearing 
tumors treated with Apt-DOX shown a remarkable longer survival rate compared to 
any other group as indicated (Fig. 5-5b).
To further confirm the CSC-targeting and -eradicating ability of Apt-DOX in vivo, the 
in vitro tumorphere formation assay based on limiting dilution assay was conducted, 
using single cells dissociated from in vivo treated HT29 tumors (Table 5-2). 
Encouragingly, DOX delivery by EpCAM aptamer greatly enhanced DOX sensitivity 
in HT29 CSCs in tumor and resulted in an 18.1-fold greater reduction of CSC 
frequency than that of free DOX treatment. It is worth noting here that free DOX 
treatment also led to a 9-fold drop of CSC frequency compared to that of saline or free 
aptamer treatment groups. This could be derived from the plasticity of non-CSCs 
according to the dynamic CSC model which indicates that not only could the CSCs 
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differentiate into non-CSCs, but the non-CSCs could de-differentiate into CSCs [458-
460], and thus, free DOX killing non-CSCs might result in less conversion of non-
CSCs to CSCs, thereby reducing the CSC frequency eventually. Even through the 
sphere formation assay and cell surface marker analysis are valuable information for 
the assessment of self-renewal and abundance of CSCs, they are surrogates for the 
gold standard in vivo limiting dilution assay for direct assessing the targeting of CSC 
[431]. To demonstrate that Apt-DOX treatment indeed eliminated CSCs, single 
suspension tumor cells derived from various treatment groups were studied in vivo
limiting dilution assay to directly enumerate CSCs. Consistent with the in vitro and ex
vivo data, in addition to the increased tumor latency, a 30-fold decrease of CSC 
frequency was observed in tumor cells isolated from mice treated with APT-DOX 
compared to that received free DOX. Taken together, these results suggested that the 
aptamer-guided drug delivery was able to transform free DOX to an agent capable of 
effectively targeting and eradicating CSCs.
To further confirm the targeting of CSCs, the variation in the putative CSC population 
(ALDH+ cells) [416-421, 423] in the treated tumors was assessed in vivo. As illustrated 
in Figure 5-8, Apt-DOX treatment resulted in a significant reduction of tumorigenic 
ALDH+ cells in treated HT29 tumors, compared to free DOX treatment. In these 
studies, both the changes of cell populations based on cell surface markers for CSCs 
and cellular content of ALDH1 enzymes were explored to provide complementary 
evidence [130-132]. The reduction of ALDH+ cells induced by Apt-DOX in vivo
supports the hypothesis that the aptamer-guided drug delivery can effectively target 
and subsequently eliminating the population of cells with CSC characteristics. DOX 
has been well studied and shown to be able to cause cell apoptosis by activation of 
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p53 and eviction of histones from regions of accessible chromatin leading to 
impairment of DNA repair, which in turn promotes apoptosis of tumor cells [220, 461, 
462]. The effects of apoptosis on putative colorectal CSCs following Apt-DOX 
treatment was examined via TUNEL assay using sorted EpCAM+CD24+CD44+ cells 
and formalin-fixed, paraffin-embedded tissue sections that were both prepared from 
treated tumors. The greatly elevated  apoptosis in sorted CSC  (EpCAM+CD24+CD44+)
cells is mostly due to the successful uptake of Apt-DOX followed a high intracellular 
DOX concentration and a prolonged drug retention observed inside CSCs (Fig. 5-9a 
and b). 
Despite the extensive application for cancer therapy in clinics, the mechanisms of 
DOX-induced cell death remain to be fully elucidated [374]. DNA damage is the key 
to DOX-induced cytotoxicity which associates with several mechanisms, including  
inhibition of topoisomerase II that leads to the DNA double-strand breaks (DBB), and 
formation of intercalating DOX DNA adducts and preventing DNA replication [220, 
374, 463]. In the case of DBB, cells react immediately to repair the lesion and arrest 
the cell cycle for repair [464]7KHȖ+$; plays a key role in recruiting repair proteins 
to strand breaks, acting as an indicator of the cellular response to DBB [437-440].
Following the treatment of Apt-DOX, there was a remarkable increase in the level of 
Ȗ+$; compared to other groups (P < 0.001), probably due to the more apoptosis 
induced by the conjugate owing to much higher intracellular concentration of DOX 
achieved via APT-DOX in vivo (Fig. 5-10a and b). Despite the quantitative difference 
LQȖ+$;LQVWUXFWLRQWKHGDWDREWDLQHGLQWKLVVWXG\VXJJHVWWKDW$SW-DOX eradicate 
CSCs via the same cellular pathways as utilized by free DOX in killing non-CSC cells. 
154
 
In summary, the high concentration and prolonged retention of DOX delivered by Apt-
DOX significantly improved the sensitivity of CSCs to DOX, which resulted in 
overcoming chemoresistance and impairment of tumorigenic capacities of colorectal 
CSCs. The eradication of CSC in vivo translates to suppressed tumor growth and 
extended overall survival of mice bearing xenograft tumors. This novel strategy of 
aptamer-guided DOX delivery may open a new avenue to overcome chemoresistance 
by transforming a traditional chemotherapeutic drug into a CSC killer. 
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CHAPTER 6
CONCLUSIONS AND FUTURE PERSPECTIVES
6.1 General conclusions
A novel strategy for specific targeting and killing cancer stem cells has been 
established by directly conjugating a traditional anticancer agent, doxorubicin, into a 
cancer stem cell-targeting RNA EpCAM aptamer. A new concept derived from this 
work is that one does not necessarily has to develop new drugs or novel molecular 
entities to eradicate cancer stem cells.  By cancer stem cell-targeted delivery of 
existing chemotherapeutic agents, we can transform a classic anticancer-drug with 
abundant clinical data on its pharmacokinetics and safety track record into a cancer 
stem cell-killer.
The general conclusions of this work are described below: 
1) Aptamers, as “chemical antibodies” not only bind to their targets with high 
affinity and specificity but also possess a number of superior benefits to 
antibodies in terms of tumor penetration, intracellular accumulation and 
retention. 
2) A cancer stem cell-targeting system has been successfully generated by 
conjugating DOX into an engineered RNA EpCAM aptamer (aptamer-
doxorubicin), which could specifically target EpCAM-expressing cancer cells, 
release the drug inside cells and sustain longer drug retention compared to that 
of free drug counterpart.
3) Aptamer-guided doxorubicin delivery successfully targeted the cancer stem 
cells in vitro and suppressed tumorigenicity.
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4) Doxorubicin conjugated into a PEGylated aptamer displayed a much improved 
pharmacokinetic profile than free doxorubicin in vivo.
5) EpCAM aptamer-guided doxorubicin delivery effectively targeted the putative 
cancer stem cells, overcame chemoresistance, and prevented tumor initiation, 
thereby functionally impaired tumorigenicity of colorectal cancer stem cells. 
6) Aptamer-doxorubicin conjugates significantly suppressed tumor growth and 
extended overall survival of the tumor-bearing mice by inducing tumor 
apoptosis and nuclei DNA double-stranded breaks.  
7) Doxorubicin delivered as an aptamer conjugate appeared to eradicate 
colorectal cancer stem cells via the same molecular and cellular mechanisms 
under which doxorubicin is known to function as a cytotoxic agent.  
8) The results of this work has established a new principle regarding how to 
eliminate cancer stem cells. As long as cytotoxic agents can reach a sufficiently 
high intracellular concentration over a pharmacologically meaningful period, 
the cancer stem cells can be eradicated.
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6.2 Future perspectives
In this study, an aptamer-doxorubicin conjugate system has been developed that is 
able to specifically target colorectal cancer stem cells and impair their tumorigenic 
capacities, which in turn translated into the inhibition of the tumor growth and 
prolonged the overall survival of mice-bearing colorectal tumors. 
The results from this work help to mitigate the following two challenges on developing 
effective anti-cancer stem cell therapies: First, the journey from the discovery of a new 
chemical entity or new molecular entity  in the laboratory to the clinic is very long and 
costly, with a dauntingly low success rate (~10%) [465, 466]. Second, targeting cancer 
stem cell-relevant signal transduction pathways is complicated by the extreme 
diversity and redundancy of the participating elements.  In addition, as the Wnt, Notch, 
and Hedgehog pathways that regulate self-renewal are shared by both normal and 
cancer stem cells, significant side effects may result from targeting these pathways.  
Indeed, the inhibitors to these pathway show significant on-target and/or off-target 
adverse effects, such as gastrointestinal toxicity [467, 468].
Therefore, the results from this proof-of-principle study will provide an important 
framework for drug discovery and cancer treatment as well as open up new and 
practical avenues to overcome pathway redundancy and drug resistance in cancer 
therapy to achieve long-term remission in a clinical setting. By delivering a 
chemotherapy drug via cancer-targeting aptamers, our innovation can transform a 
conventional chemotherapy drug into a robust cancer stem cell killer with great 
potential to minimize dose-limiting toxicities which is the major problem for the 
success of current cancer chemotherapy.
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In addition to these results, the following works can also be carried out in the future 
for the development of a universal scheme that can be translated into clinics for cancer 
treatment based on the aptamer technique. 
1) It is worth exploring whether this aptamer-drug delivery system can also be 
used to delivery other types of chemotherapeutics for effectively targeting 
cancer cells or cancer stem cells.
2) The in vivo tumor diagnostic potential of aptamer and aptamer-doxorubicin 
can be explored for development of a more promising theranostics system for 
clinical usage.
3) The stringent preclinical safety profile of aptamer and aptamer-drug 
conjugates needs to be further established.     
The success of studies proposed in this application shall greatly accelerate the progress 
of developing novel and efficacious cancer stem cell therapeutics as we captilize on 
the available clinical safety and pharmacology data for existing chemotherapy drugs 
accumulated over several decades. Furthermore, as both the aptamers and the 
therapeutic agent used in our system target the bulk tumor cells as well as cancer stem 
cells, the success of this project will bring us a few vital steps closer towards the goal 
of providing a cure for cancer. This shall translate into much improved survival rates 
and better quality of life for patients with cancer and aid to substantially reduce the 
social and economic impact of this devastating disease.
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